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Ttc7fsn/fsn mice exhibit systemic autoimmunity characterized by hyperactivated B 
cells, increased interleukin-4, autoantibodies, kidney disease and reduced lifespan. 
Because the pathology is similar to systemic lupus erythematosus, Ttc7fsn/fsn mice are a 
useful model with which to study early events that lead to autoimmune disease.  
Although the Ttc7fsn mutation has been identified the gene function is unknown. 
The phenotype of Ttc7fsn/fsn mice mimics the Th2 autoimmunity of the IL-4 transgenic 
(Erb et al 1997). It was previously unknown whether the over-production of IL-4 was an 
intrinsic defect of Ttc7fsn/fsn lymphocytes that led to autoimmunity, or, whether excess IL-
4 was produced as a result of hyper-activated lymphocytes, which then drove pathology. 
Because the transcription factor, signal transducer and activator of transcription (Stat)-6 
is unique to the IL-4 pathway and influences both IL-4 production and lymphocyte 
activation, we evaluated the regulation of Stat6 in B cells as an indication of IL-4 
signaling. We examined the activation status and IL-4 production in 4-and 10-week T 
cells to determine if activation preceded the IL-4-driven pathology.   
Immunoprecipitation and Western blot revealed that Stat6 appeared constitutively 
activated in Ttc7fsn/fsn B cells, however, ex vivo functional analysis of Stat6 with confocal 
microscopy determined that when the IL-4 signal was removed, Stat6 became 
deactivated.  
The use of actinomycin D in mRNA expression studies revealed that IL-4 mRNA 
stability was increased in Ttc7fsn/fsn T cells which resulted in IL-4 production in 
unstimulated cells and extended IL-4 production after transcription was blocked as 
determined by ELISA. Using cyclosporine A in the same assays suggested that IL-4 
production was dependent on TCR stimulation. Flow cytometry established that Ttc7fsn/fsn 
mice have more activated and memory T cells at 4-weeks, suggesting that activation 
occurs before the over-production of IL-4. 
Genetically deleting Stat6 from Ttc7fsn/fsn mice unexpectedly did not improve the 
disease phenotype but increased the percentage of immature B and activated T cells. The 
neutralization of IL-4 improved renal pathology but did not alter the status of Ttc7fsn/fsn 
lymphocytes. Therefore, we suggest that the Ttc7fsn mutation results in autoreactive 
lymphocytes that are induced to produce IL-4, leading to systemic autoimmunity. 
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INTRODUCTION 
Autoimmunity results from the production of cells that react to self-antigens 
during the normal development of a diverse repertoire of cells needed to populate the 
immune system. Autoimmune disease results when the mechanisms in place to regulate 
and delete auto-reactive cells fail, helping to set-off a cascade of events leading to 
pathology that is still not fully understood. Autoimmune diseases affect between 14 to 
23 million Americans but remain difficult to study, diagnose and treat due to the 
underlying complexity of the pathology which drives them and the heterogeneity of the 
known syndromes. There are over 80 recognized clinically distinct diseases, some that 
are organ specific such as Type I diabetes and pancreatic beta cells, and some that are 
systemic such as systemic lupus erythematosus, or SLE (May 2007). SLE, or Lupus,  
patients often exhibit multi-organ abnormalities and inflammation including skin 
lesions, vasculitis, immune complex deposition, renal disease and failure, anti-nuclear 
autoantibodies, arthritis, neurological disorders and cytokine abnormalities. Lupus can 
affect children as well as the elderly, but is most often diagnosed in women of child-
bearing years. There exists great variation between one patient and another, even 
among genetically similar individuals, suggesting that a complex interaction between 
environmental agents and disease susceptibility genes determines disease progression 
and outcome (Kammer, Perl et al. 2002). Some underlying defects contributing to the 
pathogenesis of  SLE have been identified  and include impaired clearance of dying 
cells (Gaipl, Munoz et al. 2007), impaired T cell signaling (Kammer, Perl et al. 2002), 
cytokine imbalances, abnormal B cell activation, inhibition of apoptosis, and abnormal 
cell proliferation. These defects may have multiple causes, known or unknown, and 
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may be genetic and/or acquired during the course of infection or aging, making the 
diagnosis of autoimmune disease and the study of it difficult and complex. This mutli-
factorial etiology therefore requires research in a variety of systems to represent the 
subsets that exist among the human population (Wakeland, Wandstrat et al. 1999; 
Marrack, Kappler et al. 2001; Whitelaw and Martin 2001). 
A number of mouse models of SLE and systemic autoimmunity have been 
developed or identified to delineate the pathways critical to the development of disease. 
MRL-lpr/lpr mice lack functional CD95, which is important for apoptosis and develop 
a lymphoproliferative disease similar to lupus (Giese and Davidson 1992; Singh, 
Saxena et al. 2003). The murine New Zealand Black/New Zealand White F1 hybrid 
develops spontaneous systemic autoimmunity and has been helpful in identifying a 
number of SLE susceptibility loci (Wakeland, Wandstrat et al. 1999). BXSB/MpJ mice 
carry the Y-linked autoimmune acceleration gene (Yaa) and spontaneously develop 
autoantibodies and glomerulonephritis similar to human SLE (Singh, Saxena et al. 
2003). These models and others have been crossed to produce congenic strains as well 
as genetically modified to add or delete desired traits. The use of these models have 
greatly contributed to the pool of knowledge regarding autoimmunity, however, there 
are still many unanswered questions. 
Flaky skin mutant mice display systemic immune dysfunction and autoimmunity 
which includes lymphadenopathy and splenomegaly, alterations in immunoglobulin 
profiles, the presence of antinuclear autoantibodies and glomerulonephritis (Pelsue, 
Schweitzer et al. 1998; Withington, Maltby-Askari et al. 2002). In addition, these mice 
exhibit an alteration of splenic architecture and cell populations, as well as a substantial 
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increase in the number of lymphocytes in the spleen and lymph nodes. Flaky skin mice 
acquired their name from the characteristic thickening and flaking of their skin due to the 
underlying inflammation of the dermis and epidermal layers. They are anemic at birth, 
and easily identified by the paleness of their ears and tail, reduced size, hunched stance 
and hair striations on their bellies.  
The flaky skin mutation arose spontaneously in A/J mice at the Jackson 
Laboratory (Bar Harbor, Maine) and has been maintained on the BALB/cByJ strain 
(Pelsue, Schweitzer et al. 1998). The mutation in the flaky skin gene has been recently 
identified as an early transposon (ETn) retroviral insertion in the tetratricopeptide repeat 
7 (Ttc7Pfsn P) gene located on the distal end of mouse Chromosome 17 (Helms, Pelsue et al. 
2005; White, McNulty et al. 2005). Hence, flaky skin mice are presently referred to as 
Ttc7Pfsn/fsnP mice. Ttc7 codes for an 858 amino acid protein which has seven 
tetratricopeptide repeat (TPR) sequences. The insertion adds 61 amino acids into one of 
the TPR domains which is thought to disrupt protein function (Helms, Pelsue et al. 2005). 
Many proteins with several TPR repeats function as adaptor, scaffolding or chaperone 
proteins (Das, Cohen et al. 1998; Klee, Ren et al. 1998; Brinker, Scheufler et al. 2002; 
D'Andrea and Regan 2003; Jordan, Singer et al. 2003; Smith 2004), however, the 
function of Ttc7 is currently unknown. Tools for studying Ttc7 are not yet available, but 
are currently being developed by our lab. 
One of the hallmarks of Ttc7Pfsn/fsnP mice is the dramatic increase in interleukin-4 
(IL-4) production (Pelsue, Schweitzer et al. 1998; Welner, Hastings et al. 2004). The 
phenotype of Ttc7Pfsn/fsnP mice is consistent with that of the IL-4 transgenic mouse as 
described by Erb, et al (Erb, Ruger et al. 1997). Both exhibit increased expression of 
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MHC class II on the surface of hyper-proliferative B cells, increased IgG1,  thymic 
involution, anemia, proteinuria, glomerulonephritis associated with complement and 
immune deposition in the glomeruli, and show increased production of autoantibodies, 
particularly anti-DNA. In addition, they each suffer a severely reduced life span of 
approximately 15 weeks as well as splenomegaly and lymphadenopathy without a 
coincident increase in the percentage of T lymphocytes as compared to B cells. However, 
one of the major differences between the IL-4 transgenic and Ttc7Pfsn/fsnP is that Ttc7Pfsn/fsnP 
mice are anemic at birth, before the onset of the IL-4-driven autoimmune pathology 
whereas treatment with the neutralizing monoclonal antibody, 11B11, starting at 3 days 
of age prevents the formation of anemia in the transgenic model, which develops by 4-
weeks of age (Erb et al., 1997). In contrast to Ttc7Pfsn/fsnP, the IL-4 transgenic as described 
by Erb et al also has not reported evidence of skin pathology. Because of the complexity 
of the phenotype of Ttc7Pfsn/fsnP mice and the many factors involved in the progression to 
autoimmune disease, it is important to have an understanding of the elements that 
contribute to normal and abnormal regulation and signaling of IL-4 in the immune 
system. 
 
IL-4: Description and Function 
IL-4 is a pleiotropic cytokine whose effects have been found to play a protective 
role in immunity to extracellular parasites, to suppress a cellular autoimmune response 
such as that in Type I diabetes, and to have an active role in tumor resistance. 
Overexpression of IL-4 has been implicated in allergy and humoral-immune related 
autoimmunity (Parronchi, de Carli et al. 1992; Chan, Brown et al. 1996; Webb, 
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McKenzie et al. 2000; Li-Weber and Krammer 2003), while underexpression has 
resulted in autocrine growth of tumors and increased susceptibility to some infectious 
diseases such as leishmaniasis (Miralles, Stoeckle et al. 1994). Variables such as the 
relative amount expressed, timing of production, site of expression, the presence of 
other cell signals and the genetic background of an organism influence the effects of 
IL-4 on physiologic processes. 
IL-4 was first identified in 1982 as a B cell growth factor (Howard, Farrar et al. 
1982). Since then, the structure and function of this molecule has been studied 
extensively. IL-4 is predominately produced by activated T lymphocytes, as well as 
NK1+T cells, mast cells and basophils. It has been shown to mediate numerous effects 
on many different cell types, including T cells, B cells, monocytes, dendritic cells, mast 
cells, endothelial cells, keratinocytes, hepatocytes, fibroblasts, astrocytes, and 
osteoblasts. IL-4 acts as a co-stimulant for growth in B cells as well as in T cells and 
mast cells, it diminishes the inflammatory functions of monocytes and macrophages 
while enhancing their antigen-presenting functions, it induces growth and chemotaxis 
in human fibroblasts and the production of IL-6, extracellular matrix proteins and 
ICAM-1, it regulates the expression of VCAM-1 on human endothelial cells and VLA-
4 on T cells and eosinophils, and reduces chloride ion secretion by intestinal epithelial 
cells (Keegan 2000). IL-4 is absolutely required for the differentiation of the Th2 subset 
of helper T cells and is considered to be the hallmark of Th2 cytokines along with IL-5, 
IL-6, IL-10 and IL-13 (Zamorano, Mora et al. 2001; Ansel, Djuretic et al. 2006). Many 
signal transduction pathways activated by IL-4 have been studied and dissected, with 
IL-4 signaling in B cells being a particular area of focus.   
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Optimal activation of B cells is dependent on two Th2-mediated stimuli, IL-4 
and a second signal provided by CD40L (1igand). Together, these stimulate the 
proliferation of B cells, induce the expression of the low-affinity Fc receptor for IgE 
(CD23), upregulate major histocompatibility class II molecules on the B cell surface, 
and stimulate the transcription of un-rearranged immunoglobulin heavy-chain germline 
Ig-epsilon and Ig-gammaI genes leading to class switching and IgE and IgGI synthesis 
(in mice) or IgG4 (in humans) (Nelms, Snow et al. 1998). IL-4 also regulates the 
expression of the co-activation and adhesion molecule Thy-l (CD90) on B cells 
(Snapper, Hornbeck et al. 1988), and has been shown to exert protective effects on cells, 
sparing them from spontaneous and induced apoptosis (Rush and Hodgkin 2001; Morris, 
Dragula et al. 2002; Wurster, Withers et al. 2002; Carey, Semenova et al. 2007). Mice 
lacking IL-4 have normal T and B cell development but highly reduced levels of IgG1 
and completely lack IgE (Kuhn, Rajewsky et al. 1991).   
IL-4 is an -20kDa globular secreted glycoprotein comprised of four short alpha 
helices identified as A,B,C, and D. The IL-4 gene is located on mouse chromosome 11 
and on the long arm of human chromosome 5 at q23-31 (Keegan 2000). Although  IL-4 
production has been considered to be the function of CD4+ Th2 cells and mast cells, it 
has remained a question which cell type provides the initial production of IL-4 to drive 
the polarizing response. There is evidence that NK-T1 cells may provide the initial hit 
(Brown and Hural, 1997), but recent evidence suggests that naïve CD4+ cells themselves 
transcribe low basal levels of IL-4 that act in an autocrine fashion and poise naïve T cells 
at the brink of becoming committed to IL-4 production (Dorado, Jerez et al. 2002; Yagi, 
Suzuki et al. 2002; Grogan, Wang et al. 2003; Baguet and Bix 2004; Omori and Ziegler 
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2007; Rose, Lichtenheld et al. 2007).    Recent evidence has shown that germinal center 
B cells may also be a possible source of IL-4, at least localized to the tonsilar and colonic 
mucosa. This was demonstrated to be an antigen-dependent response and was specifically 
seen in a small percentage of B cells prior to differentiation into memory cells. The 
regulatory mechanisms of IL-4 production in B cells remain unclear although they appear 
to require the presence of IL-4 and Th2 cells. Molecular regulatory mechanisms of IL-4 
production in B cells are thought to be different than those of T cells as B cells displayed 
a comparatively high level of production of IL-4 and a low level of mRNA in contrast to 
the co-localized IL-4 producing T cells in the system that was used to study this 
phenomenon (Johansson-Lindbom and Borrebaeck 2002; Harris, Goodrich et al. 2005). 
The endogenous mechanisms active in potentiating IL-4 activity are unclear,  but 
when injected in experimental murine systems IL-4 is rapidly cleared from the circulation 
and secreted by the kidneys in a proteolytically degraded form. The clearance of IL-4 is 
also dependent on the internalization of the IL-4 receptor complex and processing in 
lysosomes. Additionally, in both mouse and humans a naturally occurring soluble version 
of the IL-4Ralpha chain exists which may function to extend the half-life of IL-4 in the 
serum by acting as a carrier protein. Conversely, it may also block the binding of IL-4 to 
the IL-4 membrane-bound receptor thus reducing IL-4 bio-activity. The exact function of 
this soluble receptor has not yet been elucidated (Weisman, Creaner et al. 1996; Sang, 
Ouma et al. 1999; Keegan 2000). 
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IL-4 Regulation and Signaling 
The fate of antigen activated naïve T cells is dictated in part by the surrounding 
cytokine milieu. IL-4 is generally considered to be a hallmark cytokine for humoral 
immunity due to its role in skewing T helper cells into the Th2 direction, which then 
provide B cell help. As mentioned earlier, the cell responsible for the first IL-4 “hit” has 
yet to be definitively determined, but IL-4 is capable of upregulating its own production 
and acting as an autocrine growth factor for Th2 cells (Yagi, Suzuki et al. 2002). In fact, 
recent evidence suggests that neonatal resting CD4+ cells are programmed to very rapidly 
produce high levels of IL-4 upon activation and remain in such a state of transcriptional 
permissivity until about 3-weeks of age, where chromatin changes cause transcriptional 
repression until the proper priming occurs resulting in a more adult-like response. This 
early response was shown to be signal transducer and activator of transcription-6 (Stat6) 
independent and cell-cycle independent which is in contrast to the adult CD4+ 
differentiation program (Baguet and Bix 2004; Rose, Lichtenheld et al. 2007).  
Differentiation into adult CD4+ IL-4+ cells requires several rounds of cell division (Bird, 
Brown et al. 1998) during which DNA demethylation (Kim, Fields et al. 2007) and 
chromatin remodeling occurs to make the IL-4 control region more accessible to 
transcriptional machinery (Guo, Hu-Li et al. 2002). To gear up for IL-4 production in 
adult resting CD4+ cells, IL-4 binds to the IL-4 receptor which phosphorylates and 
activates JAK (Janus kinase) kinases and Stat6. Stat6 translocates to the nucleus, the 
transcription factor GATA-3 is activated which is absolutely necessary for IL-4 
production, chromatin is remodeled and becomes acetylated, and then c-Maf is activated. 
NFAT and NIP45 are upregulated, which then participate in regulating expression of IL-
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4. The absence of Stat6 during this stage of differentiation results in cells that produce 
markedly reduced levels of IL-4 and lack of differentiation into Th2 effector/memory 
cells (Kaplan, Wurster et al. 1999; Ansel, Djuretic et al. 2006). However, after CD4+ 
cells have differentiated into effector memory cells (CD62LPloP/CD44PHiP) or central 
memory cells (CD62LPhiP/CD44PhiP) IL-4 production becomes Stat6 and IL-4 independent 
(Zamorano, Mora et al. 2001; Grogan, Wang et al. 2003; Yamashita, Shinnakasu et al. 
2004). 
It appears that IL-4 also has a hand in down-regulation of its own expression. 
When Th2 cells are activated through the TCR receptor, calcium is mobilized to the 
cytoplasm which activates the calcium-calmodulin dependent phosphatase calcineurin. 
Calcineurin then dephosphorylates the transcription factor NFAT, which is present in an 
inactive phosphorylated form in the cytoplasm. NFAT then performs a conformational 
change that allows it to translocate to the nucleus to promote transcriptional activity. This 
is a cyclosporine (CsA) sensitive event, as this immunosuppressive drug inhibits 
calcineurin and blocks IL-4 production. NFAT binds to a region defined as the P1 site in 
the IL-4 promoter region and is required for the upregulation of IL-4 early in activation. 
In later phases, Stat6 appears to complex with P1, competing with NFAT for the P1 site 
(Dorado, Jerez et al. 2002; Rengarajan, Mowen et al. 2002). When Stat6 is bound to P1, 
inhibitory molecules such as SHP-1, suppressors of cytokine signaling (SOCS) proteins, 
and B cell lymphoma protein-6 (Bcl-6) are able to be transcribed that help to attenuate 
IL-4 production (Losman, Chen et al. 1999; Jiang, Harris et al. 2000; Nicola and 
Greenhalgn 2000; Lyons, Lynes et al. 2003) (Figure 1). 
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  The end result of the competition between NFAT and Stat6, i.e. decrease in IL-4 
mRNA, depends on the presence of other transcription factors as well as attenuation of 
the stimulating signal. Low levels of IL-4 transcript continue to be present until the 
abolishment of signals to induce production (Dorado et al., 2002).  
 
IL-4 Receptor 
To produce a biological response, IL-4 must bind to specific high-affinity (KBdB = 
110-150 pM) receptors present on target cells (Noben-Trauth, Shultz et al. 1997). These 
are expressed at varying levels on many cell types of both hematopoietic and non-
hematopoietic lineage, attesting to the importance of IL-4 in physiologic systems. 
 
 
 
 
 
Figure 1. IL-4 Regulation in Th2 Cells 
Used with permission (Dorado, Jerez et al. 2002) 
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Kawakami, et al. (Kawakami, Kawakami et al. 2001), showed receptor densities to be at 
approximately 300-600 binding sites on basophils, less then 50 on endothelial cells, ~500 
on resting T and B cells, and 200-300 on monocytes. Numbers can range up to 5000 
receptors per cell however, which can serve as a determinant for IL-4 inducibility. 
Interestingly, the IL-4R is dramatically upregulated on many tumor cell types. 
The IL-4 receptor consists of a ligand-binding 140-kDa alpha chain (IL-4Ra) and 
a second chain referred to as the common gamma (γс) chain that is shared by cytokine 
receptors for IL-2, IL-4, IL-7, IL-9 and IL-15. IL-4Ra is a member of the hematopoietin 
receptor superfamily which shares the presence of type III fibronectin domains in the 
extracellular region; these motifs include conserved paired Cys residues and a WSXWS 
motif that has been proposed to maintain the receptor in a conformation favorable for 
cytokine binding. It is here that helices A and C of the IL-4 molecule associate with the 
IL-4 receptor alpha chain. Helix D contacts the associating receptor chain, either the 
common gamma (cy) chain (Type I, more prevalent) or the IL-13 receptor alpha chain 
(Type II), one of which is needed to form an active receptor complex upon 
heterodimerization (Leonard and Lin 2000). 
The cytoplasmic portion of the murine IL-4Ra chain is 553 amino acids long and 
contains five, highly conserved tyrosine residues, Y497, Y575, Y603, Y631, and Y713, 
as well as a short, proline-rich sequence in the membrane proximal region termed a "box 
motif'. This region has been found to be a site of association with JAK1, a tyrosine kinase 
critical in the initiation of signaling by hematopoietin receptors. Neither the alpha chain 
nor the cγ chain have endogenous kinase activity, therefore upon ligand binding to the 
IL-4R, JAKl (most likely aided by the common gamma chain associated JAK3) must 
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provide the initial signal to activate the signaling cascade. An adjacent acidic region has 
been shown to interact with the Src-family kinase, Fes, which has also been shown to be 
activated by IL-4 stimulation (Nelms, Snow et al. 1998). Activation of the JAK kinases 
via autophosphorylation or crossphosphorylation between JAKl and JAK3, leads to the 
tyrosine phosphorylation of the IL-4Ra chain at the appropriate conserved Tyr residues. 
These are also sites of potential interaction with the Src-homology 2 (SH2) regions or the 
phosphotyrosine-binding (PTB) domains of downstream signaling molecules. 
Biochemical characterizations of pathways activated by IL-4R engagement have 
identified critical residues that initiate specific signaling cascades. Phosphorylation of 
Y497 appears to be required for the IL-4 mediated activation of cellular proliferation via 
interaction with insulin receptor substrate (IRS)-1/2 (Deutsch, Koettnitz et al. 1995). 
Y575, Y603 and Y631 are critical for the upregulation of IL-4 induced genes through the 
activation of the IL-4 specific transcription factor, Stat6. Residue Y713 appears to be 
located within the immunoregulatory tyrosine-based inhibitory motif (ITIM) (Jiang, 
Harris et al. 2000). Studies have demonstrated the interaction of the phosphatases SHP-1, 
expressed primarily in hematopoietic tissue, and SHIP with this region. These molecules 
appear to exhibit an inhibitory role on specific kinases. Research on the mutant mouse 
strain motheaten, in which SHP-1 is defective through the result of aberrant splicing, has 
shown SHP-1 to be constitutively expressed and to affect JAKl through 
dephosphorylation and subsequent inactivation (Hilton 1999). SHIP appears to act on the 
5' phosphates of phosphotidylinositol (PtdIns)(3,4,5) triphosphate (PI3), thus regulating 
the phophoinositide (PI)-3 kinase pathway by dephosphorylating the products of this 
enzyme (Nelms, Snow et al. 1998). However, evidence suggests that SHIP has a positive 
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effect on B cell proliferation and survival which is in contrast to the proposed inhibitory 
function of the ITIM. This may reflect a cell type specific role of SHIP that modifies its 
function depending on location in the cell (Losman, Chen et al. 1999). Each of these 
pathways will be explored below, with particular emphasis placed on Stat6 regulated 
signaling in B cells. 
 
IRS-1/2 Pathway 
Upon binding of IL-4 to the IL-4 receptor, JAKs 1,2 and 3 potentially become 
activated and phosphorylate specific tyrosine residues. The phosphorylation of Y497 
(Insulin Receptor Motif) on the IL-4Ra chain results in the phosphorylation of Insulin 
Receptor Substrates (IRS)-1/2 and induces an interaction with the receptor via the N-
terminal phosphotyrosine-binding domain (PTB). IRS-1/2 has 20 potential 
phosphorylation sites, many with SH2 binding domains, as well as pleckstrin homology 
domains that are thought to allow for interaction with membrane-associated lipids. The 
regulatory subunit of PI-3K; p85, associates with the activated IRS-1/2 leading to a 
conformational change in p85, which then activates the catalytic subunit, p 110. The pl10 
subunit phosphorylates membrane lipids, mediating the transfer of gamma phosphate 
from ATP to the D3 position of inositol in membrane-associated phosphotidylinositol 
producing Ptdlns(3,4,5)P3 or PtdIns(3.4)P2. These molecules act as second messengers to 
activate downstream kinases such as protein kinase C (PKC) leading to cell proliferation 
and/or protein kinase B (Akt) which plays a key role in cell survival (Nelms, Snow et al. 
1998; Nelms, Keegan et al. 1999). 
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PI-3K also appears to be able to phosphorylate serine/threonine residues as well 
as the tyrosine residues involved in activation. Downregulation of this pathway may 
result from a negative feedback loop put into action by the ser/thr phosphorylation of 
IRS-1. 
Activated IRS-1/2 may alternatively (or also) bind to the adapter molecule, Grb2. 
This is constitutively associated with the nucleotide exchange protein SOS, which 
exchanges the GDP of inactive Ras, with GTP to activate Ras. Ras-GTP activates the 
serine/threonine kinase Raf, which triggers the cascade leading to the mitogen-activated 
protein kinases, ERK-1/2 in the Ras/MAPK pathway. These translocate to the nucleus to 
induce gene expression through phosphorylation of transcription factors in the nucleus, 
such as c-fos. The Jun nuclear kinase, JNK, as well as small GTPases are also Ras 
activated, which results in upregulation of gene expression through activation of 
transcription factors such as c-Jun. When c-Jun and c-Fos are activated, they 
heterodimerize to form the transcription factor complex AP-1, which upregulates genes 
involved in the entry of the cell into the cell cycle and proliferation and differentiation. 
The Ras/MAPK pathway is not consistently observed to be upregulated by IL-4 in all cell 
lines, and in fact IL-4 generally fails to activate the Grb-2 linked Ras/Mapk pathway 
(Satoh, Nakafuku et al. 1991). However, in keratinocytes, IL-4 induces IL-6 secretion 
through the rapid activation of p38 MAPK (Wery-Zennaro, Zugaza et al. 2000).  
The adapter molecule Shc, may also function to activate the MAPK pathway 
instead of IRS-1/2. This is a good example of the specificity of signaling being regulated 
in part by the particular molecules present in various cell types as this pathway was 
identified specifically in B cells and keratinocytes (Crowley, Harmer et al. 1996). Shc has 
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a PTB domain which links it to the IL-4 receptor, as well as an SH2 domain linking it to 
Grb2/Sos and the pathway described above. In B cells, Shc also functions as an adapter 
molecule in the BCR signaling pathway in which it has been found to associate with 
Grb2/Sos as well, perhaps resulting in cross-talk between pathways. Another adapter 
protein, Cbl appears to act in a similar manner to Shc in other cell types, such as T cells, 
although when hyperphosphorylated Cbl appears to act in an inhibitory manner (Nelms, 
Keegan et al. 1999). 
Downregulation of the Ras pathway may be provided by FRIP, or IL-4 receptor 
interacting protein, which is a homolog of p62dok(downstream of kinases), a previously 
discovered phosphoprotein found to bind to Ras-GAP. Phosphorylated FRIP associates 
with the IL-4Ra chain where it recruits and binds to Ras-GAP (GTPase activating 
protein), which catalyzes the conversion of Ras-GTP to inactive Ras-GDP. Thus, Ras-
GAP functions as an inhibitory protein of the Ras pathway. FRIP is expressed at high 
levels in T cells; however, it has not been shown to be expressed at high levels in B cells 
(Nelms, Snow et al. 1998). 
 
Stat6 
Upon binding of IL-4 to the IL-4receptor, JAK kinases become activated and 
phosphorylate tyrosine residues on the receptor alpha chain. Stat6 is recruited to the 
receptor alpha chain and binds to the cytoplasmic portion of the chain at specific residues 
via its SH2 domains when the chain is tyrosine phosphorylated on highly conserved 
residues Y575, Y603, or Y631. Stat6 then becomes phosphorylated on its C-terminal 
tyrosine residue, Tyr641, by the JAKs. This facilitates the disengagement of the Phospho-
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Stat6 (pStat6) from the receptor, which then dimerizes with another pStat6 monomer and 
activates a cascade that allows for the translocation of the Stat6 dimer to the nucleus. 
Here, it binds to specific DNA elements on IL-4 responsive genes identified by the 
recognition sequence TTC-N4-GAA (Quelle, Shimoda et al. 1995; Nelms, Snow et al. 
1998). 
As mentioned previously, Stat6 is a transcription factor unique to the IL-4 
pathway (it may also be active in the IL-13 pathway but evidence is conflicting) 
(Arinobu, Sugimoto et al. 2000; Andrews, Rosa et al. 2001). Its importance in mediating 
the effects of IL-4 has been illustrated in studies done with Stat6 deficient mice. Stat6 
was found to be required for the surface expression of MHC class II antigens as well as 
the IL-4 receptor and CD23. Lymphocytes from these Stat6 deficient animals failed to 
proliferate in response to IL-4 and B cells were unable to produce IgE. T lymphocytes 
failed to differentiate into Th2 cells in response to IL-4 or IL-13 (Kaplan, Schindler et al. 
1996; Mikita, Campbell et al. 1996; Peng, Moslehi et al. 1997). 
Regulation of the Stat6 pathway and the mechanisms by which Stat6 initiates 
transcription are still being elucidated. Natural deletion mutants, the result of alternative 
splicing of Stat6 transcripts, called Stat6b and Stat6c have been found in some cell types 
(Patel, Pierce et al. 1998; Hebenstreit, Wirnsberger et al. 2006). There is not much known 
about these, however, Stat6b contains an N-terminal truncation that still functions when 
dimerized with a full length Stat6. Stat6c contains a SH2 domain deletion which prevents 
dimerization with intact Stat6 molecules. This is hypothesized to be an inhibitory 
measure in the activation pathway, possibly only in mast cells (Patel, Pierce et al. 1998).  
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Activation of the Stat6 pathway upregulates gene transcription of the SOCS/CIS 
(cytokine induced SH2)/JAB (JAK binding)/SSI-1 (stat-induced stat inhibitor) family. 
These inhibitor proteins are specific for the JAK/Stat pathway. Socs-2 and Socs-3 have 
been shown to be induced by IL-4, while Socs-1 has an inhibitory effect on IL-4 
signaling, and may be the primary Socs inhibitor in this pathway (Losman, Chen et al. 
1999). The exact mechanism of action has not been worked out, but these proteins appear 
to function by inhibiting JAK activity by either binding to the JAK activation loop or by 
functioning as a block between the activated JAK and receptor. In addition, Socs proteins 
have a conserved Socs box motif located at their C terminus which appears to bind to 
elongin B and elongin C, molecules that target proteins to the proteasome for 
ubiquitination and degradation. Thus, a two-step model of inhibition has been proposed, 
first, inhibition of signaling by binding of Socs to activated proteins, and second, 
targeting of the signaling components for degradation. This system may also be the way 
in which inhibitory cross-talk between pathways is conducted (Greenhalgh and Hilton 
2001). To complicate matters further, another family of proteins, the Pim kinases, appears 
to be involved in regulating SOCS proteins in a positive manner. Whether the Pims 
protect the Socs from degradation or operate by a different mechanism remains unclear 
(Losman, Chen et al. 1999). 
Another family of proteins called protein inhibitors of activated STATs, or PIAS 
proteins, appear to be constitutively expressed in a number of cell lines. These are 
thought to act as buffers and bind to active STAT dimers and interfere with DNA binding 
activity, thus maintaining an equilibrium of available to unavailable STAT dimers (Hilton 
1999). The exact mechanism of action has not yet been determined, but it appears that the 
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methylation state of the STAT dimers influences PIAS’ binding activity. Inhibition of 
methylation enhances the ability of PIAS to bind to activated STATs and reduces their 
DNA binding capacity (Greenhalgh and Hilton 2001; Chen, Daines et al. 2004). 
As mentioned above, the IL-4Ra contains an ITIM, which also functions in an 
inhibitory capacity. In studies performed with a cell line exhibiting a mutated Y713 site 
in the IL-4Ra, Stat6 was found to be hyperactivated, showing both higher levels of 
phosphorylation and longer periods of activation. The effect of the mutated Y713 was not 
as dramatic on the IRS-1/2 pathway leading researchers to conclude that this was a 
regulatory measure functioning in gene expression, although they were unsure of the 
mechanisms involved (Kashiwada, Giallourakis et al. 2001). 
The STAT family of transcription factors shares a conserved overall structure 
which includes a central DNA binding domain, followed by a linker domain and the SH2 
domain. The carboxy-portions of the proteins contain a single phosphorylated tyrosine 
residue absolutely required for DNA binding activity. The C-terminal portion is also 
required for transcriptional activity but the mechanisms are still poorly understood. 
However, it has been demonstrated that the C-terminal transactivation domain is 
regulated independently of the DNA binding activity and that IL-4 induces signals that 
provide regulation at the transcriptional level. Recent evidence suggests that serine 
phosphorylation is one of the signals that acts on a transcriptional level. This appears to 
occur downstream of JAK activation and tyrosine phosphorylation of STAT, and is not 
regulated by the PI-3K regulated kinases such as Akt, PKC, or p70 S6 (i.e., the IRS-1/2 
pathway)(Pesu, Takaluoma et al. 2000). 
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It is possible that pStat6 dimers may upregulate the expression of IL-4 inducible 
genes by themselves, however, it is likely that they form complexes and interactions with 
other transcription factors activated through other signaling pathways. The promoter 
regions of IL-4 inducible genes contain several cis-acting elements and it appears that the 
cooperation between different transcription factors (TFs) is critical for efficient regulation 
of gene transcription. Stat6 appears to be the only TF that is functionally regulated by IL-
4, whereas the other factors are either regulated by costimulatory signals, as exemplified 
by CD-40 regulation of NF-KB, or other signaling pathways. Stat6 cooperates with other 
TFs through various mechanisms depending on the TFs involved. For example, C/EBP 
stabilizes the DNA binding of Stat6, while the interferon regulatory factor (IRF)-4 and 
NF-KB promote transcriptional activation and involve physical interaction with Stat6 
(Pesu, Aittomaki et al. 2002). 
Recent evidence obtained with gene chip analysis suggests that Stat6 not only 
cooperates with TFs from other pathways, but upregulates transcription factors at the 
transcriptional level which then function to modulate Stat6/IL-4 induced effects 
(Schroder, Pavlidis et al. 2002; Daines, Andrews et al. 2003). These factors include 
transcriptional repressors, such as Bcl-6, which is needed for germinal center formation 
in B cells. A lack of Bcl-6 results in an increase in Th2 mediated inflammatory responses. 
Krox20 is upregulated by Stat6 and has been found to be needed in the CD23 promoter 
for expression of CD23 in B cells. Other factors induced by Stat6 include NKIL3, IRFs 1 
and 4, Stat4, Bcl-3, and Xbp-1. The significance of these factors in IL-4 signaling has not 
yet been determined, although mice deficient in IRF-4 have profound defects in the 
 20
function of mature B and T cells (Schroder, Pavlidis et al. 2002; Hebenstreit, Wirnsberger 
et al. 2006). 
Stat6 may be activated in an IL-4 independent manner through the cross-linking 
of CD40. CD40 is a glycoprotein receptor on the surface of B cells that interacts with T 
cells (CD401igand) and mediates immune responses to monomeric protein antigens. 
CD40 engagement results in cellular activation, homotypic cell adhesion, proliferation, 
germinal center formation, rescue from apoptosis, and induction of the transcription 
factors NF-KB, NF-AT and AP-l. It also produces expression of Bcl-2 in germinal 
centers and (with IL-4) promotes survival of mature B cells and isotype switching 
(Karras, Wang et al. 1997). 
It appears that CD40-CD40L interaction plus IL-4 is necessary for the proper 
induction of isotype switching in B cells and CD23 expression (Siepmann, Wohlleben et 
al. 1996; Tinnel, Jacobs-Helber et al. 1998; Rush and Hodgkin 2001). Evidence for the 
necessity of this was provided when it was discovered that the contributory factors to 
hyper-IgM syndrome were mutations in the CD40L gene resulting in defective isotype 
switching (Siepmann, Wohlleben et al. 1996). CD40 induces B cell proliferation that may 
help drive isotype switching, and it also may open up the Ig locus for transcription of 
downstream isotypes and augment the responsiveness of the B cells to the effects of IL-4 
by helping to increase the level of the IL-4 receptor and modifying the way in which it 
signals. Preincubation of B cells with anti-CD40, and the subsequent addition of IL-4 
seems to result in "pathway switching" which may influence the way the IL-4 receptor 
signals (Siepmann, Wohlleben et al. 1996). Signaling through CD40 is not well 
understood but there is evidence for interaction with TRAF proteins, particularly TRAF3 
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in B cells (Basaki, Ikizawa et al. 2002), as well as JAK3 (Bacharier and Geha 2000; 
Zhang, Zhang et al. 2002). 
Further evidence for the necessity of CD40 cosignals in IL-4/Stat6 signaling 
comes from Pesu and colleagues (Pesu, Aittomaki et al. 2002) and their examination of 
p38 mitogen-activated protein kinase (MAPK), which is directly activated by CD40 
engagement and is responsible for activating downstream serine kinases. Inhibition of 
p38MAPK resulted in a block of CD23 expression in a Stat6 dependent manner. 
p38MAPK was not found to directly phosphorylate Stat6 in B cells, however it appears to 
regulate the unknown kinase that is involved in the serine-phosphorylation of Stat6 and 
its subsequent transcriptional activity. This then provides a link to CD4O and IL-4 
interaction and the transcriptional activity of Stat6. Zhang and colleagues (Zhang, Zhang 
et al. 2002) found similar results for the requirement of CD40 activated p38 MAPK in 
class switching to IgE. 
 
CD23 in B cell signaling and maturation 
 CD23 is the low affinity IgE receptor which participates in protective responses 
to helminthic parasites (Oettgen 2000). It is also a marker of B cell maturation and 
activation and is expressed on splenic Transitional 2 and mature B cells. CD23 is 
thought to participate with the survival factor BAFF (B cell activation factor of the 
TNF family) in maintaining the viability of these subsets (Hsu, Harless et al. 2002). 
Recent work has determined that when IgE is bound to CD23, antigen-capturing by B 
cells is enhanced which can lead to augmented immune responses (Oettgen 2000). High 
CD23 expression is a hallmark of B-chronic lymphocytic leukemia (Kneitz, Goller et 
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al. 2000) and with IgE, participates in inflammatory and allergic responses (Tinnel, 
Jacobs-Helber et al. 1998; Bacharier and Geha 2000; Oettgen 2000) 
CD23, exists in two isoforms (in humans) CD23a, which is exclusively 
expressed on B cells and CD23b, which is present on a variety of cells of the myeloid 
lineage as well (Kneitz, Goller et al. 2000). It is encoded by a single gene and is a type 
II membrane protein which has a cytoplasmic NH2 terminus and a extracellular region 
that shares a high degree of homology with C-type animal lectins such 
asialoglycoprotein receptors and rat mannose binding proteins (Richards and Katz 
1997). Tinnell et al. (Tinnel, Jacobs-Helber et al. 1998) studied the requirement for 
Stat6 in the upregulation of CD23. The results of their study showed that while Stat6 
enhanced the expression of CD23, it was not absolutely required. They did demonstrate 
the presence of other Stat family members, namely Stat3 and Stat5 that may act in a 
similar manner as Stat6 in the CD23 promoter region in the absence of Stat6. However, 
CD23 expression is a hallmark of IL-4 induced B lymphocyte development and 
activation and appears to be Stat6 dependent. 
Alignment of the CD23 and Ig-epsilon promoters reveal remarkable homology 
to each other with common response elements suggesting that a similar cassette of 
transcription factors is activated by IL-4, resulting in the enhanced expression of the 
two genes. This would make sense in light of the evidence that CD23 surface 
expression seems to regulate IgE responses in an inverse manner and would work in 
sync. Richards and Katz (Richards and Katz 1997) divided the Iε and CD23 promoters 
into 7 functional motifs. Motif 1 appears necessary for CD23 but not IgE induction 
although a binding element has not been identified. Motif 2 contains a consensus site 
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CCAAT/enhancer binding protein B (C/EBPB)', needed for IgE but not CD23. Motif 3 
is a Stat6 binding site required for both IgE and CD23. Motif 4 contains NF-κB binding 
sites in both the IgE and CD23 promoters and is required for both. Motif 5 is identified 
as a stretch of DNA required for CD23, but not entirely necessary for IgE. However, 
this runs into Motif 6 which has a NF-κB-like sequence in the IgE promoter and there is 
similarity between both promoters in this region. Motif 7 contains a B cell specific 
activator protein (BSAP or Pax5) region that is LPS sensitive and present in both 
promoters. It is not known whether this is a required site however, as evidence is 
conflicting, but BSAP appears to be constitutively active in B cells and is also activated 
by CD40. Thus it may help couple the IL-4/CD40 signals to transcription (Thienes, 
DeMonte et al. 1997). CD40 also appears to be responsible for the activation of NF-κB, 
possibly at both promoter sites and is required for synergy with IL-4 signaling (Iciek, 
Delphin et al. 1997). This is also found to be true in the Ig-gamma promoter region. 
Specificity may be obtained by the combination of NF-κB subunits (Warren and Berton 
1995). In fact, Messner and colleagues (Messner, Stutz et al. 1997) determined the 
composition of two NFκB complexes that were found in the IgE promoter. NFκB1 was 
of the classical type, or p50/p65. NFκB2 was comprised of p50/relB and appeared to be 
more functionally significant as an IL-4 response element. Alterations in regulation or 
function of many of these factors results in loss or expansion of B cell subsets and 
autoimmunity.  
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Isotype switching and IgE Production 
The process of IgE (and IgG;(Schaffer, Cerutti et al. 1999)) production by B 
cells involve germline ε (or gamma) transcript expression, IgE class switching (from 
IgM), clonal expansion of B cells, and differentiation into IgE-secreting plasma cells. 
These activities are controlled by a variety of cytokines in addition to IL-4, as well as 
direct cell-to-cell contact between B cells and T cells via CD40/CD40L(CD154). The 
first signal is cytokine dependent and activates transcription at a specific locus 
determining isotype specificity, and the second signal activates the recombination 
machinery. The second signal also upregulates CD80 (B7.1) on B cells which provides 
a counter signal to T cells via CD28 to upregulate IL-4 (Warren and Berton 1995; 
Bacharier and Geha 2000). 
The Ig heavy chain gene segments encode constant regions that rearrange by 
class switch recombination resulting in the production of other isotypes. Induction of 
isotype switching to a particular heavy chain region correlates with the transcriptional 
activation of that particular gene in the germline configuration. Induction of germline 
transcripts is necessary to target a switch region for recombination and switching. In the 
case of IgE class switching, IL-4 activates ε germline transcription through the tyrosine 
phosphorylation pathway to activate Stat6 and targeting the promoter region described 
above. Mice deficient in Stat6 fail to produce IgE in response to extracellular pathogens 
or IL-4/CD40 stimulus (Linehan, Warren et al. 1998). As mentioned previously, the 
germline ε promoter also contains binding sites for NF-KB, PU.1 and C/EBP 
transcription factors in addition to Stat6. PU.1 has been shown to be regulated via a 
separate pathway than Stat6. PKC-δ and PKC-ζ have been implicated in the IL-4-
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induced threonine phosphorylation of PU.1; possibly through the IRS 1/2 or Fes kinase 
pathway and the recruitment of PI3K. PKC activation does not appear to be required for 
CD23 expression however (Ikizawa, Kajiwara et al. 2001). 
Mao and Stavnezer (Mao and Stavnezer 2001) have provided conflicting 
evidence for the necessity of the presence of C/EBP in the murine ε germline promoter. 
They have demonstrated through the use of electrophoretic mobility shift assays 
(EMSA), that AP-1 binds to the putative C/EBP binding site instead. Functional 
evidence suggests a synergy with Stat6 in transcriptional activation, while C/EBP shuts 
down promoter activity in reporter gene assays. CD40 has been shown to upregulate c-
fos, FosB, JunB and JunD providing the subunits necessary for AP-1 heterodimer 
formation, which in this case appears to be cFos/JunB. They have not ruled out the 
possibility of C/EBP acting as a regulatory molecule in this promoter site. Interestingly, 
their evidence supports the presence of C/EBP in the human ε germline promoter, 
identifying a possible area of divergence between human and mouse systems. How AP-
1 and Stat6 interact has not yet been determined. 
Less is known about the negative regulation of transcription and class switch 
recombination. Bcl-6, a transcriptional repressor upregulated by IL-4/Stat6 competes 
for Stat6 at the Stat6 binding site and can attenuate transcription (Oettgen 2000). 
Interferon-gamma induces the activation of Statl, which also competes with Stat6, 
possibly providing the mechanism by which Thl cells modify Th2 responses (and vice 
versa). Recently, another transcriptional regulator has been described by Monticelli and 
colleagues (Monticelli, Ghittoni et al. 2001), Myb, a member of a protein family known 
to be cell cycle sensors, was shown to overlap the Stat6 binding site of the ε promoter 
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and compete with Stat6, suppressing ε gene expression in reporter assays. Myb has 
been shown to interact with nucleolin, a protein important in the CSR machinery, thus 
it has been proposed that Myb may physically bridge the products of transcription and 
the recombination machinery (Ying, Proost et al. 2000). How it actually functions to 
repress transcription is currently unknown. 
CD45, via its function as a Janus kinase phosphatase, directly dephosphorylates 
JAKl and JAK3, thus regulating IL-4 signaling and has a direct impact on class 
switching by preventing the phosphorylation of Stat6. CD45 is present at all stages of B 
cell development and has emerged as a potentially important regulatory molecule in the 
negative regulation of cytokine signaling (Yamada, Zhu et al. 2002). It is thought to 
also be important in B cell development as CD45-/- B cells have a developmental block 
in the transition from T 2 to mature follicular FO cells (Monroe and Dorshkind 2007). 
The CTLA-4 receptor has been widely described in T cells as having a 
pleotropic inhibitory effect on activated cells. Less is known about the receptor in B 
cells. Pioli and colleagues (Pioli, Gatta et al. 2000) found that this receptor is present on 
the cell surface and in intracellular compartments at a level comparable to T cells in IL-
4 and CD40 activated B cells. Furthermore, CTLA-4 engagement inhibits IgGI and IgE 
production and limits the number of IgG+ and IgE+ cells. This is probably 
accomplished in a few ways. CTLA-4 inhibits NFκB activation by counteracting the 
degradation of IκBa in B cells. It may also activate SHP (phosphatase) activity, thus 
inactivating Stat6 (or not allowing activation). It is speculated to have a counter-
regulatory role to CD40 in germinal centers thus influencing the Thl/Th2 polarization 
as blockage of CTLA-4 accelerates a typical type 2 response. These effects are 
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mediated through costimulation by CD80 or CD86, which may be provided by other B 
cells or APCs. It is interesting to note that CTLA-4 engagement does not affect CD23 
expression suggesting that CD23 may require less stringent conditions for expression, 
may be regulated differently or it may be a function of timeliness of activation (Pioli, 
Gatta et al. 2000). 
IgE is believed to be one of the major mediators of immediate hypersensitivity 
reactions that underlie atopic conditions such as urticaria and eczema, seasonal allergy, 
food allergy, asthma, and anaphylaxis (Tachibana, Kubo et al. 2001). A mutant Stat6 
molecule was identified that may be one mechanism by which IgE is upregulated in an 
abnormal manner. The mutant Stat6 has two mutations in the SH2 domain that rendered 
it transcriptionally active even in the absence of IL-4 signaling, was JAK independent 
for phosphorylation, was resistant to degradation by proteolysis and exhibited an 
enhanced DNA binding capacity. Other constitutively active forms of Stats have been 
identified as well, which have been associated with pathological conditions. Gain-of 
function polymorphisms in the IL-4 gene as well as the IL-4 receptor alpha chain have 
been shown to be associated with higher serum IgE levels and asthma, hence this may 
result in a similar phenotype as IgE is Stat6 dependent (Daniel, Salvekar et al. 2000). IL-
13 shares many similarities with IL-4 perhaps mediated by the sharing of the IL-4Ra, 
along with IL- 13Ra, as the functional IL-13 receptor. Andrews (Andrews, Rosa et al. 
2001) and colleagues have recently explored the observation that murine B cells are 
relatively unresponsive to IL-13. This was apparently due to the lack of expression of IL- 
13Ra1. The functional effect of this was an observed variation in IgE levels in 
experimental systems depending upon treatment with IL-13. This led them to the 
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conclusion that IL13Ra may be expressed at various stages of development of B cells and 
may help to clarify the overlap between IL-4 and IL-13 signaling (Andrews, Rosa et al. 
2001). 
The "final" step in B cell differentiation is conversion to either a memory cell or 
an antibody secreting plasma cell. Recent research has focused on a transcription factor 
known as a transcriptional repressor that appears to be a "master switch" in terminal 
differentiation and exerts an influence on many of the factors discussed above. IL-4 has 
been shown to repress the expression of B lymphocyte-induced maturation protein-1 or 
BLIMP-1, which appears to broadly inhibit gene expression programs controlling mature 
B cell functions, such as switch recombination, and those driving proliferation (Kallies 
and Nutt 2007). Among many of the transcription factors found to be influenced by 
BLIMP-1 are Stat6, Pax5, and Bcl-6 (Schebesta, Heavey et al. 2002). Bcl-6 and BLIMP-
1 are thought to antagonize the actions of each other, particularly in germinal centers, 
where Bcl-6 is highly expressed. Thus, when Bcl-6 is active, cells undergo differentiation 
and proliferation, when Bcl-6 becomes downregulated, BLIMP-1 expression rises and 
cells become plasma cells. How this process actually occurs is unknown, but it may be 
the result of somatic mutations causing the affinity of the BCR to become greater and 
creating some kind of threshold that leads to loss of Bcl-6 and subsequent upregulation of 
BLIMP-1 (Shaffer, Yu et al. 2000). At first glance this seems to contradict information 
presented above. However, work completed in the lab of Paul Rothman and colleagues 
(Harris, Chang et al. 1999) has fine-tuned the role of Bcl-6 in B cells to be a co-regulator 
of IgE production which is expressed selectively to control the amount of IgE actually 
secreted. Thus, when a certain level of transcription has occurred in the IgE promoter, 
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i.e., a threshold, it would be active to shut down transcription. Since 30% -40% of diffuse 
large-cell lymphomas have Bcl-6 gene rearrangements, it would seem that Bcl-6 is an 
important regulator of B cells (Harris, Chang et al. 1999). Considering the wide ranges of 
influence BLIMP-1 and IL-4 have, other regulatory factors are likely to come into play as 
well (Knodel, Kuss et al. 2001; Shaffer, Lin et al. 2002). 
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Protective effects of IL-4 on cell survival 
In 2000, the lab of Fred Finkleman reported the results of experiments done in a 
murine model which demonstrated that IL-4 promoted a dramatic increase in splenic B 
cells due to the migration of B cells into the spleen as well as increased splenic B cell 
survival. This was shown to be a Stat6, CD4+T cell, and FcyRII/III independent process 
but that it was IL-4R dependent (Mori, Morris et al. 2000). Numbers of mature blood and 
bone marrow B cells decreased, giving credence to this being a redistribution of B cells, 
and they were able to show that it did not depend on the production of new B cells in the 
spleen. There were no observable losses of B cells from lymph nodes, Peyer's patches or 
intestinal lamina propria. They have proposed that the mechanism of action is a retention 
of B cells in the spleen by the possible upregulation of an adhesion molecule or the loss 
of a molecule required for exit from the spleen as B cells normally migrate to the spleen, 
however, this does not account for the reduced number of mature B cells in the bone 
marrow (enhanced migration out of the bone marrow). They also exhibited an increase in 
the survival of splenic B cells, determined by the presence of a decrease in B cell 
expression of HSA, a cell marker that helps to identify the maturity of B cells. Hence, a 
decrease in HSA indicates an increase in B cell age. There was no mechanism of action 
offered for this process (Mori, Morris et al. 2000). 
The protective effects of IL-4 on cell survival, such as prevention of cell death by 
neglect after growth factor withdrawal and rendering activated cells insensitive to Fas 
ligation, is an active area of research and has been mentioned previously. In contrast to T 
cells (Zamorano, Mora et al. 2001), IL-4 mediated protection from cell-death in B cells 
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appears to be Stat6 dependent and not directly dependent on IRS-2 activation or Akt 
activation. Stat6 has been shown to be directly responsible for the upregulation of IL-4 
induced transcription of an anti-apoptotic factor, Bcl-xL, which is antagonistic to pro-
apoptotic stimuli. This is thought to function by preserving mitochondrial membrane 
integrity and prevent the release of cytochrome C into the cytoplasm. This doesn't answer 
the whole question however, as the protection offered from overexpression of Bcl-xL was 
only ~50%, leading researchers to believe that there are other as yet undiscovered 
pathways and factors that may be responsible for the IL-4 induced protective effects in B 
cells (Zamorano, Mora et al. 2001; Wurster, Withers et al. 2002; Carey, Semenova et al. 
2007).  
One of these undiscovered pathways of IL-4/Stat6 mediated cell-survival may 
have recently been delineated by Thomas Chiles group at Boston College (Dufort, 
Bleiman et al. 2007). They discovered that IL-4 increases glucose transport and 
glycolysis in B cells through a Stat6 dependent mechanism that was independent of IRS-
2 and PI3K activity. This effectively links glucose metabolism and apoptosis;  if glucose 
metabolism is impaired, mitochondrial membrane integrity becomes impaired, triggering 
apoptosis. Thus, in Stat6 deficient B cells, IL-4 induced glycolysis is significantly 
reduced as is primary B cell viability.  
Finkelman and colleagues (2002) have found evidence to support the Stat6 
dependence of IL-4 conferred protection in B cells specifically working with autoreactive 
B cells. They also confirmed evidence that this mechanism is Stat6 independent in T 
cells, therefore appears to be regulated differently, but a mechanism for this was not 
offered (Morris, Dragula et al. 2002). Previous work done by Erb et al (Erb, Ruger et al. 
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1997) suggested that IL-4 did not prevent deletion of autoreactive B cells, but, 
Finkelman’s group, working with soluble, oligovalent self-antigen instead of particulate, 
multivalent antigen used by Erb and colleagues, found that the ability of IL-4 to prevent 
Ag-induced B cell deletion decreases as the intensity of the Ag-induced mIg cross-linking 
increases. Thus, IL-4 might inhibit the deletion of B cells that are specific for soluble, 
oligovalent self-Ags that are present at low concentration, but not prevent the deletion of 
B cells specific for polyvalent cell membrane Ags. This appeared to be dependent on the 
concentration of IL-4 as well. They found that as the amount of IL-4 increased, the 
protective effects increased even as the intensity of the stimulus required for deletion 
increased (Morris, Dragula et al. 2002). There has been uncertainty of the role of IL-4 in 
autoimmunity, as it is difficult to evaluate the local concentrations that cells may be 
exposed to. However, finding that IL-4 can aid in the survival of autoreactive B cells, and 
that IL-4 deficient MRL/Mp-lpr/lpr mice show reduced autoreactivity (Peng, Moslehi et 
al. 1997), as well as the evidence that IL-4 transgenic mice show increased autoreactivity 
(Erb, Ruger et al. 1997) give credence to the notion that overexpression of endogenous 
IL-4 can drive autoimmunity in susceptible animals.  
IL-4 also seems to have a protective effect on T cells but the picture is foggier 
than it is for B cells. Past research has shown that when pathways that promote cell 
survival are activated, cells can be pushed to differentiate into Th2 cells. This also 
apparently works in reverse as Th2 differentiation appears to result in resistance to 
apoptosis. The mechanisms involved in these processes are likely to be regulated by 
caspases, as there is a role for caspase activation in T cell development, proliferation and 
differentiation. When caspases were inhibited with a pan-caspase inhibitor, T cells were 
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found to produce IL-4 and differentiate into Th2 cells independently of Stat6 (Sehra, 
Patel et al. 2005). This may explain the increase in Th2 differentiation and IL-4 
production in Bcl6 and Stat6 double knock out mice. When Bcl6, a transcriptional 
repressor, is knocked out in mice, they develop a Th2-type inflammatory disease. When 
Stat6, a transcription activator (and repressor, depending on conditions) (Kelly-Welch, 
Hanson et al. 2005), is also knocked out, mice develop an even more severe Th2-type 
inflammatory disease (Linehan, Warren et al. 1998). Since Bcl6 functions to inhibit or 
downregulate the Th2 program, its absence allows for the unregulated expansion of Th2 
cells. The additional loss of Stat6 and its contribution to the regulation of IL-4 later in 
activation, allows for that expansion to become uncontrolled and uninhibited by any Stat6 
regulated repressive measures. Interestingly, the same condition ensues in CTLA-4 and 
Stat6 double knock-out mice (Bour-Jordan, Grogan et al. 2003; Kelly-Welch, Hanson et 
al. 2005).  
 
Stat6 Related Pathology 
Recently, Stat6 has been implicated in the pathology of tumors, 
lymphoproliferative diseases, and autoimmunity, as well as the previously recognized 
contribution to asthma and allergy. A gain-of-function mutation in Stat6 was identified 
by Daniel et al (Daniel, Salvekar et al. 2000) that allowed for a constitutively active and 
more stable form of Stat6 to signal for an increase in IgE production that could lead to 
atopic and asthmatic conditions. More recently, Stat6 was found to be constitutively 
activated in primary mediastinal large B-cell lymphomas as well as certain types of 
prostate cancers which resulted in the abnormal proliferation of cells (Guiter, I. et al. 
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2004.; Bruns and Kaplan 2006). The activation of Stat6 was IL-4 independent in these 
cancers but it was unclear what contributed to it. A lymphoproliferative disorder was 
recently found in mice expressing a constitutively activated Stat6 in T cells which was 
characterized by splenomegaly due to an increase in B cells and increased Th2 activity 
(Kaplan, Sehra et al. 2007). Thus, aberrantly activated Stat6 has been implicated in a 
number of pathological conditions associated with or without IL-4 signaling.  
A mutant Stat6, engineered to be constitutively active in lymphoid cells of mice 
on a C57BL/6 background, was found to have differing effects on B and T cells. There 
was an increase in peripheral B cells and  in production of IgG1 and IgE. However, even 
though the B cells had an upregulation of IL-4/Stat6 regulated genes, they did not possess 
an activated phenotype as they did not proliferate differently than WT B cells and were 
not larger in size (Bruns, Schindler et al. 2003). In contrast, T cells did have an activated 
phenotype as they were larger than WT and had increased percentages of 
CD62LPloP/CD44PhiP cells. In addition, T cells had much greater proliferation than WT cells, 
but an overall reduction in population due to increased apoptosis.  
Many groups have studied the effects of Stat6 deficiency in different model 
systems. Jacob et al (Singh, Saxena et al. 2003) created a Stat6 deficient NZM 2328 
strain of mice. NZM 2328 mice develop spontaneous systemic autoimmunity with altered 
serum immunoglobulins, autoantibodies and glomerulonephritis. The Stat6 deficient 
version of this model secreted very little IL-4, had a significant reduction in the level of 
IgG1, did not upregulate CD23 or MHC II but showed no change in the numbers of 
splenocytes or distribution of B and T cells. Stat6 deficient NZM 2328 mice showed a 
significant delay in kidney disease and a decrease in proteinuria and a significantly 
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prolonged life span. The level of overall Ig was similar and they showed evidence of 
autoantibodies, but they were of the IgG2a isotype instead of IgG1(Singh, Saxena et al. 
2003).  
Xu et al (Xu, Duan et al. 2006) also produced a Stat6 deficient version of a lupus-
prone mouse designated B6.TC, which is a congenic derivative of the autoimmune-prone 
IL-4-producing NZM2410 strain. This Stat6 deficient model displayed a significant 
decrease in spleen cellularity including a reduction in the percentage of effector/memory 
T cells and a decrease in B cell activation, and the restoration of abnormal follicular 
architecture. They also had a decrease in IgG levels, with the largest decrease in IgG1, as 
well as a decrease in anti-chromatin and anti-DNA antibodies. There was a reduction in 
the severity of glomerular disease and proteinuria, and an increase in survival. In contrast 
to a Stat6 deficient NZM2410 parental strain, IL-4 production was largely unchanged by 
Stat6 deficiency in the B6.TC, however, the Stat6 intact B6.TC produced low levels of 
IL-4 to begin with.  
Singh et al.(Singh, Saxena et al. 2003) developed a Stat6 deficient strain of NZM 
2410 mice, which in the Stat6 sufficient version overproduce IL-4 (due to unknown 
causes) and develop severe glomerulosclerosis, have an increase in IgG1 and IgE and 
produce anti-DNA autoantibodies. NZM2410 Stat6-/- mice have a significant decrease in 
IL-4 and IgE production, a decrease in proteinuria and kidney disease, an increase in 
IgG2a, but show no change in the level of anti-DNA antibodies. When these same Stat6 
deficient animals are treated with a neutralizing antibody to IL-4 (11B11) they also show 
a decrease of serum IgG1 and IgE, a decrease in proteinuria and glomerulosclerosis, but 
an increase in serum IgG anti-DNA antibodies of the IgG1 and IgG2a isotypes. Thus, it 
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appears that Stat6 plays a pivotal role in maintaining immune homeostasis under normal 
physiological conditions, and can drive autoimmune pathology in an abnormally 
activated state, or ameliorate symptoms when inhibited.  
 
Autoantibodies and Renal Disease 
It seems that one of the most debated areas of autoimmune research is the role 
that autoantibodies play in contributing to the pathology, particularly in the renal disease 
commonly associated with SLE and other systemic autoimmune syndromes. The 
evidence is often conflicting. In some systems autoantibodies appear to play a very 
limited role in pathology (Morris, Dragula et al. 2002), or a commonly considered 
“pathogenic” antibody such as IgG2a may be elevated but there is decreased renal disease 
(see above, (Singh, Saxena et al. 2003), or there may be a decrease in renal disease but an 
overall increase in levels of anti-DNA autoantibodies (Singh, Saxena et al. 2003). A 
recent report by Bizzaro (Bizzaro 2007) analyzed levels of autoantibodies in prospective 
studies of humans and found the presence of anti-nuclear antibodies (ANA), anti-dsDNA 
antibodies and many antibodies to cytoplasmic and cell-specific antigens to be predictive 
of the development of autoimmune disease. Thus, it is difficult to establish the exact role 
autoantibodies play in any given system, however, there is a strong and consistent 
correlation with an elevation of self-reactive antibodies  and the presence of autoimmune 
disease (Fields and Erikson 2003; Wardemann, Yurasov et al. 2003; Woetmann, 
Brockdorff et al. 2003; Yung and Chan 2008).  
The generation of B and T cells with self-reactive specificities is a well-accepted 
result of the need for the immune system to react to a wide-range of antigenic stimuli. In 
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normal development, these self-reactive cells should be deleted as they pass through a 
number of tolerance checkpoints in place in the immune system for regulation of 
autoreactivity. If these cells are erroneously allowed to survive and become activated the 
B cells can move on to produce self-reactive antibodies with or perhaps even without the 
help of self-reactive T cells depending on the stimuli (Fields and Erikson 2003). When 
these antibodies circulate throughout the body, they can react and bind to the cellular 
antigens of their specificity and form immune complexes. These complexes can block 
tiny capillaries and induce an inflammatory response, which signals other immune cells 
to enter the area, leading to the enhancement of inflammation, cell proliferation, tissue 
remodeling, scarring and the production of inflammatory cytokines that can cause direct 
damage to cells and tissues. This is particularly true in the glomeruli of the kidney, with 
its complex network of capillaries needed to filter blood. As the capillaries become 
damaged they become “leaky” and protein leaks from the serum into the urine. 
Progressive disease severity then, is often accompanied by increasing proteinuria. 
Immune complex deposition can be clearly seen in a number of mouse models of 
autoimmunity, and when the antibodies are eluted, they have been shown to be specific 
for a number of nuclear as well as cytoplasmic antigens (Daikh 2001; Bagavant, 
Deshmukh et al. 2006).  
It has become increasingly clear recently that the presence of immune complex 
deposition alone is not enough to drive renal disease, but that the numbers and type of 
cellular infiltrates present in the glomeruli and surrounding area make a difference in the 
severity and type of disease that is manifested. T cells have been shown to play a large 
role in driving the progression of renal disease from acute GN to chronic GN and renal 
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failure. During a longitudinal study of kidney disease in NZM 2328 mice T cell 
infiltration into the glomeruli and surrounding area resulted in an increase of disease 
severity and loss of renal function. The presence of dendritic cells and macrophages were 
thought to activate these self-reactive T cells and form a localized immune response. This 
was preceded by the presence of immune complex deposition and inflammatory 
cytokines which helped to recruit inflammatory cells into the area. (Bagavant, Deshmukh 
et al. 2006).  
Several different types of glomerular disease have been identified but there does 
not appear to be a clear one-to-one relationship between the potential cause of damage 
and the type of disease that will occur. There are basically five clinical syndromes 
associated with nephropathy, which can be acute or chronic, and much overlap between 
categories. The patterns of glomerular damage are also varied and there is as yet no clear 
association between a particular genetic background or Th1 vs Th2 skewing of the 
immune system with a particular type of damage. There is evidence, however, that 
exaggerated activity of both Th1 and Th2 type responses can lead to equally severe 
disease.  
The importance of renal pathology in the study of autoimmune disease is multi-
fold. Current therapies have decreased the high mortality rate associated with renal 
failure in humans with autoimmune disease but quality of life still remains an issue. For 
researchers and clinicians the ability to measure protein in the urine has been helpful as a 
non-invasive marker of disease progression when there are so few consistencies present 
otherwise (Daikh 2001; Dong, Wang et al. 2007). The presence of renal disease appears 
to be a constant despite the differing genetic backgrounds and systems used for studying 
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autoimmunity and for researchers provides a way to evaluate potential therapies and/or 
genetic manipulations.  
The current model of autoimmune development is a three-step process involving 
hyperactivation, dysregulation of the immune response leading to continued stimulation 
and the subsequent development of pathogenic inflammatory responses. Since IL-4 
functions to induce B cell activation and isotype switching to IgG1 and IgE through a 
Stat6-dependent pathway, and is thought to contribute to autoimmunity through antibody 
dependent and independent mechanisms as well (Singh, Saxena et al. 2003), Ttc7Pfsn/fsnP is 
a useful model to study B cell activation and IL-4 production as they relate to systemic 
autoimmunity and disease.  
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AIMS AND HYPOTHESIS 
 
One of the hallmarks of Ttc7Pfsn/fsnP mice is the dramatic increase in IL-4 
production. In addition, Ttc7Pfsn/fsnP mice have hyperactivated B cells as has been 
demonstrated by their increased size, upregulation of MHC II, increased production of 
serum Ig, especially IgE, and increased proliferative response to mitogens. Ttc7Pfsn/fsnP T 
cells have also been shown to hyper-proliferate in vitro although less has been done to 
characterize their phenotype. The transcription factor, Stat6, is a signaling molecule 
unique to the IL-4 signaling pathway and indispensable for IgE expression. Preliminary 
work determined Stat6 to be constitutively expressed in Ttc7Pfsn/fsnP B cells. Thus, the aims 
of this study were to: 
• Evaluate IL-4 signaling through Stat6 via the activation and functional responses 
of Ttc7Pfsn/fsnP B cells  
• Evaluate the activation of and IL-4 production in Ttc7Pfsn/fsnP T cells   
• Determine the contribution of IL-4 and Stat6 to the pathology of Ttc7Pfsn/fsnP mice. 
 
We hoped to provide insight into our hypothesis that the Ttc7PfsnP mutation results 
in the hyperactivation of lymphocytes which leads to the overproduction of IL-4 and 
systemic pathogenic autoimmunity.  
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MATERIALS AND METHODS 
 
Mice 
Mice were maintained and bred in our barrier and specific pathogen-free research 
animal quarters at the University of Southern Maine. Mice used in these studies were 4-
10 weeks of age. Flaky skin mice (Ttc7Pfsn/fsnP) and normal littermate controls (WT) were 
produced from breeding pairs of Ttc7 heterzygotes originally purchased from The 
Jackson Laboratory, (Bar Harbor, Maine) and have been maintained on a BALB/c 
background at our facility since 2001. Mice were maintained in HEPA filtered 
polycarbonate cages, fed irradiated Harlan-Teklab Rodent diet with food and water 
available ad libitum. The facility strictly adheres to PHS guidelines for animal care and 
use; all protocols were reviewed and approved by the USM Institutional Animal Care and 
Use Committee.  
Genotyping for breeding pairs was performed in a two-part PCR reaction to detect 
the presence of Ttc7 WT and Mutant (fsn) alleles. To detect the WT allele a reaction 
mixture of 5x reaction buffer, 25mM MgCl2, 2.5mM dNTPs, 10µM each of primer E15R 
and primer I14F, 5% DMSO, 5U/µL Flexitaq DNA polymerase, 1µL genomic DNA and 
dH2O in a 24 µL volume was reacted in a thermacycler under the following conditions: 
95C for 2 minutes, then 94C for 30 seconds, 65C decreasing to 58C for 30 seconds, 72C 
for 30 seconds for a total of 14 cycles, and 94C for 30 seconds, 60C for 30 seconds and 
72C for 30 seconds for a total of 25 cycles.  The reaction ended with a final elongation 
cycle of 72C for 5 minutes. Primers to detect the WT allele included E15R: 
GAAGAGCAGCGCTAGCAAGT and I14F: ATGGCTTCCTTGGCCATGAT.  
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To detect the Ttc7 mutant allele a reaction mixture of 5x reaction buffer, 25mM 
MgCl2, 2.5mM dNTPs, 10µM each of primer I14F and ETnR, 5% DMSO, 5U/µL 
Flexitaq DNA polymerase, 1µL genomic DNA and dH2O in a 24 µL volume was reacted 
in a thermacycler under the following conditions: 95C for 2 minutes, then 94C for 30 
seconds, 68C decreasing to 60C for 30 seconds, 72C for 1 minute for a total of 16 cycles, 
and 94C for 30 seconds, 61C for 30 seconds and 72C for 1minute for a total of 30 cycles.  
The reaction ended with a final elongation cycle of 72C for 5 minutes. Primers to detect 
the mutant allele included I14F: ATGGCTTCCTTGGCCATGAT and ETnR: 
GCCAGCAGCTCGACGTGAA. 
 
Generation of Stat6-/- x Ttc7 mice  
Stat6 deficient (Stat6Ptm1GruP) breeding pairs were purchased from The Jackson 
Laboratory (Bar Harbor, Maine) and maintained in our barrier facility at the University of 
Southern Maine. Offspring were crossed with Ttc7 heterozygotes (Ttc7+/fsn) produced in 
our facility. The resulting Stat6+/- x Ttc7+/fsn double heterozygote was backcrossed to a 
Stat6 (Stat6-/-) deficient Ttc7 WT homozygous (Ttc7+/+) animal resulting in one-quarter 
of the offspring having a Stat6 deficient Ttc7 heterozygous genotype (Sta6-/-Ttc7+/fsn). 
These Stat6-/- x Ttc7+/- individuals were intercrossed to produce Stat6-/- x Ttc7Pfsn/fsnP 
animals for study. All animals were maintained on a BALB/c background. Genotypes 
were confirmed by PCR for both the Stat6 ( protocol and primer sequences: 
Uhttp://jaxmice.jax.org/pub-
cgi/protocols/protocols.sh?objtype=protocol&protocol_id=218U) and Ttc7 genes for 
breeding as well as to confirm genotype of the animals used for study.  
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Evaluation of Stat6 Activation 
Splenocytes were isolated from Ttc7Pfsn/fsnP and normal littermate control mice by 
filtering freshly excised spleens through a nylon mesh biopsy bag (Anatomical Pathology 
USA, Pittsburgh PA) and enriched for the lymphocyte population by density gradient 
centrifugation with Lympholyte-M (Cedarlane, Ontario, Canada) following the 
manufacturer’s recommended protocol. Lymphocytes were incubated with 10 ng/mL 
mouse rIL-4 for 0-30 minutes as indicated in the results and equal numbers of cells per 
sample were lysed with 0.5% (m/v) SDS, 0.05M Tris-HCl, 0.2 mM NaVOB4B, 1 mM DTT 
and 2 µg/mL Protease Inhibitor Cocktail (Sigma), pH 8.0, and resolved by 8% SDS-
PAGE. The gel was electrophoresed to a PVDF membrane (Immulon-P, Millipore, 
Bedford, MA) in Tris-glycine buffer (25 mM Tris, 0.2M Glycine, 20% methanol, pH 8.5) 
for 2 hours at 75V with cooling and the membrane was blocked with 8% milk in TBS. 
Immunoblotting was performed using an anti-phosphoStat6 (pStat6) antibody (Cell 
Signaling Technologies, Beverly MA) at a dilution of 1:2500, incubated 2h at room 
temperature followed by washing 3 x 15 minutes with TBS (Tris-buffered saline) 
containing 0.05% Tween-20 (TBST). Horseradish peroxidase-conjugated goat anti-
mouse IgG (Southern Biotechnology Associates Inc, Burlingham AL) was diluted 
1:20,000 and incubated 2h followed by washing with TBST. Blots were developed with 
the Super Signal Chemiluminescence Detection System (Pierce, Rockford, IL). 
Chemiluminescence was detected using a Kodak 440CF Image station (Kodak Scientific 
Imaging Systems, Rochester, NY).  
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Immunoprecipitation was performed with rIL-4 (10 ng/mL, R&D Systems) 
stimulated and unstimulated splenocytes enriched as above. Stat6 was 
immunoprecipitated from 5 x 10P6P cells using anti-Stat6 (clone S-20, Santa Cruz 
Biotechnology Inc, Santa Cruz, CA) coupled to the gel component of the Seize Primary 
Mammalian Immunoprecipation Kit (Pierce, Rockford, IL) as instructed by the 
manufacturer. Samples were eluted from the immunoprecipitation columns and resolved 
and transferred to membranes as described above. Immunoblotting and detection were 
performed as above, first with the anti-pStat6, and then re-probing with the S-20 Stat6 
following stripping the blot with 0.2M NaOH and re-blocking. Analysis of pStat6 levels 
and pStat6/Stat6 ratios were performed using Kodak ID analysis software (Kodak 
Scientific Imaging Systems) (Welner, Hastings et al. 2004). 
Previously published as:  Welner, R. W. Hastings, Beth L. Hill and Stephen C. Pelsue. 
(2004). “Hyperactivation and Proliferation of Lymphocytes from the Spleens of Flaky 
Skin (fsn) Mutant Mice.” UAutoimmunityU 37(3): 227-235. 
 
B- and T-lymphocyte enrichment 
Splenic lymphocytes were enriched using a murine B-lymphocyte or T-
lymphocyte negative selection kit (StemCell Technologies, Vancouver, BC, Canada) 
according to manufacturer’s instructions. Briefly, mice were freshly sacrificed and 
spleens removed for analysis, a cell suspension was then obtained by filtering though a 
nylon mesh biopsy bag (Anatomical Pathology USA, Pittsburgh PA), followed by 
Lympholyte-M (Cedarlane, Ontario, Canada) density gradient isolation of total 
lymphocytes as instructed by the manufacturer. Approximately 1.0x10P8P cells/mL of 
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purified lymphocytes were then labeled with an antibody cocktail for the enrichment of 
B- or T-lymphocytes. After completing a wash of the cell suspension, the cells were 
labeled with the tetrameric complex and the magnetic colloid, then run over a gravity 
feed column in line with a magnet. The cells collected from the flow-through were 
washed and counted. Enrichment was approximately 85% to 95% for B- or T-
lymphocytes as determined by flow cytometry (data not shown).  
 
Stat6 Analysis in B lymphocytes 
B cells were counted on a hemocytometer using the trypan blue exclusion method 
to monitor cell viability and 2.0x10P6P cells used per sample. Cells for the Stat6 activation 
experiment were stimulated with mIL-4 (R&D Systems) at (10ng/mL) for 15 or 30 
minutes, or left unstimulated (0 min). Cells were then washed and stained as described 
below. 
Cells for the Stat6 deactivation experiment were stimulated for 30 min with mIL-
4. The samples were then washed and processed for staining either immediately after 
stimulation (0 min) or allowed to incubate for 15 or 30 minutes prior to analysis.  
Purified, stimulated or unstimulated, cells were fixed in a 4% 
paraformaldehyde/0.1M phosphate buffer/0.03M sucrose solution for 20 min and washed 
2X with PBS/1% BSA. Cells were then permeabilized with a 0.2% saponin/PBS/0.03M 
sucrose/1%BSA solution for 5 min, washed 2X 5 min with PBS/1% BSA, blocked for 15 
min with 5% rat serum in PBS/1%BSA followed by one wash. Cells were then stained 
for 60 min with an antibody specific for Stat6 (S-20, Santa Cruz Biotechnology) at 1:200 
dilution, a secondary antibody specific for anti-rabbit conjugated with PE at 1:500 
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(Biosource International, Camarillo, CA) and finally Sytox green (1.0 µM, Molecular 
Probes, Eugene, Oregon) to identify the nucleus. Following a final spin the cell pellet was 
suspended in Fluoromount-G (Southern Biotechnology, Birmingham, Al), dropped onto 
14mm 3-well slides (Erie Scientific Co), covered with a cover slip and sealed with nail 
polish. Cells were visualized by laser scanning confocal microscopy (Olympus FV300, 
Melville, NY), capturing multiple images per sample. Each experiment was repeated 
three times with separate mice.  
 
Immunofluorescent Staining of Spleen Sections  
Spleens of 8-week-old WT and Ttc7Pfsn/fsnP mice were frozen with liquid nitrogen 
and kept at –70°C until needed. Frozen spleens were embedded in Cryomatrix Frozen 
Specimen embedding medium (Shandon, Pittsburgh, PA), then sectioned into 8µm 
sections (Cryotome, Shandon) and laid onto slides charged with poly-l-lysine (Sigma 
Diagnostics, St Louis, Mo). Slides were fixed for 10 min with ice-cold acetone, dried for 
10 min and frozen at -70°C. After warming to room temperature and rehydrating in PBS, 
slides were first blocked with 5% rat serum/PBS/0.1% Tween, and with 
Streptavidin/Biotin Blocking Kit (Vector Laboratories, Burlingame, CA, USA). Staining 
for each molecule was done in individual steps with 4 X 5 min washing in between. 
Primary antibodies used were a goat polyclonal IgG specific for pStat6 or the Stat6 
specific clone S-20, both purchased from Santa Cruz Biotechnology. For IL-4 staining, 
sections were stained with a hybridoma supernatant containing rat anti-mouse IL-4 (clone 
11-B-11). Secondary antibodies used were biotin-sp-conjugated donkey anti-goat IgG 
and rhodamine-conjugated donkey anti-rabbit IgG both purchased from Jackson 
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Immunoresearch Lab. Goat anti-rat Ig(H&L)FITC conjugated antibody was obtained 
from Southern Biotechnology. IgM conjugated Alexa-fluor 633 was purchased from 
Molecular Probes and CD4-conjugated RPE, biotinylated-CD4 and hamster anti-mouse 
CD3ε-RPE were all from Southern Biotechnology.  
Sections were stained for either phosphorylated-Stat6 with a biotin-conjugated 
IgG secondary antibody followed by Neutralite Avidin-FITC (Southern Biotechnology), 
or for Stat6 with a rhodamine-conjugated IgG secondary antibody. To identify B cells, 
sections were stained for IgM and for T cells using CD4-conjugated RPE on pStat6 
slides, or biotinylated-CD4 on Stat6 slides, followed by Neutralite-Avidin FITC 
(Southern Biotechnology).  Finally, slides were washed, a drop of Fluoromount-G was 
applied to the stained section and a cover slip was added and sealed with nail polish.  
To stain for IL-4, slides were prepared as above with the exception of 
Streptavidin/Biotin blocking. A neat solution of supernatant containing anti-mouse IL-4 
was pipetted onto sections and allowed to incubate for 60 min. After washing, a 1:400 
solution of anti-rat FITC was added and incubated for 45 min, followed by a washing 
step, then a 1:400 dilution of anti-CD3ε-RPE for 60 min. Finally, 1:500 anti-IgM was 
added to stain for B cells and the slides were finished as above.    
Slides were visualized with an Olympus FV300 confocal microscope using a 20X 
objective. Spleen sections from 3 separate Ttc7Pfsn/fsnP and WT mice were stained for each 
combination of antibodies with similar results.  
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Immunohistological staining of Spleen Sections  
Spleens from eight-week-old mice were sectioned and prepared as above.  
Antibodies used were biotinylated anti-IL-4 antibody (mouse clone 24G2, Endogen, 
Rockford, IL), anti-CD3ε-FL (FITC) (clone C363.29B), sheep anti-FL-HRP (horseradish 
peroxidase) and anti-SA-AP (streptavidin-alkaline phosphatase) which were all 
purchased from Southern Biotechnology. 
Slides were first warmed to room temperature, re-hydrated in PBS 20 min, and 
blocked with 1% BSA/Tween/PBS for 20 min. A 1:50 dilution of anti-IL-4 antibody was 
applied to the section and incubated at RT for 60 min. After washing 3 X 10 min, a 1:200 
dilution of anti-mouse CD3ε-FL was added, incubated, and washed as above. A 
secondary antibody solution of 1:200 anti-FL-HRP and a 1:100 dilution of anti-SA-AP 
was added and incubated as above followed by a washing step. AP was developed using a 
20 mg/mL solution of napthol-ASMX-phosphate (Sigma) with 40 mg/mL fast blue BB 
(Sigma) and 2mM levamisol (Zymed) and incubated for 37 min followed by a wash. 
HRP was detected using 16 mg/mL of 3-Amino-9-ethylcarbazole with 0.015% HB2BOB2B and 
incubating for 27-40 min. Slides were then washed, sections covered with mounting 
media and a cover slip and visualized with a light microscope at 40x magnification. 
(Protocol courtesy of Lynn Hannum) 
 
Expression of IL-4 mRNA by RT-PCR 
Cell preparation: T cells from 4- and 10-week-old WT and Ttc7Pfsn/fsnP mice were 
isolated as described above. Purified T cells were counted and 15-20 million cells used 
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for each time-point. Cells were either left untreated (0 min) or stimulated with plate-
bound anti-CD3 (10µg/mL; clone 145-2C11, Southern Biotechnology) in a 48-well cell-
culture plate at 37°C, 5% COB2B. Preliminary experiments indicated that 3 hours of 
stimulation with anti-CD3 led to optimal IL-4 gene expression for both Ttc7Pfsn/fsnP as well 
as WT T cells. Thus, after 3 hours of stimulation, the “stimulated” sample was harvested, 
spun-down to pellet the cells, resuspended in 1mL of Tri®Reagent (Sigma Chemical) and 
frozen for later RNA extraction. To evaluate RNA stability, Actinomycin D (Act D) 
(10µg/mL; Sigma) was added to stimulated samples to inhibit mRNA synthesis and 
incubated for either an additional 2 hours or 4 hours and harvested as above. 
Cyclosporine A samples were processed as described below.  
RNA extraction: Total RNA was isolated from processed cells using the 
manufacturer’s protocol for Tri®Reagent. Briefly, tubes containing cells lysed with 
Tri®Reagent were centrifuged at 12,000g for 10 min at 4°C to remove high-molecular 
weight DNA from the supernatant. This was then transferred to a new tube, 200µL of 
chloroform was added and centrifuged again at 12,000g for 10 min. The aqueous phase 
containing the RNA was transferred to a new tube, precipitated with 99P+P% isopropanol 
and washed with chilled 75% ethanol. The RNA pellet was resuspended with 35µL of 
sterile dHB2B0, an aliquot removed for analysis and the remainder frozen until use.  
RNA analysis: For RNA quantitation a 1:10 dilution was made and analyzed on a 
Nanodrop® ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, 
Delaware). Three measurements were made per sample and averaged. Two micrograms 
of RNA per sample were calculated and run on a 1% agarose gel with ethidium bromide 
(EtBr) to confirm RNA integrity and accuracy of calculations (data not shown).  
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First strand cDNA synthesis of Poly A mRNA: Two micrograms of purified total 
RNA were calculated for each sample and added to a mixture of 1.5µL Oligo dTB(15)B 
primer (0.5µg/uL, Promega), 1.5nM dNTP mix, and dHB2BO to make a 25µL reaction 
volume. After a 5 min incubation at 70°C,  RT buffer, 1.5µL of M-MuLV RT enzyme 
(200,000U/mL, New England Biolabs), and dHB2BO to make a 30µL reaction volume was 
added and incubated for one hour at 42°C. 
PCR of cDNA: PCR (of PolyA mRNA) of reverse-transcribed cDNA was 
performed as follows. For IL-4 and GADPH expression the same amount of cDNA was 
added to separate mixtures of 1X PCR Gold Buffer (Applied Biosystems), 2.5µM MgClB2B, 
1µM dNTP nucleotide mix (Promega), 0.5µM each forward and reverse primers, 0.6µL 
DMSO, 0.125µL AmpliTaq Gold™ enzyme (5U/µL, Applied Biosystems) and dHB2BO to 
25µL. The house-keeping genes GADPH, HPRT, and beta-actin were validated 
experimentally for suitability as a control. GADPH was found appropriate for use as a 
loading control and for normalization with the type of cells, time-frames and treatments 
used in these assays. Samples were run in either a BIO-Rad Gene Cycler™ thermocycler 
(IL-4) or a PTC-100 (GADPH) (MJ Research Inc, Watertown Mass) starting with an 
activation step of 10 min at 95°C, followed by a touch-down series of 94°C for 45 sec, 
higher TM + 2° for 1.5 min decreasing to lower TM – 2° for -.5° each cycle, 2 min at 
72°C (71°- 66° for 10 cycles IL-4; 69°-62° for 14 cycles GADPH), then repeat cycles of 
45 sec at 94°C, 1.5m at 66°C or 62°C and 2 min at 72°C, with a final elongation step of 5 
min at 72°C. The amount of cDNA and the number of PCR cycles were selected by pilot 
experiments and samples of the PCR reactions were taken at multiples points throughout 
the amplification process for appropriate comparison, thus, PCR was performed in the 
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linear range of the amplification reaction for each set of primers. The primer set specific 
for IL-4 was (5’-3’) Forward: CGAAGAACACCACAGAGAGTGAGCT and Reverse: 
GACTCATTCATGGTGCAGCTTATCG (Sigma Genosys, Woodlands Tx) and for 
GADPH, Forward: GCTCTACATGTTCCAGTATGACTCCAC, Reverse: 
GGGTCTCGCTCCTGGAAGAT (Operon Biotechnologies, Huntsville AL). Calculated 
bands sizes are 180bp and 117bp respectively. The PCR products were electrophoresed 
on a 1.5% agarose gel containing EtBr and visualized with a Syngene Gene Genius 
imaging system. The relative intensity of bands was determined with ImageJ NIH 
imaging software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,  
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2006). Results are expressed as the ratio 
of the intensity of the band for IL-4 to the intensity of the band for GADPH normalized 
to unstimulated WT control where indicated in the caption. The RNA stability study 
results are presented as the percent of each residual specific mRNA at each time point 
relative to the stimulated sample as indicated in the caption.  
 
IL-4 ELISA Measurement 
Four- and ten-week WT and Ttc7Pfsn/fsnP T cells were isolated and enriched from 
spleens of freshly sacrificed animals as described above. Six million cells per sample 
were resuspended in  400µL of RPMI 1640 culture media supplemented with 10% FCS, 
2mM L-glutamine, 0.05% sodium pyruvate, 100U/mL penicillin and 100µg/mL 
streptomycin. Samples were plated in 48-well culture plates in either uncoated wells 
(unstimulated samples) or stimulated in wells coated with 10µg/mL anti-CD3 antibody. 
Plates were cultured at 37°C with 5% COB2B for 24 hours. To assess protein production 
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after blocking mRNA synthesis, Act D (10µg/mL) was added to samples after 3-hours of 
stimulation with plate-bound anti-CD3 and allowed to continue incubating. Cyclosporine 
A treated samples were processed as described below. After culture, plates were spun and 
supernatant collected.  
IL-4 protein levels were measured from collected supernatants in triplicate 
samples (100µL) of each individual sample by ELISA using the IL-4 DuoSet kit 
purchased from R+D systems (Minneapolis, MN) according to the manufacturer’s 
instructions.  Optical density readings were obtained using a Packard Instruments 
Spectracount plate reader (Downers Grove, IL) set at 405nm. IL-4 concentration was 
determined by converting the mean OD values to picograms per milliliter using an 
equation determined from standard curves generated with varying concentrations of 
mouse recombinant IL-4 (5.0- 4,000 pg/mL) and plotting in Excel.  
 
Cyclosporine A Studies 
Solid cyclosporine A (CsA) (Alexis Biochemicals, San Diego, CA) was dissolved 
in DMSO to make a stock solution concentration of 40µg/mL. This was then diluted 1:50 
with culture media and added to a cell suspension for a final concentration of 1µg of CsA 
per mL of cell suspension. DMSO diluted 1:50 in media was used as a control. Cells were 
pre-treated for 30 minutes before plating onto the prepared 48-well culture plates. 
Samples were then prepared as above for RT-PCR and ELISA.  
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Flow Cytometry: Materials and Methods 
 
Reagents And Antibodies Used For Flow Cytometric Analysis Of T Cell Subsets, IL-
4 Producing T Cells, Spleen Cell Populations And Cell Cycle Analysis 
For intracellular analysis of IL-4 and IFN-γ production Monensin solution 
(eBioscience, San Diego, CA 92121) was used to inhibit protein transport. Antibodies for 
intracellular IL-4 analysis include rat anti-mouse IL-4-FITC (clone BVD6-24G2, 
eBioscience), rat anti-mouse CD4/L3T4-PE (clone GK1.5, Southern Biotechnology, 
Birmingham, AL.), rat anti-mouse CD44/Pgp-1-APC (clone KM201, Southern Biotech), 
and rat anti-mouse CD62L-PE/Cy7 (L-selectin clone MEL-14, Southern Biotech). For 
over-night stimulation, plates were coated with unlabeled hamster anti-mouse CD3e 
(clone 145-2C11, Southern Biotech). Antibodies for T cell subset analysis (naïve, 
activated, memory) include hamster anti-mouse CD69-FITC (cloneH1.2F3, Southern 
Biotech), as well as CD4, CD44 and CD62L mentioned above. Intracellular IFN-γ was 
assessed with rat anti-IFN-γ- APC (clone XMG1.2, eBioscience) and anti-CD4-PE.  
Cell cycle analysis was performed with rat anti-mouse CD4-FITC (clone GK1.5) 
and hamster anti-mouse CD3-FITC (clone 145-2C11) both purchased from Southern 
Biotech, and propidium iodide (PI) solution purchased from Becton Dickinson (Franklin 
Lakes NJ 07417) at 50µg/mL, with added  1 mg/mL RNAse A and 1 mg/mL sucrose 
(Sigma, St. Louis MO 63178). 
Spleen cell populations were determined with goat anti-mouse IgM-AlexaFluor® 
633 (µ chain, Invitrogen Molecular Probes, Carlsbad CA 92008), rat anti-mouse IgD-PE 
(clone 11-26, Southern Biotech), rat anti-mouse CD19-APC (clone 6D5, Southern 
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Biotech), rat anti-mouse F4/80-PE (clone C1:A3-1 AbD Serotec, Raleigh NC 27604 ), rat 
anti-mouse Ter119-PE (erythroid cells y-76 clone Ter119, BD PharMingen, San Diego 
CA 92121), rat anti-mouse PanNK (CD49b)-PE (clone DX5, Southern Biotech), rat anti-
mouse GR1 (Ly-6G)-PE (clone RB6-8C5, Southern Biotech ), rat anti-mouse CD8a (Lyt-
Z)-APC (clone 53-6.7, Southern Biotech) as well as CD4-PE and CD3-FITC mentioned 
above. Other markers include rat anti-mouse CD11b (Mac-1) (clone M1/70 Southern 
Biotech ), rat anti-mouse CD11c-APC (clone N418, Caltag Labs, Burlingame CA 
94010), rat anti-mouse MHC classII- FITC (clone NIMR-4, Southern Biotech) and rat 
anti-mouse CD23 (IgE Fc receptor FcεRII)-FITC (clone 2G8, Southern Biotech ). 
Isotype controls include Rat IgG-APC (BD PharMingen), Rat IgG-RPE and 
Hamster IgG-FITC, and Rat IgG-FITC, all from Southern Biotech.  
Red blood cell (RBC) lysis buffer and Rat serum were purchased from Sigma. 
Lympholyte-M was obtained from Cedarlane, Ontario Canada. Hank’s Balanced Salt 
buffer came from Mediatech Inc, Herndon VA 20171 and FacsFlow was purchased from 
BD Biosciences (San Jose, CA). RPMI-1640 (10-040-CV w/L-glut) cell culture media 
was purchased from Cell-Gro (Mediatech) and supplemented with pen/strep antibiotics 
(Gibco® Invitrogen, Carlsbad CA 92008), 10% fetal bovine serum (FBS) (Biomedia, 
Foster City, CA 94404) and 0.05% sodium pyruvate (Gibco® Invitrogen).  
 
Method: Flow Cytometry 
Spleens were harvested from freshly sacrificed Ttc7 mice, 11B11- and GL113- 
treated Ttc7Pfsn/fsnP mice, Stat6-/-Ttc7 mice and designated Ttc7 control mice and single cell 
suspensions were made by scraping through a mesh biopsy bag (Thermo-Shandon). Cells 
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were washed with Hank’s balanced saline and RBC lysis was performed per 
manufacturer’s protocol using 1-200 million cells per 1mL of lysis buffer. For all 
analyses except total spleen cell populations, the lymphocyte fraction was separated by 
gradient density separation with Lympholyte-M per manufacturer’s protocol. A cell count 
was performed using a hemacytometer and the trypan blue exclusion method to measure 
cell viability, and 2 million cells were used per sample.  
 
Intracellular IL-4 and IFN-γ: To analyze intracellular IL-4 and IFN-γ 
production in Ttc7 and Stat6-/-Ttc7 mice, cells were resuspended in RPMI-1640 
supplemented with 10% FBS, pen/strep, 2% sodium pyruvate and L-glutamine with 1x 
monensin added to block protein secretion. 6 million cells were plated in either 10µg/mL 
anti-CD3 coated plates to stimulate or uncoated wells and cultured overnight at 37°C 
with 5% COB2B. After harvesting and washing, cells were resuspended in 500µL of 2% 
FBS, 5% rat serum, and FacsFlow buffer to block at 4°C or on ice for 20 minutes. 
Samples were then spun at 500g for 10 minutes, the supernatant was discarded and cells 
were washed with 200µL of FacsFlow buffer. Appropriate antibodies for surface 
markers, CD4, CD44 and CD62L were diluted in FacsFlow with 2% FBS to a working 
concentration following manufacturer’s recommendation for number of cells used, 50µL 
of the antibody solution was added to each sample and incubated on ice in the dark for 45 
minutes.  
Following incubation, cells were washed 3x with 200µL FacsFlow/2% FBS, and 
fixed with 100 µL of 1% paraformaldehyde in PBS (diluted from 4X stock). Samples 
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were incubated for15 minutes on ice in the dark, 300 µL of FacsFlow was added and 
samples were stored at 4°C until ready for analysis.  
Immediately before analysis, cells were washed 3x with 200 µL of FacsFlow and 
appropriate samples were resuspended in 100 µL of an antibody solution containing 
either anti-IL4 or anti-IFN-γ, 0.1% saponin, 2% FBS in FacsFlow and allowed to stain in 
the dark for 45 minutes. After washing 3x in FacsFlow, all samples were resuspended in 
500 µL of FacsFlow and transferred to BD Falcon 2x75mm 5mL round-bottomed 
polystyrene tubes. 
 
Cell Cycle Analysis: Individual samples of 2 million cells each were blocked and 
washed as above and then stained for either CD3 or CD4 surface markers by incubating 
in 50 µL of an antibody solution using the manufacturer’s recommended working 
concentration for number of cells in FacsFlow with 2% FBS on ice for 45 minutes. 
Samples were washed and fixed in 1% paraformaldehyde as above, 300 µL of FacsFlow 
was added after 15 minutes of fixation and the samples were stored at 4°C in the dark 
until ready for analysis.  
Immediately before analysis, cells were washed 3x with FacsFlow and either 
resuspended in 500 µL of FacsFlow and transferred to 5mL polystyrene tubes, or cells to 
be stained with PI were suspended in 500 µL of a 50µg/mL PI solution supplemented 
with 1mg/mL of RNAse A and 10% sucrose. Samples were transferred to 5mL 
polystyrene tubes and allowed to stain for 30 minutes in the dark at RT.  
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Determination of T cell subsets: Individual samples of 2 million cells each were 
processed, washed and blocked as above. Four-color staining of cells was accomplished 
by adding the appropriate concentration per number of cells of  antibodies specific for 
CD69, CD4, CD44 and CD62L as listed under reagents to FacsFlow with 2% FBS. A 
50µL volume was added to samples and allowed to incubate for 45 minutes on ice in the 
dark. After washing and fixing as above, cells were resuspended in 500µL of FacsFlow 
and transferred to 5mL polystyrene tubes for analysis.  
 
Analysis of Spleen Cell Populations: Spleen cells were processed as above 
without Lympholyte-M separation. After blocking, individual samples of 2 million cells 
were stained with antibodies specific for CD3, CD4, CD8a, CD11b, CD11c, CD19, 
CD23, F4/80, Ter119, PanNK, GR-1, MHC classII and IgM/IgD together to determine 
ratio as well as individually for controls. All antibodies were added in 50µL volumes of 
FacsFlow with 2% FBS and then incubated for 45 minutes on ice in the dark. After 
washing and fixing, cells were resuspended in 500µL of FacsFlow and transferred to 
5mL polystyrene tubes for analysis.  
 
Flow cytometric analysis: In addition to the samples described above, single-
stained samples of each antibody were prepared in the same manner to use as controls for 
compensation as well as unstained samples for background fluorescence and isotype 
controls to determine positive staining. Acquisition of data was conducted on a Becton 
Dickinson FACSCalibur using CellQuest pro 4.0 Software (BD Biosciences, San Jose, 
CA) for data collection. Based on lymphocyte gates from forward and side scatter, at 
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least 50,000 events were recorded for each sample. Data analysis and graphing were 
accomplished with WinList 6.0 from Verity Software House, Topsham ME 04086.  
 
Production and purification of 11B11 and GL113 monoclonal antibodies  
 
Production of Antibodies: The anti-IL4 producing hybridoma cell line, 11B11 
(HB-188™) was originally purchased from American Tissue Culture Collection (ATCC) 
(Manassas, VA 20110). The isotype matched (IgG1) control monoclonal cell line GL113 
was a kind gift from Fred Finkelman, University of Cincinnati, Cincinnati, Ohio. Both 
cell lines were started in RPMI-1640 (Cell-Gro) supplemented with 2mM L-glut, 10% 
FBS (Biomedia), 2µL (5x10P-5PM) 2-Me, pen/strep and 2% sodium pyruvate, all from 
Gibco® Invitrogen, and incubated at 37°C with 5% COB2B. Cell culture media was 
gradually changed over to 100% BD Cell™Mab Medium Serum Free Media (BD 
Biosciences) supplemented with L-glut by resuspending cells in ratios of RPMI to serum 
free media of 75/25, 50/50, 25/75 and finally to 100%, allowing cells to equilibrate and 
rebound for several days in each mixture. When required cell density was obtained 
CELLine™ 1000 System growth chambers (BD Biosciences) were seeded with the 
hybridoma cells following the manufacturer’s recommendations for the 7/21 day 
procedure. Briefly, cells were suspended at 2 x 10P6 Pcells/mL in 15 mLs of serum free 
media and added to the cell compartment with a serological pipet. One liter of pre-
warmed (37°C) serum free Mab media was added to the nutrient compartment and the 
chamber was allowed to incubate for 1 week at 37°C in 5% COB2B. On day 7 cells were 
removed with a serological pipet to harvest the antibody in the media, and chambers were 
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re-seeded as before. This was repeated 3x (21 days), whereupon the nutrient chamber was 
emptied of media, refilled with fresh serum free media and the cell chamber was reseeded 
for another round of 21-day antibody production. All procedures were conducted in a 
Hepa-filtered culture hood under aseptic conditions. Cell lines were tested by the Yale 
University Virology lab using their mouse and rat contaminant panel and found to be 
negative for mouse and rat viruses and mycoplasma.  
 
Purification of antibodies from supernatant: Cells and supernatants collected 
above were centrifuged at 1000g for 10 minutes and the supernatants were filtered 
through a 0.8 µm syringe filter and again through a 0.2 µm filter to remove any cell 
debris. The filtered supernatants were tested for antibody concentration on a NanoDrop® 
ND-1000 Spectrophotometer (NanoDrop Technologies Inc., Rockland DE 19732) and 
the volumes were adjusted to the optimal binding capacity (32 mgs) for use with 
Ultralink Affinity Pak Immobilized Protein-G 2 mL pre-packed columns (Pierce, 
Rockford, IL). Purification proceeded following the manufacturer’s instructions. Briefly, 
the supernatants were mixed with an equal volume of de-gassed Immunopure®G IgG 
Binding Buffer (Pierce), and after equilibrating the columns with addition binding buffer, 
were passed through the columns 3x. The columns were washed, and the bound antibody 
was then eluted with de-gassed Immunopure®IgG Elution Buffer (Pierce) into 100µL of 
1M Tris neutralization buffer (pH 8.0) in 1 mL fractions. Elution was monitored with 
NanoDrop® absorbance readings until background values were reached. Purity and 
binding activity were evaluated with Western blot. The columns were regenerated and 
stored as recommended.  
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All collected fractions were measured for absorbance and the fractions with the 
highest readings were combined and re-measured for total recovered antibody 
concentration. Buffer exchange into sterile and filtered PBS was accomplished using 
10,000 molecular weight cut off 3-12 mL capacity Slide-A-Lyzer Dialysis Cassettes with 
3 changes of 2 liters each of PBS per manufacturer’s protocol. The recovered buffer-
exchanged antibody was again measured for concentration by NanoDrop® absorbance 
values, all samples were combined and the final concentration was adjusted to 1 mg/mL 
of 11B11 or GL113 with sterile and filtered PBS, measured into 1 mL aliquots and frozen 
at -20C for storage.  
 
Treatment of animals with 11B11 and GL113 
Five Ttc7Pfsn/fsnP mice from separate litters per each treatment group received 250µg 
(250µL) of 11B11 anti-IL4 or GL113 isotype control starting at 3 weeks of age, 3 times 
per week until 10 weeks of age for a total of 7 weeks (Singh, Saxena et al. 2003). All 
injections were administered intraperitoneally and were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Southern Maine. 
 
Materials and Methods for Serum Antibody ELISAs  
 
Quantitation of serum immunoglobulin isotype 
Sera were collected from 11B11- and GL113-treated mice, Stat6-/-Ttc7 and Ttc7 
mice after bleeding from the retro-orbital plexus. Blood was allowed to clot for 1 hr at 
room temperature and overnight at 4°C. Samples were then spun at 3000g for 15 minutes, 
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serum was pipetted from each sample, transferred to a new tube and stored at -20°C until 
analysis by ELISA.  
For quantitation of individual Ig isotypes, 96-well microtiter plates were coated 
overnight at 4°C with 2µg/mL goat anti-mouse IgG1, goat anti-mouse IgG3, goat anti-
mouse IgM+IgG+IgA(H&L) (total Ig) or 5µg/mL goat anti-mouse IgE, all purchased 
from Southern Biotechnology. After washing 3x with 0.01% Tween-20/PBS, plates were 
blocked for 1 h at RT with 1% BSA in PBS. Dilutions of sera at 1:250 and 1:500 in PBS 
(IgG1, IgG3 TIg) or 1:20 and 1:50 in PBS (IgE) were incubated in triplicate wells 
overnight at 4°C. Standard curves were generated with serial dilutions in duplicate wells 
of mouse IgG1κ (clone 15H6), mouse IgE Balb/c (clone 15.3), both from Southern 
Biotech, and mouse IgG3κ (KLH, BD PharMingen, San Diego, CA 92121). After 
washing 3x as above, detection was accomplished by incubating for 30 minutes at RT 
with horseradish peroxidase-conjugated goat anti-mouse kappa light chain antibody 
(1:8000) or rat anti-mouse IgE (1:6000, clone 23G3) both from Southern Biotech. Plates 
were again washed 3x as above and 100µL of the HRP substrate, 1-Step™ Ultra TMB-
ELISA (Pierce, Rockford, IL) were added, allowed to develop to a desired color and then 
stopped with 1N HCl. Colormetric analysis was quantified at 405nm with an EL800 
universal microplate reader (BioTek Instruments, Winooski, VT). Quantitation of serum 
Ig isotypes were calculated into µg/mL using the equation of the line generated by 
graphing the absorbance/concentration of the standard curves generated with the isotype 
standards.  
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Quantitation of IL-4 production by Stat6-/-x Ttc7 splenic lymphocytes 
Spleens were harvested from freshly sacrificed Stat6-/-Ttc7 mice. Single cell 
suspensions were obtained by filtering though a nylon mesh biopsy bag followed by 
Lympholyte-M (Cedarlane, Ontario, Canada) density gradient isolation of total 
lymphocytes as instructed by the manufacturer. Six million cells per sample were 
resuspended in  400µL of RPMI 1640 culture media supplemented with 10% FCS, 2mM 
L-glutamine, 0.05% sodium pyruvate, 100U/mL penicillin and 100µg/mL streptomycin. 
Samples were plated in 48-well culture plates in either uncoated wells (unstimulated 
samples) or stimulated in wells coated with 10µg/mL anti-CD3 antibody. Plates were 
cultured at 37°C with 5% COB2B for 24 hours. To assess protein production, supernatant  
IL-4 protein levels were measured in triplicate 100µL samples by ELISA using the IL-4 
DuoSet kit purchased from R+D systems (Minneapolis, MN) according to the 
manufacturer’s instructions. The HRP substrate, 1-Step™ Ultra TMB was added to all 
wells and allowed to develop to the desired intensity and stopped with 1N HCl. 
Colorimetric optical density readings were obtained using a BioTek Instruments EL800 
Universal Microplate Reader set at 405nm. IL-4 concentration was determined by 
converting the mean OD values to picograms per milliliter using an equation determined 
from standard curves generated with serial dilutions of mouse recombinant IL-4 (5.0- 
4,000 pg/mL) and plotting in Excel.  
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Material and Methods for Anti-DNA ELISA and Autoantibody Staining 
 
Serum 
Blood was collected from all mice used by orbital bleeds. Blood samples were 
allowed to clot at room temperature, stored overnight at 4°C, and then centrifuged at 
3000rpm for 15 min at 4°C. The supernatant (serum) was collected and stored at -20°C. 
 
Antinuclear Antibody (ANA) Determination 
Initial ANA detection was performed with a screening ANA ELISA as follows. 
100µL of a 5 mg/mL Protamine sulfate (Sigma) capture solution in dHB2BO was incubated 
for 30 minutes at room temperature to coat each well of a 96-well NUNC Polysorp 
ELISA plate (Nalge Nunc International). Unbound solution was removed and plates were 
then blocked with 100µL of a 10µg/mL salmon sperm DNA solution in dHB2BO for 30 
minutes at room temperature. After removing unbound blocking solution, sera titered 
1:50, 1:100 and 1:200 in 2% NFDM (non-fat dry milk), 0.2% Tween-20 (Fisher), and 
PBS was added and incubated for one hour at room temperature, after which sera was 
removed and plates were washed 3x with 0.2% Tween-20/PBS. Goat anti-mouse IgG- or 
IgM-HRP (Southern Biotech) at 1:3000 in 2% NFDM/0.2% Tween-20/PBS was added 
and incubated for 1 hour at room temperature. The antibody was then removed and plates 
were washed as above, developed with 1-Step™ Ultra TMB substrate (Pierce, Rockford, 
IL) for 6 minutes, and stopped with 1N HCl. Absorbances were measured on a EL800 
Universal Microplate Reader (Biotek Instruments, Winooski, VT 05404) at 450 nm 
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(Protocol and data kindly provided by Nicholas Matluk III, adapted from Stokes et al., 
1982). 
 
Autoantibody Antigen Determination 
Slides fixed with HEp-2 cells were commercially obtained from The Binding Site, 
Inc. (San Diego, Ca.) Serum samples from 11B11- and GL113-treated mice as well as 
Stat6-/- Ttc7 mice were diluted 1:40 and 1:80 in PBS and added to wells. PBS was used 
as a negative control and sera from Ttc7Pfsn/fsnP mice were used as positive controls for 
comparison. Slides were then incubated in a humidified chamber for 30 minutes at room 
temperature and washed with PBS three times for 5 minutes. Either anti-mouse IgG-FITC 
or anti-mouse IgM-FITC (both from Southern Biotechnology Inc., Birmingham Al.) was 
diluted 1:100 and added to designated wells and incubated again for 30 minutes in a 
humidified chamber at room temperature. Slides were washed as before, Fluoromount-G 
(Southern Biotech) was applied drop-wise to wells and coverslipped. These were 
examined with a Olympus 1x71 TH4-100 microscope equipped with epifluorescence and 
a FITC filter. Photographs were taken with a Photometric “Cool Snap” HQ Digital Roper 
Scientific 35 mm camera.  
 
Assessment of Renal Disease/ Proteinuria 
Renal disease was assessed by colorimetric measurement of proteinuria using 
Albustix® (Bayer Co., Elkhart In) per manufacturer’s protocol. Mild disease was 
considered less than 100 mg/dL while advanced disease was defined as over 100 mg/dL 
per Daikh and Wofsy, 2001.  
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Kidney sectioning and staining 
Kidneys were collected immediately upon sacrifice. One kidney half was fixed in 
4% paraformaldehyde in PBS and the other half was fixed in 10% formalin. These were 
sent in fixative to Dr. Harini Bagavant at the University of Virginia, Department of 
Rheumatology and Immunology for sectioning, staining, and analysis as described in 
“Materials and Methods” of Bagavant et al., 2006.  
 
Data Analysis  
Each individual experiment was repeated with at least 3 separate litters per age 
group. As all experiments were conducted with primary cells, it was necessary to pool 
spleens of age and sex-matched littermates to obtain adequate numbers of B or T cells for 
analysis. For Stat6 activation and fall-off analysis, B cells were counted in a blind fashion 
by 2 people and the results averaged. All ELISA samples were plated in triplicate and 
averaged. Arithmetic means are given with standard error of the mean. Statistical 
comparisons between samples and with controls were made by the Student’s unpaired t-
test using “Smith’s Statistical Package, Version 2.80” © Gary Smith, 2005. Differences 
were considered significant when P values of <0.05 were obtained.  
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RESULTS 
Results:  Section 1: Ttc7Pfsn/FsnP 
Previous research on Ttc7Pfsn/fsnP mice had identified high levels of IL-4 in serum as 
well as an increased capacity for IL-4 production in Ttc7Pfsn/fsnP splenocytes (Pelsue, 
Schweitzer et al. 1998; Welner, Hastings et al. 2004). The phenotype exhibited by 
Ttc7Pfsn/fsnP mice is similar to that of the IL-4 transgenic as developed by Erb et al (Erb, 
Ruger et al. 1997) with hyperproliferative, activated B cells, dramatically increased IgE, 
anemia, kidney disease, autoantibodies, autoimmune disease and reduced life span. Stat6 
is a transcription factor that is unique to the IL-4 pathway which, when constitutively 
active due to a defect in its regulation, has been shown to have transforming effects on 
cells leading to lymphoproliferative diseases, as well as high levels of IL-4 and Th2-type 
inflammation. Since the gene function of Ttc7 was (and is) unknown we undertook this 
study to determine whether an intrinsic defect in the dysregulation of IL-4 production 
was the cause of the autoimmune pathology seen in Ttc7Pfsn/fsnP mice or, whether elevated 
IL-4 was the effect of the increased autoreactivity in Ttc7Pfsn/fsnP which then determined the 
pathology. Because Stat6 is necessary for high levels of IL-4 production and pivotal in 
the IL-4 signaling pathway, we first sought to determine the activation status and 
regulation of Stat6 in Ttc7Pfsn/fsnP mice. 
 
Enhanced Stat6 activation in IL-4 Stimulated Ttc7Pfsn/fsnP Splenocytes 
To evaluate IL-4 signaling, splenocytes were collected from Ttc7Pfsn/fsnP and WT 
control mice and analyzed by Western Blot for Stat6 activation as determined by an 
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antibody specific for the phosphorylated form of Stat6 (pStat6). Figure1.1 shows the 
increased level of activated pStat6 in Ttc7Pfsn/fsnP splenocytes following IL-4 stimulation, as 
compared to WT control splenocytes. All lanes were normalized to 6 million cells per 
sample. Lower molecular weight fragments were detected by anti-pStat6 in the Ttc7Pfsn/fsnP 
samples, which were not detected in the WT splenocyte samples, nor were they detected 
by the S-20 anti-Stat6 antibody (as determined by immunoprecipitation). Proteolytic 
fragments of Stat6 corresponding to the N-terminal DNA binding domain have also been 
detected in mast cells cultured in the presence of IL-4 (Sherman 1999; Suzuki 2000). The 
S-20 anti-Stat6 antibody is reactive with the C-terminus of Stat6 and therefore would not 
detect these fragments.  
To determine if the elevation of pStat6 was a result of increased expression of 
Stat6, the ratio of pStat6/Stat6 was determined by immunoprecipitation followed by 
immunoblotting of Stat6 in IL-4 stimulated and unstimulated splenocytes (Figure 1.2). In 
the WT splenocytes, IL-4 stimulated (30 minutes) versus the unstimulated (0 minutes) 
show a 12-fold elevation in pStat6 levels. Ttc7Pfsn/fsnP splenocytes did not show a detectable 
increase in pStat6 levels under the same conditions. In fact, the levels of pStat6 in the 
unstimulated Ttc7Pfsn/fsn Psplenocytes are only 1.3-fold above IL-4 stimulated WT 
splenocytes. While the levels of Stat6 are not significantly different among all of the 
samples, the ratio of pStat6 to total Stat6 does vary considerably (Figure 1.3). The 
pStat6/Stat6 ratios in WT splenocytes were 0.025 and 0.300 respectively for the 0 and 30 
minute time points. The pStat6/Stat6 ratios in Ttc7Pfsn/fsnP splenocytes, however, were 0.670 
and 0.620 for the same time points, indicating a much higher percentage of Stat6 was 
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already activated without additional stimulation of Ttc7Pfsn/fsnP splenocytes (Previously 
published as (Welner, Hastings et al. 2004). 
 69
 
 
               
 
 
 
Figure 1.1. Stat6 Activation. Stat6 activation is enhanced in Ttc7Pfsn/fsnP 
splenocytes. Splenocytes (normalized to 6 x 10P6P cells/lane) were isolated from 
Ttc7Pfsn/fsnP and WT littermate control mice and stimulated with (10ng/mL) rIL-4 
for the time indicated above the lanes. Stat6 analyzed by Western blot for 
activated (phosphorylated) Stat6 (pStat6). Increased levels of pStat6 are 
detected from Ttc7Pfsn/fsnP splenocytes even in samples without exogenous IL-4 
stimulation. The asterisks indicate possible Stat6 proteolytic fragments. 
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Figure 1.2  Ratio of pStat6 to Stat6. Stat6 was immunoprecipitated with anti-Stat6 
antibody and immunoblotted with anti-pStat6 and anti-Stat6 as indicated in the figure. 
Ttc7Pfsn/fsnP splenocytes show an increase in pStat6 expression as well as in the ratio of 
pStat6 to Stat6 (see text). 
 
 
 
 
 
 
Figure 1.3. The ratio of pStat6 to Stat6 is elevated in Ttc7Pfsn/fsnP splenocytes. In both 
unstimulated and stimulated samples the ratio of pStat6 to Stat6 is higher in Ttc7Pfsn/fsnP 
than in WT littermates suggesting more of the total Stat6 pool is activated in Ttc7Pfsn/fsnP 
mice.  
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Activation of Stat6 in B lymphocytes 
Preliminary work indicated that Stat6 was constitutively activated 
(phosphorylated) without exogenous IL-4 stimulation in the lymphocyte fraction of 
Ttc7Pfsn/fsnP splenocytes as compared to their WT littermates, but that the overall expression 
of unphosphorylated Stat6 between the two was similar. Stat6 is phosphorylated in the 
cytoplasm upon stimulation of the IL-4 receptor by IL-4 and translocates to the nucleus 
where it binds to DNA and functions to upregulate IL-4 responsive genes. However, 
recent research has shown the presence of a factor or factors that may serve to sequester 
Stat6 in the cytoplasm after phosphorylation whereupon receiving the proper signal will 
release Stat6 to translocate to the nucleus and perform its role in transcriptional 
regulation (Daines, Andrews et al. 2003). Thus, to observe the functional regulation of 
Stat6 during activation in negatively-selected, magnetically-purified splenic B cells, we 
examined the nuclear localization of Stat6 following IL-4 stimulation. Stat6 (red) and 
Sytox green (green) double-stained confocal images (Figure 1.4) of unstimulated B cells 
(0 min) as well as B cells stimulated with IL-4 for 30 minutes, showed that the 
unstimulated Ttc7Pfsn/fsnP B cell sample exhibited a greater number of activated cells 
(yellow) than did the unstimulated WT sample, correlating with the previous data that 
Ttc7Pfsn/fsnP Stat6 was activated in vivo (Figure 1.2). Following 30 min of incubation with 
IL-4, both Ttc7Pfsn/fsnP and WT exhibited an increased number of double-positive cells, but 
had comparatively similar levels between the groups.  
To further analyze the kinetics of activation as well as numbers of activated cells 
between Ttc7Pfsn/fsnP and WT a minimum of 1500 cells were counted per time point and  
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Figure 1.4  Stat6 Localization in B cells. Purified splenic B cells are unstimulted (0) 
or stimulated with IL-4 for 30 minutes, then stained for Stat6 (red) and the nucleus 
(green) and visualized with confocal microscopy using a 60x objective. Co-
localization of Stat6 with the nucleus, denoting activation, is yellow. Ttc7Pfsn/fsnP B cells 
show more yellow, activated cells than normal even without stimulation, suggesting 
preactivation in vivo. 
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scored for percentage of activated cells (Figure 1.5). At 0 min (unstimulated) nearly 30% 
of the Ttc7Pfsn/fsnP B cells are activated compared to less than 15% of WT. We also saw 
slightly different kinetics of activation as with 15 minutes of IL-4 stimulation Ttc7Pfsn/fsnP 
activation slightly declined while WT increased as we would expect. Following 30 
minutes of stimulation there was a slight increase in both populations with similar overall 
levels of activation.  
With a P value of 0.09 the difference in Stat6 nuclear localization levels in 
unstimulated Ttc7Pfsn/fsnP and WT B cells does not  reach statistical significance, however, it 
does suggest a biologically relevant level of pre-activation since B cells have been found 
to exhibit altered signaling pathways, the upregulation of inhibitory molecules, and a 
100-1000 fold increase in responsiveness to subsequent IL-4 stimulation after initial 
activation (Siepmann, Wohlleben et al. 1996). This warranted further investigation since 
constitutively active Stat proteins, such as we have seen in Ttc7Pfsn/fsnP mice, have been 
found to contribute to disease processes such as autoimmunity and lymphomas (Daniel, 
Salvekar et al. 2000).   
 
Decay of activated Stat6 in B lymphocytes.  
The activation state of a protein can be maintained by various mechanisms 
including continuous signaling, enhanced activity in the binding/behavior of signaling 
molecules, or the inability of the cell to downregulate the signal after activation. Stat6 
decay or inactivation occurs when it becomes dephosphorylated in the nucleus and 
translocates back to the cytoplasm where it can become reactivated (Andrews, Ericksen 
et al. 2002; Hanson, Dickensheets et al. 2003). Since Stat6 appeared to be pre-activated  
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Figure 1.5  Scoring of Stat6 Activation in B cells. 1500 cells per experiment were 
counted and scored for percent of activated cells. Ttc7Pfsn/fsnP have almost 15% more 
activated cells B cells without stimulation than WT littermates, although percentages 
are then similar at 15 and 30 minutes of stimulation. While the 0 time point does not 
quite reach statistical significance, the p value of 0.09 suggests a biologically 
significant level of pre-activation. Data are presented as mean ± SEM for three 
separate experiments. 
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and constitutively expressed, we needed to determine whether Ttc7Pfsn/fsnP B cells were able 
to downregulate the activation of Stat6 in the absence of IL-4 (providing evidence that 
Ttc7Pfsn/fsnP B cells are responding to the exaggerated IL-4 production in Ttc7PfsnfsnP mice). 
To visualize the activation state of Stat6 in Ttc7Pfsn/fsnP and WT B cells when the IL-
4 signal is removed, we stimulated isolated B cells for 30 minutes with IL-4 and then 
removed the IL-4 signal through several washes of the cells and allowed them to rest for 
either 15 or 30 minutes. Analysis by confocal microscopy (Figure 1.6) suggested that 
Ttc7Pfsn/fsnP Stat6 was able to move out of the nucleus and achieve an inactive state in the 
cytoplasm in a similar manner as WT littermates as determined by comparable Stat6 
localization outside of the nucleus. 
  We counted and scored the cells to determine the percentage of activated cells 
(Figure 1.7). After 30 minutes of IL-4 stimulation (i.e. 0 min resting) the percentages of 
Stat6 activated Ttc7Pfsn/fsnP and WT B cells were similar; however, after the IL-4 stimulus 
was removed for 15 minutes both cell populations exhibited decreased activation, with 
Ttc7Pfsn/fsnP B cells showing a more rapid decline, and after 30 minutes of rest, percentages 
of activated B cells decreased further and were again similar between Ttc7Pfsn/fsnP and WT. 
This suggests that Stat6 decay in Ttc7Pfsn/fsnP B cells is similar to WT in both timing of 
turnover as well as number of cells, and is able to become de-phosphorylated in the 
nucleus and move into the cytoplasm upon removal of the IL-4 signal. Thus, it seems 
probable that the constitutively active Stat6 seen in Ttc7Pfsn/fsnP mice (Welner, Swett et al. 
2005) was due to a continuous IL-4 stimulation and signaling as described by Andrews et 
al (Andrews, Ericksen et al. 2002) and Hanson et al (Hanson, Dickensheets et al. 2003), 
rather than intrinsic defects in Stat6 regulation.   
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Figure 1.6. Decay of Stat6 activation in B cells. Purified splenic B cells were 
stimulated with IL-4 for 30 minutes, washed 3X and allowed to rest for 15 or 30 
minutes, then stained for Stat6 (red) and the nucleus (green) and imaged with confocal 
microscopy using a 60x objective. Co-localization of Stat6 with the nucleus, denoting 
activation, is yellow. Ttc7Pfsn/fsnP cells show a similar trend to WT cells at both time 
points, indicating they have the inherent ability to down-regulate Stat6 activation 
when IL-4 stimulus is removed.  
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Figure 1.7. Scoring of Stat6 Turnover in B cells. Over 1000 B cells per experiment 
were counted for each data point and scored for percent of activated cells. Both 
Ttc7Pfsn/fsnP and normal littermates show similar decay of Stat6 activation indicating 
turnover is not defective in Ttc7Pfsn/fsnP mice. Data are presented as mean ± SEM for three 
separate experiments.  
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Structural location of pStat6 in spleen sections 
In addition to the state of activation, it is important to identify the structural 
location of the Stat6-activated cells in the spleen. Previous studies have shown that the 
splenic architecture in flaky skin mice becomes increasingly disrupted and chaotic as 
mice age, which correlates with an increase in autoimmune disease pathology (Sundberg, 
France et al. 1997; Pelsue, Schweitzer et al. 1998). Normally, lymphocytes are restricted 
to specific compartments in order to regulate highly specific interactions which instruct 
cell survival and differentiation or determine if cellular responses are inappropriate which 
may lead to anergy or death. Because of the loss of follicular structure in Ttc7Pfsn/fsnP spleen 
we thought it was important to determine the structural localization of Stat6 
hyperactivated B cells. Triple staining of 8-week-old Ttc7Pfsn/fsnP and WT mouse spleen 
sections (Figure 1.8) for IgM, CD4, and Stat6 or pStat6 allowed us to visualize the 
structural location of the cells exhibiting activated Stat6.  
Figure 1.8, A and B were stained for the unphosphorylated form of Stat6 (green). 
The architectural abnormalities present in the Ttc7Pfsn/fsnP spleen are clearly shown in 
section B. This leads to the aberrant expression of Stat6 shown in what remains of the 
follicle, where Stat6 is excluded in WT littermates (Figure 1.8A), although the intensity 
and total cellular area of Stat6 staining appears similar.  
Sections stained for pStat6 (green, C and D) indicate that the cells expressing the 
activated form of pStat6 in Ttc7Pfsn/fsnP mice are likely extrafollicular immature B cells or 
plasmablasts as these cells also stain brightly for IgM (red) (Loder, Mutschler et al. 1999; 
William, Euler et al. 2005). In addition, the number of pStat6 positive B cells in Ttc7Pfsn/fsnP  
 79
 
 
 
Figure 1.8    Expression of Stat6 and pStat6 in Spleen. Visualized by confocal 
microscopy using a 20x objective.  A-D, Spleen sections from 8-week-old normal 
(left) and Ttc7Pfsn/fsnP (right) mice stained with anti-Stat6 or anti-pStat6 (green), anti-
CD4 (blue), and anti-IgM (red). Yellow indicates co-localization of B cells with 
Stat6. A and B: Overall expression of Stat6 is similar in both Ttc7Pfsn/fsnP and WT. 
However, due to the break-down of follicular structure in Ttc7Pfsn/fsnP spleen (B), Stat6 
is located inside as well as outside of the follicle, whereas WT expression occurs 
extra-follicularly (A). C and D: Expression of pStat6. Ttc7Pfsn/fsnP spleen (D) exhibits 
much more activated phosphorylated Stat6 than WT littermate (C), indicating hyper-
activated B cells residing outside of follicle, possibly contributing to survival of 
autoreactive cells.  
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spleen (D) was elevated over that of WT as we saw very little pStat6 staining on WT 
spleen sections (C). The expression of pStat6 in WT spleen was found only in the IgM 
bright B cells outside of the follicle which denote the newly arrived, more immature B 
cell population or plasmablasts.  
Not only did Ttc7Pfsn/fsnP splenic follicles express higher levels of activated Stat6, 
there were also more pStat6 positive follicles as shown in Figure 1.9. Out of 18 Ttc7Pfsn/fsnP 
counted, thirteen (72%) were positive for pStat6 as compared to only 2 (9%) out of 22 
counted for WT. While 9 WT and 5 Ttc7Pfsn/fsn Pfollicles were slightly positive for pStat6, 
none of the Ttc7Pfsn/fsnP follicles were negative for pStat6 whereas 11 (50%) of the 22 WT 
counted exhibited no pStat6 staining. Thus, we see a higher level of pStat6 in Ttc7Pfsn/fsnP B 
cells in the spleen.  
 
IL-4 expression is increased in Ttc7Pfsn/fsnP spleen  
The extensive distribution of phosphorylated Stat6 in spleen tissue of Ttc7Pfsn/fsnP mice 
suggested that their splenic B cells are responding to a higher level of IL-4 as Stat6 
regulation appears to be normal in Ttc7Pfsn/fsnP B cells (Figure 1.7). IL-4 generally acts 
locally in tissues, being produced by one cell type and exerting its influence on another 
cell near-by. Under normal physiological circumstances, tightly controlled splenic 
structure provides the proper context for the interaction of cells and cytokines for normal 
development, tolerance induction, and the immune response (Roy, Chang et al. 2005; 
Yurasov, Wardemann et al. 2005). Because it has previously been noted that Ttc7Pfsn/fsn 
Pmice have disrupted spleen structure 
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Figure 1.9. Number of splenic follicles positive for pStat6. Eighteen Ttc7Pfsn/fsn Pand 
22 WT follicles were counted and scored for the presence of phosphorylated Stat6 in 
8-week spleen sections as shown in Figure 1.8, C and D.  Scoring was designated as 
negative if sections did not show staining for pStat6, slightly positive if there were one 
to eight positive areas of staining and positive if over eight positive areas were 
counted. Thirteen positive follicles were counted for Ttc7Pfsn/fsnP whereas WT 
demonstrated only two.  
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 (Pelsue, Schweitzer et al. 1998; Mattsson, Duzevik et al. 2005), it is possible that 
abnormal IL-4 production contributes to cell survival and activation, leading to a ramping 
up of autoimmune pathology.  
Since we observed that the activated B cells were in close proximity to splenic T 
cells, and that T cells are a major producer of IL-4 in the spleen, we next wanted to 
confirm the presence of IL-4 in the spleen and compare its expression to that in WT. 
Figure 1.10A depicts a spleen section from an 8-week-old WT mouse that has been 
stained for IL-4 (blue) and CD3 T cells (red). The section clearly showed virtually no 
detectable IL-4 as expected. Analysis of a Ttc7Pfsn/fsnP spleen section (Figure 1.10B) was 
accomplished in four sections due to the enlarged spleen of these mice. We saw a 
dramatic increase in IL-4 staining throughout the spleen, especially in the CD3 positive 
regions (see arrows) (Staining and image kindly provided by Lynn Hannum and Cory 
Ernst).  
A closer examination of follicular structure in Ttc7Pfsn/fsnP spleen using 
immunofluorescent staining to detect IL-4 (green), IgM (blue), and CD3 (red) (Figure 
1.11B) revealed that IL-4 positive T cells (yellow) were located in the same 
extrafollicular region where the pStat6 positive B cells were identified in Figure 1.8, 
depicted here as blue (IgM staining). Wild type spleen showed few, if any IL-4P+P T cells 
(yellow) (Figure 1.11A). Thus, newly arriving immature B cells in Ttc7Pfsn/fsnP mice are 
subjected to IL-4 exposure at a time in their development when they are normally being 
educated in immune tolerance to self-antigen (Norvell, Mandik et al. 1995), which would 
likely alter their future responses and support antibody production.  
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Figure 1.10 IL-4 in Spleen. Gross structure of spleen longitudinal sections showing 
IL-4 production (blue) and CD3 positive cells (red). A, WT 8-week section showing 
normal follicular structure, red-stained T cell zones and non-detectable IL-4. B, 8-
week section divided into 4 parts of Ttc7Pfsn/fsnP spleen showing dramatic enlargement of 
organ size, breakdown of regular follicular structure and disintegration of distinct T 
cell zones.  Highly increased and detectable production of IL-4 is shown throughout 
spleen, but especially in follicles as indicated by arrows. 40x magnification. (Courtesy 
of Lynn Hannum and Cory Ernst) 
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Figure 1.11  IL-4+ Cell Specific Staining in Spleen. IL-4 expression in 8-week spleen 
visualized with fluorescent scanning confocal microscopy using 20x objective. Spleen 
sections stained for IL-4 (green), CD3P+P T cells (red) and IgMP+P B cells (blue). Ttc7Pfsn/fsn 
Pspleen (B) shows an increase in IL-4-positive intensely stained T cells (yellow) as 
compared to WT littermate (A). In addition, T cells are located outside of the follicle in 
the B-cell-rich zone which is consistent with the location of pStat6 positive B cells, 
possibly exposing newly arrived B cells to IL-4. All staining was repeated three times in 
three separate animals with similar results. 
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IL-4 mRNA is upregulated and shows increased stability in Ttc7Pfsn/fsnP mice 
Cytokine mRNA stability as well as transcriptional regulation have been 
demonstrated to play a role in altered cytokine responses (Dokter, Esselink et al. 1993; 
Naora and Young 1995; Pioli, Pucci et al. 1998; Butler, Monick et al. 2002). T cells have 
been shown to be a critical contributor to the development of autoimmunity through 
mechanisms such as: effector functions, B cell co-activation, and production of cytokines. 
Since one of the hallmarks of Ttc7Pfsn/fsnP mice is a high level of extemporaneous IL-4 
production (15X that of normal in the sera) (Pelsue, Schweitzer et al. 1998), we thought it 
probable that the overproduction of IL-4 by T cells was one of the factors contributing to 
their severe systemic autoimmunity. Previous work in Ttc7Pfsn/fsnP mice has demonstrated a 
rapid ramping up of symptoms as well as hyper-activation of lymphocytes in mice past 6-
7 weeks of age (Welner, Hastings et al. 2004), thus, we wanted to examine the regulation 
of IL-4 in T cells before they reach this critical point in disease development.  
RT-PCR of IL-4 expression in 4-week-old mice (Figure 1.12A) revealed that in 
unstimulated Ttc7Pfsn/fsnP T cells IL-4 mRNA expression was actually slightly lower (74%) 
than that of WT; however, following 3 hours of stimulation with plate-bound anti-CD3 
IL-4 mRNA expression jumps to slightly above that of normal (106%). When 
actinomycin D was added to stimulated samples to block mRNA synthesis and then 
analyzed at 2 and 4 hours later, we saw an overall decline in expression in both cell 
populations, but Ttc7Pfsn/fsnP IL-4 mRNA exhibited a more prolonged decline with a slight 
increase at 2 hours (Figure 1.13A). Designating the mRNA expression level after 
stimulation as 100%, 2 hours after the addition of Act D there was 95% of WT mRNA  
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Figure 1.12 IL-4 mRNA expression in T cells. RT-PCR of IL-4 mRNA was performed 
using purified splenic T cells with RNA normalized to 2µg per sample in reverse 
transcriptase  reaction. Samples include unstimulated cells (0), cells stimulated with 
plate-bound anti-CD3 (S), and cells stimulated for 3 hours with anti-CD3 before adding 
actinomycin D to inhibit transcription. These cells were then harvested 2 and 4 hours 
later as indicated. A, Representative gel of 5 separate experiments demonstrating mRNA 
turnover. Four hours after inhibition of transcription Ttc7Pfsn/fsn PT cells still exhibit 
significant presence of IL-4 mRNA. The numbers below IL-4 bands indicate the fold 
difference of WT over Ttc7Pfsn/fsnP at each time point. Ttc7Pfsn/fsnP exhibits lower initial IL-4 
expression whereupon stimulation increases expression over WT and remains higher. 
GADPH was used as a loading control and to confirm normalization. B, After 3 hours of 
stimulation, mRNA is designated as 100% and the percentage of mRNA remaining is 
indicated at designated time points as measured by densitometry. In both Ttc7Pfsn/fsn Pand 
WT cells we see mRNA turnover, but we see a higher percentage of Ttc7Pfsn/fsn  PIL-4 
mRNA remaining which is still above unstimulated levels at 4 hours, indicating longer 
half-life of  IL-4 mRNA in Ttc7Pfsn/fsn Pmice.  Data shown as representative of 5 separate 
experiments with similar results.  
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Figure 1.13  IL-4 mRNA Expression in 4- and 10-week T cells. IL-4 RT-PCR of 4- 
and 10- week T cells presented as the ratio of IL-4 to GADPH, normalized to 
unstimulated WT control as measured by densitometry. Graphs represent one data set of 
five separate experiments with similar results. A, 4-week T cells showing unstimulated 
Ttc7Pfsn/fsnP expressing IL-4 mRNA below that of WT, increasing upon stimulation with 
anti-CD3 and mRNA remaining at 2 and 4 hours after treatment with Act D.  B, 10-week 
T cells repeating same experiment as in A, showing unstimulated Ttc7Pfsn/fsnP cells 
expressing a higher level of IL-4 mRNA than 4-week and WT cells.   
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remaining compared to 103% of Ttc7Pfsn/fsnP, and after 4 hours there was 81% of WT 
mRNA remaining whereas Ttc7Pfsn/fsnP still had 97% (Figure 1.12B). While these figures 
did not reach statistical significance, this trend was similar among 5 separate 
experiments. In addition, when the percentage of mRNA remaining at 4 hours was 
compared to IL-4 mRNA in unstimulated cells, Ttc7Pfsn/fsnP mRNA was 114% above 
unstimulated levels while WT mRNA declined to 95% below unstimulated levels 
indicating differences in mRNA half-life between Ttc7Pfsn/fsnP and WT mice. A single 
experiment examining mRNA after 10 hours of treatment with Act D revealed Ttc7Pfsn/fsnP 
IL-4 mRNA was back to baseline while WT was below baseline as shown above 
(baseline equals mRNA of unstimulated IL-4) which indicated that Ttc7Pfsn/fsn  PT cells are 
able to turn over IL-4 mRNA after a prolonged period of transcriptional inhibition (data 
not shown).   
Interestingly, when the same analysis was performed with T cells from 10-week-
old mice, we saw a similar trend in all but the unstimulated samples (Figure 1.13B). 
Ttc7Pfsn/fsnP IL-4 mRNA was expressed at a higher level (113%) relative to WT and 
following stimulation increased to 133% relative to unstimulated WT control whereas 
WT mRNA increased to 123% that of unstimulated control. Four hours after treatment 
with Act D Ttc7Pfsn/fsnP IL-4 mRNA showed little decline remaining at 133% as compared 
to WT which was measured at 113% relative to control. Thus, at 10-weeks-of-age 
Ttc7Pfsn/fsnP IL-4 mRNA was expressed at a higher level in unstimulated T cells as 
compared to WT but followed a similar trend as that of 4-week-old mice upon 
stimulation and treatment. A single experiment measuring relative IL-4 mRNA at 6 hours 
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post-treatment suggested both Ttc7Pfsn/fsnP and WT mRNA was turned over to a pre-
stimulated expression level (data not shown).  
In order to normalize the concentration of RNA at 2µg per sample for RT-PCR, 
total RNA concentration was measured by spectrophotometry. Table 1.1 summarizes the 
raw data for 4-week unstimulated T cells. Measurements indicated that Ttc7Pfsn/fsnP cells 
had approximately 3X the total RNA content per cell as did WT, suggesting the in vivo 
biological impact of increased IL-4 mRNA stability in Ttc7Pfsn/fsnP may be more significant 
than demonstrated ex vivo.  
 
Cyclosporine A shuts down IL-4 mRNA production 
The immunosuppressive agent CsA has been shown to bind to the intracellular 
protein cyclophillin and inhibit the phosphatase calcineurin which thus blocks a CaP++P 
dependent pathway activated by TCR/CD3 stimulation (Dokter, Esselink et al. 1993; 
Naora and Young 1995). To investigate the effect of CsA on IL-4 mRNA expression, 4- 
and 10-week enriched splenic WT and Ttc7Pfsn/fsnP T cells were pre-treated with CsA 
(1µg/mL) or DMSO control for 30 minutes and then stimulated on anti-CD3 coated 
plates. As shown in Figure 1.14A, CsA blocked mRNA production completely in 4-week 
T cells in both Ttc7Pfsn/fsnP and WT. Ten-week T cells (Figure 1.14B) showed a slightly 
different result where CsA reduced but did not completely block IL-4 mRNA production 
in both cell populations. This suggests slightly different transcriptional control of IL-4 
between 4- and 10-week animals but that a similar pathway is involved in both WT and 
mutant mice.  
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Table 1.1  Total RNA Concentration in Splenic T cells 
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Figure 1.14 IL-4 mRNA Expression in Cyclosporin-Treated T cells. RT-PCR of 4- 
and 10-week T cells unstimulated, stimulated with anti-CD3 and stimulated with anti-
CD3 treated with Cyclosporine A.  Data are presented as the ratio of IL-4 mRNA to 
GADPH mRNA and normalized to unstimulated WT control as measured by 
densitometry. Graphs are representative of three separate experiments with similar 
results. A, 4-week T cells demonstrate an increase in IL-4 mRNA upon stimulation but 
remain at unstimulated levels with the addition of CsA blocking a CaP++P induced 
pathway in both Ttc7Pfsn/fsnP and WT. B, 10-week T cells also demonstrate an increase in 
IL-4 mRNA upon stimulation but do show a slight increase in mRNA above untreated 
unstimulated levels when treated with CsA.  
 
 92
 
T cells from Ttc7PfsnP mice show an increase in IL-4 protein production that mirrors 
IL-4 mRNA regulation  
Evidence of differentially regulated WT and Ttc7Pfsn/fsnP mRNA expression for IL-4 
in splenic T cells suggested that we confirm this effect on protein production. Previous 
work has shown an increased capacity for IL-4 production in 8-10 week Ttc7Pfsn/fsnP T cells 
(Welner, Hastings et al. 2004) but 4-week T cells had remained unanalyzed. Thus, 6 x 
10P6P cells per sample of 4-week enriched splenic T cells were plated on anti-CD3 coated 
plates or in uncoated wells for unstimulated samples. Figure 1.15A shows that in 
unstimulated cells, both Ttc7Pfsn/fsnP and WT produced 61 pg/mL of IL-4 after 24 hours of 
culture. With anti-CD3 stimulation, Ttc7Pfsn/fsnP cells produced more than WT, at 2790 
pg/mL and 2358 pg/mL respectively. After 3 hours of anti-CD3 stimulation the addition 
of Act D resulted in a much lower IL-4 measurement of 325 pg/mL from Ttc7Pfsn/fsnP T 
cells and to 81 pg/mL in WT (p=0.0002).  
Figure 1.15B shows that 10-week unstimulated Ttc7Pfsn/fsnP T cells out-produced 
WT by almost 1200-fold, with IL-4 measured at 1198 pg/mL while WT IL-4 was barely 
detectable at 0.133 pg/mL. Upon stimulation, Ttc7Pfsn/fsnP T cells showed little increase, 
rising only to 1215 pg/mL agreeing with previous data (Welner, Hastings et al. 2004), 
while WT increased to 525 pg/mL. When Act D was added after 3 hours of stimulation 
IL-4 remained high in Ttc7Pfsn/fsnP assays at 1062 pg/mL whereas WT IL-4 was back to 
background levels at 0.133 pg/mL. All three measurements comparing Ttc7Pfsn/fsnP to WT 
were statistically significant with p values of 0.00005, 0.0002 and 0.0001 respectively.  
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Figure 1.15 IL-4 Production in 4- and 10-week T cells. IL-4 protein production in 4- 
(A and C) and 10-week (B and D) mice was measured by ELISA using 6.0x10P6P cells per 
well of enriched splenic T cells previously cultured for 24 hours in 400uL volume 
samples in 48-well culture plates. ELISA samples assayed in triplicate with 100uL 
samples. A and B: IL-4 was produced upon plate-bound anti-CD3 stimulation in both WT 
and Ttc7Pfsn/fsnP, although at higher levels in Ttc7Pfsn/fsnP. Ttc7Pfsn/fsn Pcells produced IL-4 at 10 
weeks even without stimulation. After three hours of stimulation, actinomycin D was 
added to sample to inhibit transcription. In both 4- and 10-week Ttc7Pfsn/fsnP mice, IL-4 
protein remained elevated, suggesting altered mRNA stability and regulation. Graphs 
represent one data set of four separate experiments with similar results. See text for p 
values.  
C and D:  IL-4 protein production is shut down by the addition of Cyclosporine A to 
culture of T cells. Enriched splenic T cells are pre-treated with CsA or the same 
concentration of DMSO (stim) for 30 minutes and then plated at 6.0x10P6P cells per well 
into an anti-CD3 coated culture plate and allowed to stimulate for 24 hours.  In both C, 4-
week, and D, 10-week T cells, CsA shuts down production of IL-4. This indicates that 
Ttc7Pfsn/fsn Pmice respond to TCR stimulation through a calcium-dependent pathway as do 
WT, suggesting IL-4 production is not being induced through an alternate pathway. 
Graphs present one data set of two separate experiments with similar results. 
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Previous flow cytometry data has shown a slight increase in the ratio of CD4P+ PT 
cells over that of CD8P+P T cells (2.8/2.0) in the spleens of Ttc7Pfsn/fsnP mice (Pelsue, 
Schweitzer et al. 1998) which may explain some of the increase in IL-4 that we see over 
that of WT. However, the similar expression of IL-4 in stimulated and unstimulated 
samples of the 4-week data suggests that this ratio may not affect the magnitude of IL-4 
expression as much as other regulatory measures. In addition, there were no detectable 
differences in cell viability between Ttc7Pfsn/fsnP and WT during and after 24-hour cell 
culture as measured by Trypan blue exclusion (data not shown).  
To measure the effect of CsA on IL-4 protein production, T cells were plated with 
either CsA (1µg/mL) or DMSO for stimulated control samples. In both 4-week (Figure 
1.15C) and 10-week (Figure 1.15D) T cells CsA shut down production of IL-4 at 
background or non-detectable levels. This suggests that in both Ttc7Pfsn/fsnP and WT at 4- 
and 10-weeks IL-4 production is stimulated by a CsA sensitive, CaP++P dependent pathway.  
 
Ttc7Pfsn/fsnP mice show an increase in activated and memory T cells as compared to 
WT littermates  
Differences in IL-4 production and IL-4 mRNA stability between Ttc7Pfsn/fsnP and 
WT T cells suggested the possibility of differences in T cell subsets as well. It has 
previously been demonstrated that naïve T cells produce IL-4 mRNA rapidly upon TCR 
stimulation which then degrades more quickly than the IL-4 mRNA in effector/memory 
cells (Carter and Malter 1991). The presence of more total RNA in Ttc7Pfsn/fsnP mice also 
suggested the presence of more activated T cells. Since the full-blown effects of 
autoimmunity develop at 5-6 weeks of age in Ttc7Pfsn/fsnP mice, we decided to examine the 
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distribution of splenic T cells in naïve, activated and memory subsets at 4-weeks-of-age 
to see if changes in T cell phenotype occur before full-blown disease, and at 10-weeks to 
examine phenotypic changes in T cells as disease progresses.  
Using four-color flow cytometry and previously identified CD4+ cell surface 
markers to designate subset phenotypes as naïve: CD44PloP/ CD62LPhiP; activated: CD44PhiP/ 
CD62LPhiP; memory: CD44PhiP/CD62LPloP; (Bingaman and Farber 2004); (DeRyckere and 
DeGregori 2005); Eaton-Bassiri et al, 2000; Lynch and Ceredig, 1989; Swain et al, 1990; 
Yagi et al., 2001) we examined the distribution of CD4+ T cells. A representative 
example of the gating done to identify these subsets is shown in Figure 1.16. These data 
are summarized in Table 1.2. 
At 4-weeks-of-age Ttc7Pfsn/fsnP mice have a significantly different distribution of 
CD4+ T cells in all subsets with 13.4% fewer naïve cells, 15.2% more activated cells, and 
16% more memory cells than their wild-type littermates (Figure 1.17). This trend 
continues with 10-week Ttc7Pfsn/fsnP mice having 6.3% fewer naïve cells, 9.03% more 
activated cells, and 11.24% more memory cells than their wild-type littermates (Figure 
1.18). The actual CD4+ population of gated lymphocytes is different between the two 
ages with CD4+ T cells comprising 13.7 ± 2.42% of the gated lymphocytes in 4-week 
WT animals while Ttc7Pfsn/fsnP only make up 5.16 ± 1.5% of gated cells. In 10-week 
animals WT CD4+ T cells make up 23 ± 3.08% of gated lymphocytes while Ttc7Pfsn/fsnP 
mice are 14.4 ± 3.9%.  
Even though the percentages of CD4+ T cells are reduced in the spleens of 
Ttc7Pfsn/fsnP mice as compared to WT, Pelsue and colleagues (1998) have previously 
demonstrated that due to the increased cellularity of the spleens of Ttc7Pfsn/fsnP mice there  
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Figure 1.16. Representative CD62L/CD44 dot plots of CD4+ T cell, lymphocyte 
gating of Ttc7Pfsn/fsnP and WT splenocytes. Data from this analysis was used to generate 
Table 1.2, where naïve cells were CD62LPhiP/CD44PloP (upper left quadrant), activated cells 
were CD62LPhiP/CD44PhiP (upper right quadrant) and memory cells were CD62LPloP/CD44PhiP 
(lower right quadrant). The results presented are representative of all mice examined 
where n=5 for each age and genotype. 50,000 lymphocyte events were recorded for 
each analyses. IL-4+ cells were analyzed similarly with the addition of a gate on each 
quadrant identifying the IL-4+ cells in that quadrant (Eaton-Bassiri, 2000).  
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4- and 10-Week Splenic CD4+ T cell Populations 
     
  Naïve % Activated % Memory % 
4-Week  CD62Lhi/CD44lo CD62Lhi/CD44hi CD62Llo/CD44hi
 Ttc7WT 35.0 ± 9 9.6 ± 2.39 15.0 ± 2.39 
 Ttc7Pfsn/fsnP 21.6 ± 9.4* 24.8 ± 6.6* 31.0 ± 9.53* 
  p=0.049 p=0.0046 p=0.0175 
10-Week     
 Ttc7WT 33.4 ± 3.7 8.07 ± 4.3 16.53 ± 6.2 
 Ttc7Pfsn/fsnP 27.1 ± 6 17.1 ± 6.6* 27.77 ± 4.7* 
   p=0.038 p=0.014 
n=5     
 
Table 1.2      4- and 10-Week Splenic CD4+ T cell Populations 
Summary of data from Figure 1.17. 
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Figure 1.17. 4-Week CD4+ T cell Populations.  Distribution of 4-week CD4+ cells 
by phenotype. Ttc7Pfsn/fsnP mice have a lower percentage of CD4+ naïve cells (p=0.049), 
and a higher percentage of activated (p=0.0046) and memory (p=0.0175) splenic T 
cells than WT littermates. Data are presented as the mean percent of five separate 
experiments ± SEM.  
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Figure 1.18. 10-Week CD4+ T cell Populations. Distribution of 10-week CD4+ T 
cells by phenotype. Ttc7Pfsn/fsnP mice have a lower percentage of naïve cells and a higher 
percentage of activated (p=0.038) and memory (p=0.014) splenic T cells than WT 
littermates. Data are presented as the mean percent of five separate experiments ± 
SEM.  
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was an actual 2.5-fold elevation of total CD3+ T cells. When we calculate the actual 
numbers of CD4+ cells in spleens of 4-week mice Ttc7Pfsn/fsnP animals have almost twice as 
many with 6.05 x 10P6 PCD4+P Pcells compared to WT with 3.76 x 10P6P CD4+ cells. 10-week 
Ttc7Pfsn/fsnP mice have almost 10X more than WT with 1.15 x 10P8P CD4+ cells compared to 
WT with 1.19 x 10P7P CD4+ cells in their spleens. Thus, the differences in percentages 
become more magnified when translated into total cell numbers. The functional 
consequences of elevated total numbers of activated and memory cells can be seen in the 
elevation of IL-4 production and the difference in IL-4 mRNA.  
 
Ttc7Pfsn/fsnP CD4+ T cells show an increase in the percentage of IL-4 positive cells 
without exogenous stimulation 
Given the differences in CD4+ T cell subsets between Ttc7Pfsn/fsnP and WT mice we 
next wanted to examine IL-4 expression among the subsets. We used the same activation 
markers to designate phenotype, i.e. CD62L/CD44, and stained for intracellular IL-4 in 
unstimulated as well as CD3 stimulated cells in both 4- and 10-week mice. At 4-weeks, 
in both the unstimulated and stimulated groups Ttc7Pfsn/fsnP mice had higher percentages of 
IL-4+ cells than their WT littermates (Figure 1.19). In addition, the difference in 
percentages between the IL-4+ stimulated and unstimulated cells within groups were 
higher in the Ttc7Pfsn/fsnP mice suggesting that more cells were responding to CD3 
stimulation. These data are summarized in Table 1.3.  It is important to note that the 
numbers given are percentages of the subsets designated in the table of splenic T cell 
populations and not percentages of total T cells.  These results suggest that changes in T  
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Figure 1.19. 4-Week CD4+ IL-4+ T Lymphocytes.  Data presented are the 
percentage of IL-4+ cells in each indicated subset as shown in Figure 1.17. Stimulated 
samples were cultured for 24 hours in plates coated with anti-CD3 to trigger IL-4 
production in media containing Monensin to prevent protein secretion. In all subsets 
shown in 4-week cells Ttc7Pfsn/fsnP showed a slightly higher percentage of IL4+ cells in 
both stimulated and unstimulated samples, but were not statistically significant. These 
data are summarized in Table 1.3. 
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4-Week IL-4+ CD4+ T cell Populations 
     
  Naïve % Activated % Memory % 
  CD62Lhi/CD44lo CD62Lhi/CD44hi CD62Llo/CD44hi
unstimulated     
 Ttc7WT 2.39 ± 1.3 5.48 ± 1.9 2.95 ± 0.9 
 Ttc7Pfsn/fsnP 3.05 ± 1.8 9.3 ± 4.4 5.6 ± 2.3 
α-CD3 
stimulated 
    
 Ttc7WT 3.14 ± 1.8 10.01 ± 8 5.46 ± 3.4 
 Ttc7Pfsn/fsnP 7.96 ± 4.2 14.47 ± 9.9 14.2 ± 2.3 
n=5     
% Stimulated 
- % 
Unstimulated 
    
 Ttc7WT 0.75 4.53 2.51 
 Ttc7Pfsn/fsnP 4.91 5.17 8.6 
 
Table 1.3     4-Week IL-4+ T cells. Summary of data presented in Figure 1.19.  
 
 
 
 
10-Week IL-4+ CD4+ T cell Populations 
  Naïve % Activated % Memory % 
  CD62Lhi/CD44lo CD62Lhi/CD44hi CD62Llo/CD44hi 
unstimulated   MFI  MFI  MFI 
 Ttc7WT 2.22±0.98 6 8.05±6.3 7.4 7.39±5 7.4 
 Ttc7Pfsn/fsnP 40.79±1.8* 5.5 63.1±45 6.6 51.19±25.2 5.77 
  p=0.0042      
Anti-CD3 
stimulated 
       
 Ttc7WT 26.11±5.5 4.1 83.32±0.65 5.37 89.87±5.48 3.78 
 Ttc7Pfsn/fsnP 34.17±2.7 3.46 63.4±31 4.6 75.5±0.8 3.77 
        
n=5        
 
Table 1.4   10-Week IL-4+ T cells.  Summary of data presented in Figure 1.20.  
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cell populations occur before the onset of full-blown autoimmune disease with more 
activated/memory cells in Ttc7Pfsn/fsnP mice poised to produce IL-4. 
 10-week animals exhibited pronounced differences in percentages of IL4+ CD4+ 
cells in the unstimulated subsets, especially in the naïve population which reached a 
statistically significant elevation in Ttc7Pfsn/fsnP mice (Figure 1.20 and table 1.4). With 
plate-bound anti-CD3 stimulation, WT T cells responded as expected with an increase in 
IL4+ cells in all subsets, while the percentage of IL4+ Ttc7Pfsn/fsnP CD4+ T cells only 
increased in the memory population. These results mirror the IL-4 ELISA results 
presented previously where we showed spontaneous IL-4 production in unstimulated 
Ttc7Pfsn/fsnP T cells and the presence of IL-4 lingering after shutting down transcription with 
actinomycin D. An expanded memory population with more cells producing IL-4 would 
contribute to an increase in more stable IL-4 mRNA seen in Ttc7Pfsn/fsnP. This would allow 
for translation to continue accounting for the increase in IL-4 over WT in Ttc7Pfsn/fsnP after 
the halt of transcription.   
Another important result revealed by this analysis is that this suggests the 
production of IL-4 in vivo may be an antigen-driven process. Foucras et al (Foucras, 
2002) demonstrated that the presence of soluble antigens in vivo can push naïve cells into 
activated/memory cells of the Th2 phenotype. This, coupled with a Th2 skewed BALB/c 
background, may certainly contribute to an increase of IL-4. Thus, we suggest that it is 
the presence of self-antigens in Ttc7Pfsn/fsnP that induce autoreactive naïve T cells to 
produce IL-4 and subsequently push them into the expanded populations of 
activated/memory T cells seen in Ttc7Pfsn/fsnP mice.  
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Figure 1.20. 10-Week CD4+ IL-4+ T Lymphocytes. Data presented are the 
percentage of IL-4+ cells in each indicated subset as shown in Figure 1.18. Stimulated 
samples were cultured for 24 hours in plates coated with anti-CD3 to trigger IL-4 
production in media containing monensin to prevent protein secretion. In the 
unstimulated 10-week samples, all subsets showed a higher percentage of IL-4+ cells 
for Ttc7Pfsn/fsnP, with the naïve subset having a significantly higher percentage (p=0.004). 
However, upon 24-hour stimulation with plate-bound anti-CD3 the WT cells had a 
higher percentage of IL4+ cells in the activated and memory subsets, while Ttc7Pfsn/fsnP 
was still higher in naïve cells. These data are summarized in Table 1.4.  
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Results: Section 2: Stat6-/-Ttc7Pfsn/fsnP phenotype and functional study 
 
Stat6-/-Ttc7Pfsn/fsnP mice have severe autoimmunity and inflammation including 
increased renal disease, splenomegaly, altered subsets of activated B and T cells, and 
increased production of IL-4 
Preliminary data identified the presence of constitutively activated Stat6 in the B 
cells of Ttc7Pfsn/fsnP mice. This was associated with high serum levels of IL-4 and the 
upregulation of IL-4/Stat6 responsive genes such as MHC II and CD23. High serum 
levels of IgE suggested hyper-active B cells, which were responding to IL-4 and help 
from hyper-active T cells. Many groups have identified similar characteristics in animals 
with engineered, constitutively active Stat6 (Daniel, Salvekar et al. 2000; Bruns, 
Schindler et al. 2003; Kaplan, Sehra et al. 2007), and many groups have knocked Stat6 
out and reported a dramatic reduction or elimination of these traits (Kaplan, Schindler et 
al. 1996; Linehan, Warren et al. 1998; Kaplan, Wurster et al. 1999; Mori, Morris et al. 
2000; Singh, Saxena et al. 2003). Stat6 deficient animals have also been found to have a 
dramatic reduction in the amount of IL-4 produced (Kaplan, Schindler et al. 1996; 
Dorado, Jerez et al. 2002). Thus, we crossed our Ttc7 heterozygotes with Stat6 deficient 
animals to produce double-mutant animals with the Stat6-/-Ttc7Pfsn/fsnP genotype to analyze 
the contribution Stat6 made to the phenotype of Ttc7Pfsn/fsnP mice. All genotypes were 
confirmed with PCR and the lack of functional Stat6 was confirmed with Western 
blotting. Our expectation was the ameliorization of some of the autoimmune phenotype 
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displayed by Ttc7Pfsn/fsnP mice, especially that which is associated with hyper-active 
lymphocytes. We performed a general survey to evaluate the resulting phenotype.  
 
Gross Morphology 
Figure 2.1 illustrates the resulting gross morphology of Stat6-/-Ttc7Pfsn/fsnP mice. 
Shown in the foreground of Figure 2.1A is a 10-week-old male which clearly 
demonstrates its reduced size, hunched-over stance due to extreme splenomegaly, and the 
paleness of its ears due to extreme anemia as compared to its Stat6-/-Ttc7WT littermate 
in the background. Figure 2.1B is the same animal held in a position to display the 
characteristic distended belly and hair striations indicative of the Ttc7fsn mutation. 
Figure 2.2A presents an 18-week-old female on the right, again with smaller size and 
hunched stance, but also clearly showing the characteristic skin pathology around the 
head, neck and eyes (foreground, Figure 2.2B) from which Flaky Skin was named. Figure 
2.3 presents a thirteen-week female with reduced size (Figure 2.3A), a close-up of skin-
pathology around the eyes (Figure 2.3B), and the pale ears and distended abdomen 
(Figure 2.3C) typical to Ttc7Pfsn/fsnP mice. These figures demonstrate some of the typical 
features seen in Ttc7Pfsn/fsnP mice, and also some of the variation seen between individuals 
with a genetically identical background. There are no differences typically associated 
with gender, which appears to be true of Stat6 deficient Ttc7Pfsn/fsnP mice as well. Overall, 
the appearance of the Stat6-/-Ttc7Pfsn/fsnP and the Stat6WTtc7Pfsn/fsnP animals looks very 
similar. 
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Figure 2.1. Stat6-/-Ttc7Pfsn/fsnP and 
Stat6-/-Ttc7WT Littermates. 
Photograph of 10.5 week Stat6-/-
Ttc7fsn/fsn (foreground A) and Stat6-
/-Ttc7WT (background A) male
littermates. A. Photo shows
characteristic hunched stance due to
splenomagaly, pale ears due to
anemia, and size difference of
Ttc7Pfsn/fsnP mutation. B. Can see
distended belly and striations of fur
characteristic of Ttc7Pfsn/fsnP. 
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Figure 2.2. Stat6-/-Ttc7Pfsn/fsnP and Stat6-/-Ttc7WT Littermates.  Photograph of 18-
week Stat6-/-Ttc7Pfsn/fsnP (right A and foreground B) and Stat6-/-Ttc7WT (left A and 
background B) female littermates. A. Size difference and stance is clearly shown with 
characteristic Ttc7Pfsn/fsnP skin pathology on head, neck and around eyes. B. Closer view 
of skin on neck. Fur loss and skin pathology affects males and females equally.  
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Figure 2.3. Stat6-/-
Ttc7Pfsn/fsnP and Stat6-
/-Ttc7WT 
Littermates 
 Photograph of 13-
week Stat6-/-Ttc7Pfsn/fsnP
(left A, B, and
foreground C) and
Stat6-/-Ttc7WT 
female littermates. A.
Characteristic skin
pathology of Ttc7Pfsn/fsnP
is clearly shown on
face, around eyes and
in B. close-up. C.
Distended belly, fur
striations, pale ears,
and skin inflammation
of Ttc7 fsn/fsn
C
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Body Weight 
Figure 2.4 represents a comparison of body weight of 10-week-old animals, with 
the females, who are generally smaller, graphed separately from males. Figure 2.4A, left 
columns, compare Stat6-/-Ttc7Pfsn/fsnP females to Stat6-/-Ttc7WT females, showing the 
statistically significant reduced body weight of the Ttc7Pfsn/fsnP animals (p=0.03). The right 
columns compare Stat6-/-Ttc7Pfsn/fsnP males to Stat6-/-Ttc7Wt males showing the reduced 
body weight of the Ttc7Pfsn/fsnP animals (p=0.0062). Figure 2.4B compares female Stat6-/- 
animals to Stat6 WT. The left columns compare Ttc7Pfsn/fsnP females, with the Stat6-/- 
reduced in size from Stat6WT (p=0.0060). The right columns compare Ttc7WT females, 
with the Stat6-/- also reduced in size from their Stat6WT counterparts (p=0.0019). Thus, 
Stat6 deficient animals are generally smaller in body weight than their Stat6 intact 
counterparts, despite their Ttc7 status; however, the double-mutants show a further 
reduction over WT.  
 
Lifespan 
The lifespan of Ttc7Pfsn/fsnP mice is dramatically reduced from their normal WT 
littermates to about 12-15 weeks of age. They generally start showing severe autoimmune 
pathology around 5-6 weeks and get progressively sicker until death. We let several 
Stat6-/-Ttc7Pfsn/fsnP mice age and found no significant difference between these animals and 
their Stat6 intact counterparts. Figure 2.5 depicts the variation in lifespan of several mice, 
which closely followed the trend in Stat6 sufficient Ttc7Pfsn/fsnP mice, with the average 
difference only a few days.  
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Figure 2.4  Stat6-/-Ttc7 Body Weight. A. Stat6-/-Ttc7Pfsn/fsnP females (left, p=0.03) and 
males (right, p=0.0062) are significantly smaller than their Stat6-/-Ttc7WT 
counterparts. B. Female Stat6-/-Ttc7Pfsn/fsnP (p=0.0060)and Stat6-/-Ttc7WT (p=0.0019) 
are significantly smaller than their Stat6 intact counterparts. N=5 of each animal.  
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Figure 2.5. Stat6-/-Ttc7 Lifespan. Stat6-/-Ttc7Pfsn/fsnP Lifespan averages 11.5 weeks. 
The average lifespan of the Stat6 deficient Ttc7Pfsn/fsnP mice (n=8) is similar to the Stat6 
intact Ttc7Pfsn/fsnP, and varies between animals in a similar manner, an example of which 
is shown on left side of graph.  
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Spleen Cellularity 
Ttc7Pfsn/fsnP mice have a dramatic increase in spleen cellularity over their WT 
littermates with altered lymphocyte populations such as a decrease in the percentage of 
CD3+ cells, a decrease in percentage of CD19+ cells (although increased overall 
numbers) and an increase in the percentage of immature red blood cells (Pelsue, 
Schweitzer et al. 1998). We performed flow cytometry on whole Stat6-/- spleens to 
evaluate any alterations in cell populations due to the absence of Stat6 (data are 
summarized in Table 2.1) 
In Stat6-/-Ttc7Pfsn/fsnP the total spleen cellularity ranges from 0.7 to 3.4 times that of 
Ttc7Pfsn/fsnP mice; specifically, Stat6-/-Ttc7Pfsn/fsnP cell numbers averaged 25 ± 36.7 x 10P8 Pcells 
while Ttc7Pfsn/fsnP averaged 13.0 ± 5.4 x 10P8 Pcells as determined by cell count with a 
hemacytometer and the trypan blue exclusion method. (Stat6 deficient and intact Ttc7 
WT were both similar, 2.7 ± 0.8 x 10P8 Pcells). CD3+ cells recovered slightly in Stat6-/-
Ttc7Pfsn/fsnP mice to 17.95 ± 3.9 percent (p=0.0003) as did CD4+ cells. The CD8+ data was 
highly variable due to technical difficulties, but did show an overall recovery. Stat6-/-
Ttc7Pfsn/fsnP spleens exhibited a slight reduction in CD19+ cells, although as mentioned 
above, due to the high cellularity would still have a large CD19+ population. As 
expected, the Stat6-/-Ttc7Pfsn/fsnP animals expressed very low levels of CD23 (p=0.0007), 
but surprisingly, MHC II was expressed by over 20% of the cells, however, still below 
that of Stat6 intact animals (p=0.0005). Interestingly, Stat6-/-Ttc7Pfsn/fsnP animals had a 
slight decrease (to 15%) in the high level of immature red blood cells (Ter-119)  
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Table 2.1. Stat6-/-Ttc7 Spleen Cell Populations.  All numbers represent percentages 
of total spleen. 
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expressed by their Stat6 intact counterparts (18%). Stat6Ttc7Pfsn/fsnP animals also had a 
slight increase in F4/80 macrophages and GR-1 granulocytes.  
In contrast to our findings, others have reported a decrease of 25% in splenic 
cellularity in a lupus-prone Stat6-deficient model (Xu, Duan et al. 2006) as well as no 
change in cellularity in a different lupus-prone Stat6-deficient model (Singh, Saxena et al. 
2003). The latter also reported no change in the number of T cells, B cells or CD4 and 
CD8 distribution. In addition, most reports of Stat6 deficiency declare a dramatic 
decrease in the percentage and number of CD4+ Th2 cells (Jankovic, Kullberg et al. 
2000; Bruns, Schindler et al. 2003; Singh, Saxena et al. 2003). Other reports have 
indicated an increase in cellularity only when Stat6 is constitutively expressed, with a 
concomitant increase in CD4+ Th2 T cells (Bruns, Schindler et al. 2003; Kaplan, Sehra et 
al. 2007). The reason(s) for the opposite effects of Stat6 deficiency in Ttc7Pfsn/fsnP mice is 
most likely due to the presence of the defective Ttc7 gene, as our Ttc7 WT mice appear 
to be consistent with published data. However, since the function of this gene is presently 
unknown, further research will be needed.  
 
Stat6 deficiency increases the percentage of immature, IgDPloP/IgMPhiP B cells in 
Ttc7Pfsn/fsnP spleen 
Previous work in our lab (Farrington 2006) established an alteration in B cell 
subsets in Ttc7Pfsn/fsnP spleen with an increase in the percentage of immature B cells 
(IgDPloP/IgMPhiP), a significant decrease in mature B cells (IgDPhiP/IgMPloP, p=≤ 0.01), and a 
decrease in transitional B cells (IgDPhiP/IgMPhiP) as compared to Ttc7 WT littermates  
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Figure 2.6. IgM/IgD Flow Cytometry Gating Example for B cell Subsets. Flow 
cytometric gating determination of the ratio of IgM/IgD in splenocytes. Box labeled 
R1 represents the immature population of B cells with an IgDPloP/IgMPhiP phenotype. The 
box labeled R2 represents the mature population of B cells with an IgDPhiP/IgMPloP 
phenotype. The box labeled R3 represents the transitional population of B cells with 
an IgDPhiP/IgMPhiP phenotype. Results from this type of gating are shown in Figure 2.7 for 
Stat6-/- and Figure 3.2 for anti-IL-4 treated Ttc7Pfsn/fsnP mice.  
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Figure 2.7  Ratio of IgM/IgD: B cell Subsets.  Stat6-/-Ttc6Pfsn/fsnP mice have a 
significantly increased population of immature B cells than Stat6 intact Ttc7Pfsn/fsnP 
mice. A. Stat6 intact Ttc7Pfsn/fsnP mice have an increased percentage of immature B 
cells, a significantly decreased percentage of mature B cells (p=≤ 0.01) and a 
slightly decreased percentage of transitional B cells than their WT littermates. B. 
Stat6-/-Ttc7Pfsn/fsnP mice have a significantly higher percentage of immature B 
cells (p=0.0014), a significantly decreased percentage of mature B cells 
(p=0.049) and a significantly decreased percentage of transitional B cells 
(p=0.0066) than their Stat6-/-Ttc7WT littermates. C. Stat6-/-Ttc7Pfsn/fsnP mice have 
a significantly increased percentage of immature B cells (45.19 ± 7.5%, 
p=0.0009) than Stat6 intact Ttc7Pfsn/fsnP mice (20.9 ± 3%) but the mature and 
transitional populations are unchanged. Data shown are mean percentages of 5 
separate experiments ± SEM. 
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(Figure 2.7A). Because of the functional differences in these subsets, and the observed 
increase in spleen cellularity of our Stat6-/-Ttc7Pfsn/fsnP mice, it was important to examine 
the distribution of B cells in the spleens our Stat6 deficient Ttc7Pfsn/fsnP animals. We 
performed flow cytometry on single cell suspensions of whole spleen and then gated on 
the lymphocyte portion of the forward and side scatter plots. Determination of IgM and 
IgD expression was gated as shown in Figure 2.6.  
There was very little difference in the percentage of B cells comprising the mature 
B cell subset, with Stat6-/-Ttc7Pfsn/fsnP at 8.9 ± 5.1% and Ttc7Pfsn/fsnP at 9.2 ± 1.2%. The 
transitional subset was also very similar with Stat-/-Ttc7Pfsn/fsnP at 9.06 ± 4.9% and 
Ttc7Pfsn/fsnP at 9.0 ± 4.6%. However, the immature subset was dramatically different. While 
Ttc7Pfsn/fsnP mice measured 20.9 ± 3%, Stat6 deficient animals measured 45.19 ± 7.5% 
immature B cells (p=0.0009). The functional consequences of this difference have yet to 
be determined, but because this subset includes B-1 and marginal zone B cells we can 
imagine this population to be an active participant in B cell associated pathogenesis as it 
has been implicated in the production of autoantibodies and autoimmunity (Sato, Ono et 
al. 1996; Ying, Proost et al. 2000; Wurster, Rodgers et al. 2002; Amano, Amano et al. 
2003; Hardy 2006).  
 120
 
Results of Stat6-/- T cell Populations and IL-4 Production 
 
Stat6-/-Ttc7Pfsn/fsnP mice have a statistically significant higher percentage of activated 
CD4+ T cells than Ttc7Pfsn/fsnP mice 
The effect of Stat6 activation on lymphocytes has been well-studied by several 
groups. When constitutively activated, Stat6 was found to induce an activated phenotype 
in T cells compared to normal which was found to enhance autoimmune disease in mice 
(Daniel, Salvekar et al. 2000; Bruns, Schindler et al. 2003). Many groups have also found 
that knocking out Stat6 results in reduced lymphocyte activation and the dramatic 
reduction or complete absence of disease pathology (Daniel, Salvekar et al. 2000; Bruns, 
Schindler et al. 2003; Singh, Saxena et al. 2003; Kaplan, Sehra et al. 2007). Since we 
found that significantly more Ttc7Pfsn/fsnP T cells exhibited an activated phenotype than WT 
T cells, we wanted to examine the effect of the absence of Stat6 in Ttc7Pfsn/fsnP using our 
Stat6-/-Ttc7Pfsn/fsnP cross. Thus, we performed 4-color flow cytometric analysis on 10-
week-old animals using the same cell-surface markers as previously described above. 
These data are summarized in Table 2.2. 
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Stat6-/- CD4+ T cell Populations 
 Naïve % Activated % Memory % 
 CD62Lhi/CD44lo CD62Lhi/CD44hi CD62Llo/CD44hi 
Stat6-/-Ttc7WT 43.95 ± 1.66 13.97± 0.33 13.03 ± 1.01 
Stat6-/-Ttc7Pfsn/fsnP 23.37 ± 2.8* 38.76 ± 1.7* 22.25 ± 3.89* 
n=3 p=0.0011 p=0.0010 p=0.0467 
    
Ttc7Pfsn/fsnP 27.1 ± 6 17.1 ± 6.6 27.77 ± 4.7 
Stat6-/-Ttc7Pfsn/fsnP 23.37± 2.8 38.76 ± 1.7* 22.25 ± 3.89 
  p=0.001  
 
Table 2.2. Stat6-/-Ttc7 CD4+ Splenic T cell Populations. Summary of data presented 
in Figure 2.8. 
 
 
The changes in the populations of naïve and memory T cells were very small; 
with a slight but not significant reduction in percentages of both naïve and memory 
Stat6-/-Ttc7Pfsn/fsnP T cells from Ttc7Pfsn/fsnP T cells. To our surprise, however, the absence of 
Stat6 more than doubled the percentage of T cells with an activated phenotype in Stat6-/-
Ttc7Pfsn/fsnP mice (Figure 2.8C). Ttc7Pfsn/fsnP activated T cells represented 17.1% of the CD4+ 
lymphocyte population while the Stat6-/-Ttc7Pfsn/fsnP T cells were 38.76% of the CD4+ 
lymphocyte population. This was statistically significant with a p-value of 0.001. The 
actual number difference may be even greater between the Stat6-/- and Stat6WT animals 
as the Stat6-/- CD4+ population recovers slightly from the reduced population in 
Ttc7Pfsn/fsnP from 8.7% of the spleen population to 9.9% of the spleen population in Stat6-/-
Ttc7Pfsn/fsnP (see Table 2.1: Stat6-/- spleen cell populations). Since activated T cells have  
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Figure 2.8. Stat6-/-Ttc7 Splenic CD4+ T cell Populations. Stat6-/-Ttc7Pfsn/fsnP 
mice have an increased percentage of activated CD4+ T cells. Populations 
were determined by gating as shown in Figure 1.16. To collect flow data, the 
lymphocyte population was gated and 50,000 events were recorded per sample. 
CD4+ cells were gated and then analyzed for CD62L/CD44 surface markers.  
A. Stat6-/-Ttc7Pfsn/fsnP mice have a significantly lower percentage of naïve T 
cells, a significantly higher percentage of activated T cells and a significantly 
higher percentage of memory T cells than their Stat6-/-Ttc7Wt littermates. B. 
Stat6 intact T cell populations as shown previously in Figure 1.18. C. Stat6-/-
Ttc7Pfsn/fsnP mice have a slightly lower percentage of naïve T cells, a significantly 
higher percentage of activated T cells and a slightly lower percentage of 
memory T cells than Stat6 intact Ttc7Pfsn/fsnP mice. These data are summarized 
with p values in Table 2.2. Data shown are mean percentages of 5 separate 
experiments ± SEM. 
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been found to participate in the pathogenesis of autoimmunity directly through cytokine 
secretion and effector mechanisms as well as indirectly by providing help to autoreactive 
B cells, this expanded activated T cell population may well be contributing to the severity 
of disease we find in the Stat6-/-Ttc7Pfsn/fsnP animals.  
 
Stat6-/-Ttc7Pfsn/fsnP CD4+ T cells have a lower percentage of intracellular IL-4+ cells 
than Ttc7Pfsn/fsnP T cells but when stimulated with plate-bound anti-CD3 exhibit an 
expanded IL-4+ population 
Stat6 has been found to be an important regulator of IL-4 production but the 
magnitude of IL-4 produced has varied greatly in Stat6-/- animals based on genetic 
background, experimental design, previous activation, type of activation, stage of cellular 
differentiation and antigenic specificity (Kaplan, Wurster et al. 1999; Mori, Morris et al. 
2000; Dorado, Jerez et al. 2002; Yagi, Suzuki et al. 2002). In general, Stat6 has been 
found to augment IL-4 production early in activation although it is not absolutely 
required (Kaplan, Wurster et al. 1999; Mori, Morris et al. 2000), IL-4 production is 
reduced in Stat6 deficient animals (Bruns, Schindler et al. 2003), and late in activation 
via CD3 stimulation, Stat6 functions to reduce the IL-4 transcript by competing with the 
transcription factor NFAT to shut down IL-4 production (Dorado, Jerez et al. 2002). 
Using 4-color flow cytometry to measure the percentage of IL-4 positive cells we found 
higher percentages of IL-4+ cells in naïve, activated and memory CD4+ cells of Ttc7Pfsn/fsnP 
than WT mice in both unstimulated and CD3 stimulated cells. Thus, we wanted to 
examine how Stat6 deficiency would change the production of IL-4 in CD4+ T cells of 
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Ttc7Pfsn/fsnP mice that produce high endogenous levels of IL-4. It was not possible to 
generate sufficient numbers of stimulated CD4+ cells to measure each subtype accurately 
for a direct comparison as we had great difficulty keeping the Stat6-/-Ttc7Pfsn/fsnP cells alive 
in culture for the 24 hours necessary for stimulation. However, we were able to analyze 
the total CD4+ population of both for the presence of intracellular IL-4. These data are 
summarized in Table 2.3. 
In Stat6-/-Ttc7WT animals, the percentage of IL4+ CD4+ cells was reduced in 
both the unstimulated and stimulated groups as compared to Ttc7WT animals (Figure 
2.9A, Table 2.3A). Stat6 deficient cells responded with an increase in the percentage of 
IL-4+ cells upon stimulation, but at a lower level than Stat6 sufficient cells, which may 
be expected based on literature reports. However, when we compared Stat6-/-Ttc7Pfsn/fsnP 
cells to Stat6 sufficient Ttc7Pfsn/fsnP cells we found the same trend in the unstimulated cells, 
with a lower percentage of IL-4+ cells in the Stat6-/-Ttc7Pfsn/fsnP samples, but when 
stimulated with anti-CD3 we found an expanded population of IL-4+CD4+ cells in the 
Stat6 deficient Ttc7Pfsn/fsnP cells (Figure 2.9B and Table 2.3B). Although the actual 
measured percentages are similar, because the CD4+ population recovers in the Stat6-/-
Ttc7Pfsn/fsnP animals, there are over twice as many IL-4+CD4+ cells. We can surmise that 
this is due to the expanded population of activated T cells found in these animals. As 
Dorado and colleagues demonstrated in 2002, this expansion may be due to the reduced 
ability of cells to down-regulate IL-4 production in the absence of Stat6 late in activation. 
This would be consistent with the pre-activated (hyperactivated) phenotype we find in 
Ttc7Pfsn/fsnP CD4+ T cells, where, in Stat6 sufficient cells Stat6 may be functioning 
somewhat normally to reduce IL-4 but overwhelmed by high levels of endogenous 
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stimulation, and when Stat6 is removed, T cells then are free to produce IL-4 unfettered. 
This might suggest a cooperative mechanism between Ttc7 and Stat6 in T cell activation 
and the production of IL-4.  
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Figure 2.9. Stat6-/-Ttc7 CD4+ IL-4+ T cells Comparison of percentages of IL4+ 
CD4+ T cells between Stat6-/- and WT animals. Splenic lymphocytes were stained for 
intracellular IL-4 after culture with or without anti-CD3 stimulation. A. Stat6-/-
Ttc7WT versus Stat6 intact Ttc7 WT mice. Stat6-/- have a slightly higher percentage 
of CD4+ cells but a lower percentage of IL-4+ cells in both the unstimulated and 
stimulated groups. B. Stat6-/-Ttc7Pfsn/fsnP versus Stat6 intact Ttc7Pfsn/fsnP mice. Stat6-/-
Ttc7Pfsn/fsnP mice have a significantly higher percentage of CD4+ cells than Ttc7Pfsn/fsnP 
Stat6 intact mice but a lower percentage of IL-4+ cells. When stimulated the 
percentage of Stat6-/- IL-4+ cells rises to almost the same percentage as Ttc7Pfsn/fsnP 
Stat6 intact mice, suggesting that more cells are producing IL-4 in response to 
stimulation. These data are summarized in table 2.3 A and B. Data shown are 
percentages of 5 separate experiments ± SEM. 
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A 
10-Week Stat6-/-Ttc7WT vs. Ttc7WT IL-4+ CD4+ T cells 
  % CD4+ % IL-4+ MFI 
unstim Stat6-/-Ttc7WT 25.51± 2.5 1.66 ± 0.13 3.34 
 Ttc7WT 21.36 ± 2.6 3.48 ± 0.8 3.06 
     
stim Stat6-/-Ttc7WT 23.0 ± 2.25 5.85 ± 0.35 3.78 
 Ttc7WT 17.48 ± 0.31 9.87 ± 1.1 4.93 
n=3     
 
 
 
 
B 
10-Week Stat6-/-Ttc7Pfsn/fsnP vs. Ttc7Pfsn/fsnP IL-4+ CD4+ T cells 
  % CD4+ % IL-4+ MFI 
unstim Stat6-/-Ttc7Pfsn/fsnP 19.95 ± 0.6* 1.57 ± 0.7 3.35 
 Ttc7Pfsn/fsnP 9.82 ± 0.87 8.9 ± 3.6 3.55 
  p=0.00008   
Stim Stat6-/-Ttc7Pfsn/fsnP 22.71 ± 2.9 7.44 ± 2.4 3.8 
 Ttc7Pfsn/fsnP 7.69 ± 6.9 8.35 ± 1.24 5.53 
n=3     
 
 
Table 2.3. Stat6-/-Ttc7 CD4+ IL-4+ Splenic T cells. A.Summary of Stat6-/- vs. 
Stat6+/+ Ttc7 WT IL-4+ T cells. B. Summary of Stat6-/- vs. Stat6+/+ Ttc7Pfsn/fsnP IL-4+ 
T cells. MFI = mean fluorescent intensity 
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Stat6-/-Ttc7Pfsn/fsnP CD4+ cells do not have an exaggerated IFN-gamma response to 
CD3 stimulation 
Ttc7Pfsn/fsnP T cells have been previously shown to produce similar levels of IFN-
gamma, the counter-regulatory cytokine to IL-4, as WT T cells upon anti-CD3 
stimulation (Welner, Hastings et al. 2004). Because Stat6 functions to down-regulate 
IFN-gamma production, we wanted to examine how Stat6-/-Ttc7Pfsn/fsnP T cells responded 
to stimulation with anti-CD3. We used intracellular staining of IFN-gamma and CD4 to 
evaluate the percentage of IFN-gamma+CD4+ cells in Stat6-/-Ttc7Pfsn/fsnP and Ttc7Pfsn/fsnP 
cells in both unstimulated as well as stimulated samples. In the unstimulated cells, the 
percentage of IFN-gamma+ cells was very similar, with Stat6-/- cells comprising 1.37 ± 
0.51% of the CD4+ population while Stat6 sufficient cells were 2.1 ± 1.46% of the CD4+ 
population (Figure 2.10). When taking the difference in CD4+ percentages between the 
two groups into consideration, the numbers normalized to 0.36% of the Stat6-/- CD4+ 
being IFN-gamma+ while Stat6WT were 0.29% IFN-gamma+. Both sets of cells 
responded to stimulation with anti-CD3 in a similar manner with the Stat6-/- group rising 
to 2.74 ± 0.57% IFN-gamma + and the Stat6 sufficient group rising to 3.07 ± 1.44% IFN-
gamma+. Although the Stat6-/-Ttc7Pfsn/fsnP CD4+ cells had a slightly higher percentage of 
IFN-gamma+ cells, we did not see the exaggerated response as was shown for IL-4. In 
addition, the MFIs for both Stat6-/- and Stat6WT, unstimulated and stimulated CD4+ 
cells were quite similar, suggesting none of the groups were producing higher levels of 
IFN-gamma than others. Thus, we conclude that the effect we see for IL-4 is specific for 
IL-4 and not a defect in IFN-gamma regulation. 
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Figure 2.10. Stat6-/-Ttc7Pfsn/fsnP and Ttc7Pfsn/fsnP CD4+ IFN-γ+ T cells. Comparison of 
percentages of IFN-γ+ CD4+ cells between Stat6-/-Ttc7Pfsn/fsnP and Ttc7Pfsn/fsnP Stat6 intact 
mice. Splenic lymphocytes were stained for intracellular IFN- γ after culture with or 
without anti-CD3 stimulation. Stat6-/-Ttc7Pfsn/fsnP mice have a significantly higher 
percentage of CD4+ cells than Ttc7Pfsn/fsnP Stat6 intact mice but have similar percentages 
of IFN- γ+ cells in both unstimulated and stimulated groups. Data are summarized in 
Table 2.4. Data shown are mean percentages of 2 separate experiments ± SEM. 
 
 
 
Stat6-/-Ttc7Pfsn/fsnP vs. Ttc7Pfsn/fsnP CD4+ IFN-γ+ T cells 
  % CD4+ % IFN-γ+ MFI 
unstim Stat6-/-Ttc7Pfsn/fsnP 26.79 ± 0.59* 1.365 ± 0.51 3.14 
 Ttc7Pfsn/fsnP 14.01 ± 0.54 2.1 ± 1.46 3.43 
  *p=0.0019   
Stim Stat6-/-Ttc7Pfsn/fsnP 26.32 ± 2,6 2.74 ± 0.57 3.96 
 Ttc7Pfsn/fsnP 13.5 ± 0.47 3.07 ± 1.44 4.10 
n=2     
 
Table 2.4. Summary of data presented in Figure 2.10. P 
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Results:  Stat6-/- ELISAs 
 
Stat6-/-Ttc7Pfsn/fsnP lymphocytes produce 5.8 times the concentration of IL-4 as do 
Ttc7Pfsn/fsnP lymphocytes 
To compare the production of IL-4 between Stat6-/-Ttc7Pfsn/fsnP splenic lymphocytes 
and Ttc7Pfsn/fsnP splenic lymphocytes we cultured six million cells per sample for 24 hours 
with or without plate-bound anti-CD3 (10µg/mL) and then performed an IL-4-specific 
ELISA with the harvested supernatants. The concentration of IL-4 in the unstimulated 
samples was similar between the two groups with Ttc7Pfsn/fsnP lymphocytes producing 98.5 
± 66 pg/mL IL-4 and the Stat6-/-Ttc7Pfsn/fsnP lymphocytes producing 32 ± 0.001 pg/mL 
(Figure 2.11). However, after 24 hours of stimulation with anti-CD3, the Stat6-/-Ttc7Pfsn/fsnP 
lymphocytes produced 22,912 ± 2697 pg/mL of IL-4 while Ttc7Pfsn/fsnP lymphocytes 
produced 3946 ± 71 pg/mL. The level of IL-4 produced by the Stat6-/-Ttc7Pfsn/fsnP 
lymphocytes was surprising, which prompted us to repeat the ELISA two additional 
times; both of which confirmed the results. Thus, it appears that Stat6-/-Ttc7Pfsn/fsnP 
lymphocytes produce almost 6-fold more IL-4 than the already high levels of IL-4 
produced by Ttc7Pfsn/fsnP lymphocytes.  
The reason for this is presently unclear. The expansion of activated T cells may 
certainly account for some of the elevation of IL-4 production noted in the Stat6-/-
Ttc7Pfsn/fsnP IL-4 ELISA. It is also possible that the lack of Stat6 fails to induce negative 
regulatory measures that function to down-regulate IL-4 production, which may already 
be overwhelmed or defective in Ttc7Pfsn/fsnP mice.  
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Figure 2.11. Stat6-/-Ttc7Pfsn/fsnP IL-4 Production. Stat6-/-Ttc7Pfsn/fsnP lymphocytes 
produce almost 6X the amount of IL-4 as do Ttc7Pfsn/fsnP splenocytes. Purified splenic 
lymphocytes from 10-week Stat6 intact and deficient Ttc7Pfsn/fsnP animals were cultured 
for 24 hours with plate-bound CD3 and an ELISA was performed on the supernatant. 
Stat6-/-Ttc7Pfsn/fsnP lymphocytes produced 22,912 ± 2697 pg/mL of IL-4 (p=0.044) 
compared to 3946 ± 71 pg/mL produced by Stat6 intact Ttc7Pfsn/fsnP lymphocytes. Data 
shown are mean percentages of 2 separate experiments ± SEM. 
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It is interesting to note that Dent et al (Linehan, Warren et al. 1998), also noted a 
dramatic increase in the production of IL-4 when their Stat6 deficient mice were crossed  
with a Bcl-6 deficient line. Isolated T cells from these mice produced levels of IL-4 that 
were 7- to 1000-fold greater than the single knock-outs alone. These mice also exhibited 
a severe, Th2-type inflammatory disease and died prematurely at between 5- and 6-weeks 
of age. The authors concluded that bcl-6 may function as a negative regulator of Th2 
differentiation (and Stat6 responsive genes) and that their data suggest an alternative 
pathway of Th2 development that does not require IL-4 and/or Stat6. Thus, it appears that 
there may be other, as yet undiscovered, pathways of Th2 differentiation as well. 
 
Stat6-/-Pfsn/fsnP mice have elevated serum IgG1 and total serum Ig, and elevated IgM 
anti-DNA antibodies 
Previous work by Pelsue et al (1998) determined serum immunoglobulin (Ig) 
levels of Ttc7Pfsn/fsnP mice to be altered from those of Ttc7WT mice. Specifically, total Ig 
was 1.8 x more than WT; IgG1 was 2.7 x that of WT; IgG3 was 5.6 x lower than that of 
WT; IgE was 7000 x more than WT; and IgM was 1.9 x that of WT. Other groups have 
found a constitutively active form of Stat6 to increase the expression of IgG1 and IgE and 
in fact, Stat6 was found to be essential for B cells to effect this class switching for Ig 
production (Linehan, Warren et al. 1998; Bruns, Schindler et al. 2003).  Stat6 deficient 
mice have been shown to have a reduction in T and B cell activation, and hence, a 
reduction in serum levels of IgG1, IgG3 and IgE (Linehan, Warren et al. 1998; Singh, 
Saxena et al. 2003; Xu, Duan et al. 2006). Because high serum Ig levels, including IgG1 
and IgG3, have been associated with increased anti-DNA antibodies, increased renal 
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disease and autoimmunity, and knocking out Stat6 has been found to reduce the presence 
of anti-DNA antibodies and kidney pathology, we wanted to examine the serum Ig 
composition of our Stat6-/-Ttc7Pfsn/fsnP mice. All serum concentrations were measured with 
isotype-specific ELISAs and described in the Materials and Methods section.  
Interestingly, serum IgG1 concentration of Stat6-/-Ttc7Pfsn/fsnP, which averaged 112 
µg/mL, was largely unchanged from that of the Ttc7Pfsn/fsnP (129 µg/mL) that we tested 
(Figure 2.12B). Given that IgG1 may be more IL-4 than Stat6 dependent (Mao and 
Stavnezer 2001) this may not be surprising given the high levels of IL-4 expressed in 
these animals. However, Stat6-/-Ttc7WT mice showed greatly reduced levels of IgG1 
(average 7.2 µg/mL, p=0.0002), even compared to Ttc7WT animals (47 µg/mL) 
suggesting that Stat6 does exert an influence in the expression of this Ig. Figure 2.12A 
presents serum data per animal to illustrate the variation typically found among 
individual animals in murine models of autoimmunity, including Ttc7Pfsn/fsnP mice.  
As mentioned above, previous data showed a reduction in serum IgG3 of almost 
6-fold in Ttc7Pfsn/fsnP mice from that of Ttc7WT mice. However, Stat6-/-Ttc7Pfsn/fsnP mice 
actually had a slightly elevated but not statistically significant IgG3 serum concentration 
of 48.7 µg/mL compared to that of Ttc7Pfsn/fsnP mice at 43 µg/mL and Stat6-/-Ttc7WT 
animals at 32 µg/mL (Figure 2.13B). IL-4 has been found to decrease production of 
IgG3, while IFN-gamma increased its production (Snapper, McIntyre et al. 1992), 
however, it is unknown why IL-4 may exert its influence over Stat6-/-Ttc7Pfsn/fsnP in IgG1 
production and have the opposite effect for IgG3. There are evidently more complicated 
regulatory issues that have yet to be determined. Enhanced IgG3 production has been 
associated with increased autoimmunity (de Stahl, Dahlstrom et al. 2003), but  
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Figure 2.12. Stat6-/-Ttc7 Serum IgG1. Stat6-/-Ttc7 mice were bled at 10-weeks of 
age and an ELISA specific for IgG1 was performed with serum using Ttc7 Stat6 intact 
mice as controls. Concentrations were determined by comparing OD numbers to a 
standard curve generated with IgG1-specific antibody. A. The numbers on the X-axis 
represent individual animals, gray arrows below denote those with the Ttc7Pfsn/fsnP 
mutation. Stat6-/-Ttc7WT mice have significantly lower IgG1. B. The average serum 
IgG1 for Stat6-/-Ttc7Pfsn/fsnP is similar to that of Stat6 intact Ttc7Pfsn/fsnP at 112.09 ± 29.6 
µg/mL. Stat6-/-Ttc7WT mice have significantly lower levels of IgG1 (7.2 ± 7.01 
µg/mL, p=0.0002) as would be expected in the absence of Stat6 as Stat6 deficient B 
cells are usually greatly inefficient in class switching to IgG1. Stat6 deficient Ttc7Pfsn/fsnP 
have 15X more IgG1 than their Ttc7 Stat6 deficient littermates, while Stat6 intact 
Ttc7Pfsn/fsnP mice produce 2.7X more than Stat6 intact Ttc7 WT littermates.  
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Figure 2.13. Stat6-/-Ttc7 Serum IgG3.  IgG3 specific ELISA performed with serum 
from Stat6-/- Ttc7 mice. Animals were bled at 10-weeks and an ELISA was performed 
using Stat6 intact Ttc7 mice for controls, with an IgG3-specific antibody to generate a 
standard curve to calculate concentrations. A. As above, individual animals on the X-
axis with gray arrows denoting Ttc7Pfsn/fsnP. Stat6-/-Ttc7Pfsn/fsnP animals produce slightly 
more IgG3 than their Stat6-/-Ttc7WT littermates. B. The average serum concentration 
of IgG3 in Stat6-/-Ttc7Pfsn/fsnP is higher at 48.7 µg/mL than their Stat6-/-Ttc7WT 
littermates (32 µg/mL) while Ttc7Pfsn/fsnP mice have a lower concentration of IgG3 (43 
µg/mL) than their Ttc7 WT littermates (52 µg/mL).  
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even in the presence of low levels of IgG3, Ttc7Pfsn/fsnP mice exhibit enhanced 
autoimmunity due to an overall up-regulation of antibody production. It is of note that 
Stat6-/-Pfsn/fsnP mice have more severe renal disease than do Stat6 sufficient Ttc7Pfsn/fsnP mice, 
but it is unknown what the contribution of IgG3 may be. Figure 2.13A again presents the 
data per individual animal.  
One of the hallmarks of Ttc7Pfsn/fsnP mice is the huge increase of over 7000-fold in 
serum IgE spontaneously produced in these animals (Pelsue et al., 1998). Stat6 has been 
shown to be absolutely required for the production of IgE, whose production has also 
been shown to be dependent on T cell help (Mao and Stavnezer 2001). Thus, we checked 
the status of IgE production in Stat6-/-Ttc7Pfsn/fsnP mice to confirm the absence of this Ig. 
We ran Stat6-/-(Ttc7Pfsn/fsnP and WT) samples against Ttc7WT samples in order to more 
closely match the anticipated concentration of IgE to better-fit the standard curve. Our 
results determined an average serum IgE concentration of Ttc7WT mice to be 0.835 ± 
0.77 µg/mL while all Stat6-/- samples did not register above background values. 
Therefore we deduce that Stat6 is not being aberrantly expressed in Stat6-/- mice (which 
was confirmed by Western Blot previously), but was required for Ttc7Pfsn/fsnP IgE 
production. In addition, IgE is not contributing to the pathology of Stat6-/-Ttc7Pfsn/fsnP mice, 
and IgE is being regulated normally in Stat6-/- animals. 
Overall, total serum Ig did not differ significantly between Stat6-/-Ttc7Pfsn/fsnP mice 
and Stat6 sufficient Ttc7Pfsn/fsnP mice (Figure 2.14B). Our measured average value of 4101 
± 186 µg/mL for Ttc7Pfsn/fsnP Stat6 intact mice was not statistically different than the 3479 ± 
1080 µg/mL measured for the Stat6 deficient Ttc7Pfsn/fsnP mice. This is in contrast to other 
Stat6-/- models which generally have significantly reduced Ig over their Stat6 intact  
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Figure 2.14. Stat6-/-Ttc7 Total Serum Ig. Total serum Ig was similar between Stat6 
deficient and Stat6 intact Ttc7Pfsn/fsnP mice. 10-week animals were bled and serum was 
used to perform an ELISA to measure total serum Ig concentration. As above, Stat6 
intact Ttc7 animals were used as controls and a standard curve was generated to 
determine concentration. A. Individual animals showing the variation between serum 
Ig levels. B. The average concentration of Ig in Stat6 deficient Ttc7Pfsn/fsnP (3479 ± 1080 
µg/mL) is not significantly different than that of Ttc7Pfsn/fsnP Stat6 intact animals (4101 ± 
186 µg/mL), but is significantly higher than Stat6-/-Ttc7WT littermates (2318 ± 309 
µg/mL, p=0.03).  
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controls (Wurster, Tanaka et al. 2000; Singh, Saxena et al. 2003; Xu, Duan et al. 2006). 
However, both the Stat6-/- and Stat6 sufficient Ttc7WT groups had similar Ig serum  
concentrations, which were significantly reduced from their Ttc7Pfsn/fsnP littermates (see 
Figure 2.14A for values from individual animals). Thus we conclude that the defective 
Ttc7 gene must have an activating effect on B and T cells that drives Ig production, 
which Stat6 can only slightly modify.  
The significance of variations in serum Ig in autoimmunity is multi-fold. For 
example, antibodies function to mark cells or debris for clearance which may be 
defective, they can activate complement for clearance of tissue or which can drive 
inflammation, and they form immune complexes that can also drive inflammation. The 
extent and actual mechanism of  damage that antibodies contribute to pathology have 
been the subject of much debate, however it appears that there are self-reactive antibodies 
that are part of the natural antibody repertoire of an animal that are highly correlated with 
the disease state. The specificities of these antibodies can be varied, but anti-DNA 
antibodies seem to be the most well-studied as well as indicative of systemic 
autoimmunity (Daikh 2001; Bizzaro 2007). Ttc7Pfsn/fsnP mice have been shown previously 
(Withington, Maltby-Askari et al. 2002) to have anti-nuclear antibodies, including anti-
dsDNA antibodies. Also, knocking out Stat6 has been shown in other murine models to 
significantly reduce the titer of anti-DNA antibodies as compared to their intact Stat6 
counterparts (Xu, Duan et al. 2006). Thus, we measured the absorbance values by ELISA 
of serum anti-DNA antibodies to determine if deleting Stat6 from Ttc7Pfsn/fsnP mice would 
change the expression of anti-DNA.  The result of this study is summarized in Figure 
2.15A.  
 140
 
 
 
 
Figure 2.15. Stat6-/-Ttc7 anti-DNA Antibodies. Serum from 8-10 week (A) and 12-
week (B) animals was used to perform DNA specific ELISAs to determine the 
concentration of IgG or IgM anti-DNA antibodies present in Stat6-/-Ttc7 mice. “0” on 
the X-axis denotes blank well for background fluorescence. Values are given in OD at 
450 nm. A. The values for individual animals are graphed to show the variation 
between individuals, as above, the gray arrows denote Ttc7Pfsn/fsnP mutant mice. Stat6-/-
Ttc7Pfsn/fsnP consistently have higher absorbance values than their Ttc7WT littermates for 
both IgG and IgM. B. Four of the same animals as in A were bled and serum was used 
to repeat an ELISA to measure anti-DNA antibodies. Animal #860 showed a 
significant increase in absorbance for IgM anti-DNA while animal #815 actually 
decreased. C. Stat6 intact Ttc7 anti-DNA absorbance values are mostly higher for IgG, 
or at a similar value.  
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Stat6-/-Ttc7Pfsn/fsnP mice consistently showed absorbance values well over those of 
their Stat6-/-Ttc7Wt littermates, with many also over absorbance values of Stat6+/+ 
Ttc7Pfsn/fsnP mice (Figure 2.15C). The major difference however, was that the absence of  
Stat6 changed the class of antibody from IgG in Stat6 sufficient Ttc7Pfsn/fsnP to IgM in Stat6 
deficient Ttc7Pfsn/fsnP mice (Figure 2.15A). There is very little research literature on the role 
of IgM anti-DNA antibodies in the pathology of autoimmunity. However, we suggest that 
since the autoimmune disease is at least as severe, if not more so, in our Stat6-/-Ttc7Pfsn/fsnP 
mice as compared to Ttc7Pfsn/fsnP mice, that IgM antibodies are as capable of driving 
autoimmune disease as IgG. It is difficult to determine the exact contribution these 
antibodies make, because, as shown in Figure 2.15B, absorbance values in sick animals 
can spike and decline or vary with age, while their WT littermates stay consistently low.  
 
Stat6-/-Ttc7Pfsn/fsnP sera contain antibodies with mostly cytoplasmic specificities of 
both IgG and IgM  
The presence of anti-DNA antibodies in the sera of Stat6-/-Pfsn/fsnP mice suggested 
there may be autoantibodies present with specificities directed towards other cellular 
antigens as has been found in Ttc7Pfsn/fsnP mice (Withington, Maltby-Askari et al. 2002). To 
analyze auto-reactive antibody staining patterns we used indirect immunofluorescence 
assays (IFAs) on fixed HEp-2 cells. Previous work in our lab evaluating IFAs had 
determined the staining pattern of Ttc7Pfsn/fsnP to include several nuclear patterns indicative 
of SLE as well as a diffuse cytoplasmic pattern more often associated with inflammatory 
conditions (Withington, Maltby-Askari et al. 2002). Because our anti-DNA ELISA 
indicated the presence of IgM antibodies, we used both IgG- and IgM-conjugated 
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detection antibodies to identify the staining patterns of Stat6-/-Ttc7Pfsn/fsnP mice. All Stat6-/-
Ttc7Pfsn/fsnP mice had positive staining at dilutions of 1:40 while Stat6-/-Ttc7WT mice were 
consistently negative. Figure 2.16 shows several representative images of staining 
identified by this assay. Interestingly, the lack of Stat6 changed the pattern from mostly 
nuclear in Ttc7Pfsn/fsnP Stat6 intact mice to mostly sub-nuclear and cytoplasmic in the 
double-mutants. This was true for both IgM and IgG (Figure 2.16A, B and D). Figure 
2.16C shows an IgM staining pattern typical of golgi staining, while A, B and D show a 
more dense, cytoplasmic speckled staining pattern typical of ribosomal or RNA staining, 
associated with SLE. Only one of 8 Stat6-/-Ttc7Pfsn/fsnP animals (#815) exhibited an IgG 
nuclear homogeneous staining pattern; IgM detection in this animal identified the 
cytoplasmic staining typical of the others.  
These results suggest that although the absence of Stat6 in Ttc7Pfsn/fsnP mice changes 
the class and specificity of autoreactive antibodies, it appears that these antibodies may 
still be contributing to an autoimmune pathology and/or an inflammatory condition. The 
presence of a higher number of immature B cells in Stat6-/- mice may account for the 
increase in IgM antibodies. 
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Figure 2.16   Stat6-/-Ttc7Pfsn/fsnP HEp-2 Slide Staining: IgM and IgG 
Autoantibodies. HEp-2 cell staining for autoantibody staining patterns of Stat6-
/-Ttc7Pfsn/fsnP serum. Commercially prepared HEp-2 slides were incubated with 
serum from Stat6-/-Ttc7 animals and detected with either IgM or IgG-FITC 
conjugated antibodies and visualized with Fluorescent microscopy. Images are 
representative of 8 animals with similar staining patterns. A-C. Three different 
Stat6-/-Ttc7Pfsn/fsnP animals detected with IgM showing representative 
cycloplasmic patterns found with all animals analyzed (n=8). C shows a staining 
pattern typical of autoantibodies to golgi antigens. D and E are 2 different Stat6-
/-Ttc7Pfsn/fsnP animals both with IgG detection. Most IgG detection was 
cytoplasmic (D), but one animal of the eight had a nuclear staining pattern with 
IgG only (E). Stat6-/-Ttc7WT were negative (shown below). 200X  
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Results: Section 3: Anti-IL-4 Treatment of Ttc7Pfsn/fsnP Mice 
 
Treatment with anti-IL-4 (11B11) reduces CD23 and MHC II expression and alters 
serum Ig subsets 
As mentioned previously, one of the hallmarks of Ttc7Pfsn/fsnP mice is the over-
abundance of IL-4 present in vivo, which results in Th2 driven and phenotypic 
autoimmunity. To assess the contribution of IL-4 to disease expression in Ttc7Pfsn/fsnP mice, 
we treated 5 mice from separate litters with a neutralizing rat anti-mouse-IL-4 mAB 
(11B11) for seven weeks, starting at 3-weeks of age. Since the disease pathology starts 
accelerating at 5-6 weeks of age, we hoped to neutralize endogenous IL-4 before the 
disease process began. We also treated 5 Ttc7Pfsn/fsnP mice from separate litters with an 
isotype-matched rat IgG1 mAb (GL113) as an isotype control treatment. All animals 
were sacrificed at 10-weeks, one day after the final mAb injection whereupon blood and 
organs were collected for analysis.  
At time of sacrifice, there was no obvious difference between treatment groups. 
The pattern and extent of skin, hair, and eye pathology was similar, as were their size and 
overall demeanor. Both groups had distended abdomens due to extreme splenomegaly, 
and the spleens when removed were similar in size. Spleen cellularity was similar, with 
untreated Ttc7Pfsn/fsnP mice having an average of 13.0 ± 5.4 x 10P8 Pcells and 11B11-treated 
mice having an average of 15.1 ± 6.0 x 10P8P cells.  
Flow cytometry data of spleen cell populations is summarized in Table 3.1. There 
is direct evidence that the 11B11-treated group responded to the anti-IL-4 as both IL-4 
responsive B cell markers of activation CD23 and MHC II expression had decreased  
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Table 3.1. Spleen Cell Populations of 11B11-Treated and GL113-treated Ttc7Pfsn/fsnP 
mice. All numbers represent percentages of total population.  
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significantly, from 36% to 3% for CD23 (p=0.0009) and from 60% to12% for MHC II 
(p=0.0000006). The percent of CD19+ cells declined to 22% in the 11B11-treatment 
group, from approximately 30% in untreated and isotype controls. It also appeared that 
the percentage of CD3+ cells increased in the 11B11-treatment group, from 8.5% to 18%, 
however the isotype control group was also elevated (15%) so this may have been a result 
of antibody treatment and not directly related to IL-4 neutralization.  
 
Anti-IL-4 Treatment alters T cell subsets  
To assess the effect of anti-IL-4 treatment on T cell activation we performed 4-
color flow cytometry with antibodies to CD69/CD4/CD62L/CD44 cell surface markers 
and gated as previously described for Ttc7Pfsn/fsnP and Stat6 deficient mice (see Figure 3.1). 
The percentage of naïve CD4+ cells (CD62LPhiP/CD44PloP) was virtually the same among 
treated, isotype control and untreated Ttc7Pfsn/fsnP mice. The 11B11 group had a higher 
percentage of activated (CD62LPhiP/CD44PhiP) CD4+ cells (29.1%) than untreated Ttc7Pfsn/fsnP 
CD4+ cells (17.1%) (Figure 3.1B), however when compared to the isotype control CD4+ 
cells (34.5%) the percentage was actually slightly lower (Figure 3.1A). Thus, it appeared 
that the mAb treatment may have had an overall effect on activation, but that neutralizing 
IL-4 may have slightly reduced the reactivity of the cells to treatment. The memory cell 
subset (CD62LPloP/CD44PhiP) was also slightly altered, with the percentage of the 11B11-
treatment group (18.2%) lower than the isotype control (20.6%) (Figure 3.1A), and even 
lower than untreated Ttc7Pfsn/fsnP mice (27.77%) (Figure 3.1B). These results suggest that in 
vivo, IL-4 may serve to help alter the CD4+ T cell population into a more activated state, 
perhaps augmenting the underlying defect leading to hyperactivation. However, since  
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Figure 3.1. Anti-IL-4 Treated Ttc7Pfsn/fsnP T cells. CD4+ T cell subset distribution of 
anti-IL-4 Treated Ttc7Pfsn/fsnP mice. Lymphocytes were purified from spleen, stained and 
analyzed by flow cytometry. Gating on CD62L/CD44 surface markers was performed 
as described in Figure 1.16. A. Comparison of 11B11-treated and GL113-treated 
isotype control animals showing  a slight increase in naïve, a slight decrease in 
activated and a slight decrease in memory subsets of the 11B11-treated group. B. 
Comparison of 11B11-treated and untreated Ttc7Pfsn/fsnP showing a slight increase in 
naïve, an increase in activated (29.1 ± 13.4% vs. 17.1 ± 6.6% respectively), and a 
decrease in memory (18.2 ± 9.8% vs. 27.77 ± 4.7% respectively) subset of the 11B11-
treated group. Data shown is the mean percentage of CD4+ cells of 5 different animals 
per group ± SEM.  
 
A 
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neutralization of IL-4 had no effect on the naïve population it appears that the defect in 
Ttc7 was more responsible for the reduction in the naïve population. 
 
Anti-IL-4 Treatment decreases the immature B cell subset 
Previous work in our lab (Farrington 2006) established an alteration in B cell 
subsets in Ttc7Pfsn/fsnP spleen with an increase in the percentage of immature B cells 
(IgDPloP/IgMPhiP), a significant decrease in mature B cells (IgDPhiP/IgMPloP, p=≤ 0.01), and a 
decrease in transitional B cells (IgDPhiP/IgMPhiP) as compared to Ttc7 WT littermates (Figure 
3.2C). Because of the functional differences in these subsets, it was important to examine 
the distribution of B cells in the spleens of our 11B11-treated Ttc7Pfsn/fsnP animals. We 
performed flow cytometry on single cell suspensions of whole spleen from 11B11- and 
GL113-treated mice and then gated on the lymphocyte portion of the forward and side 
scatter plots. Determination of IgM and IgD expression was gated as shown for Stat6-/- 
in Figure 2.6.  
There was very little difference in the percentage of B cells comprising the mature 
B cell subset, with 11B11-treated at 7.9 ± 3.7% and Ttc7Pfsn/fsnP at 9.2 ± 1.2% (Figure 
3.2A). The transitional subset was also very similar with 11B11-treated slightly higher at 
11.38 ± 4.7% and Ttc7Pfsn/fsnP at 9.0 ± 4.6%. However, the immature subset was reduced. 
While Ttc7Pfsn/fsnP mice measured 20.9 ± 3%, 11B11-treated animals measured 14.8 ± 6.0% 
immature B cells. These data suggest that in vivo IL-4 may be functioning to both drive 
the proliferation and activation of immature B cells instead of allowing them to 
differentiate, and/or helping this population to survive to become a functional group able 
to contribute to the pathogenesis of autoimmunity 
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Figure 3.2. Anti-IL-4 Treated B cell Subsets.  B cell subset distribution of 
anti-IL-4-treated Ttc7Pfsn/fsnP mice. Splenocytes were stained for IgM and IgD and 
analyzed by flow cytometry. Gating on IgM/IgD was performed as described in 
Figure 2.6. A. 11B11-treated Ttc7Pfsn/fsnP mice have a reduction in the percentage 
of immature B cells, a slight reduction in the percentage of mature B cells and a 
slight increase in the percentage of transitional B cells as compared to untreated 
Ttc7Pfsn/fsnP animals. B. 11B11-treated vs. isotype control showed a similar 
distribution as in A. C. Comparison of untreated Ttc7Pfsn/fsnP vs. Ttc7 WT animals 
for reference. Data shown is the mean percentage of 5 different animals per 
group ± SEM. 
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Anti-IL-4 treated Ttc7Pfsn/fsnP mice have reduced serum IgE, reduced IgG1, slightly 
reduced IgG3, elevated total serum Ig and slightly reduced anti-DNA serum 
antibodies 
As mentioned previously in the Results section for the Stat6-/- study, Ttc7Pfsn/fsnP 
mice have elevated total serum Ig, elevated IgE, IgG1, and lower serum IgG3 than their 
WT littermates. They also have an increase in anti-DNA antibodies and antibody 
complex deposition in their kidneys. Therefore we performed serum ELISA assays to 
assess the difference treatment with an IL-4 neutralizing mAb may have on serum 
antibody production.  
The results for serum IgE are shown in Figure 3.3. Overall, there was a reduction 
in serum IgE in the 11B11 treated group which averaged 6.59 ± 1.26 µg/mL, while the 
untreated Ttc7Pfsn/fsnP mice averaged 10.64 ± 1.1 µg/mL (Figure 3.3B). Our measurements 
were actually lower than reported previously by Pelsue et al in 1998 (72 µg/mL). Figure 
3.3A presents the data for individual mice. Serum IgG1 was also reduced in the 11B11 
treated mice as shown in Figure 3.4B. The average serum IgG1 concentration in the 
11B11 treated was 70.8 ± 8.2 µg/mL while the untreated group measured 173 ± 34 
µg/mL. Again, the result per individual animal is presented in Figure 3.4A. Since both 
IgE and IgG1 are influenced by IL-4 we would expect a reduction in production of these 
antibodies when IL-4 is neutralized.  
There was also a slight reduction in IgG3 as shown in Figure 3.5B. The 11B11-
treated group averaged 64.79 ± 1.8 µg/mL whereas the untreated group had an average of 
85.5 ± 6.72 µg/mL. The average of the isotype control group was in between the two with  
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Figure 3.3. 11B11- and GL113-Treated Serum IgE. ELISA specific for IgE was 
performed on sera collected from 10-week 11B11 or isotype control animals before 
sacrifice. A. Serum IgE concentrations in µg/mL of individual mice showing 
variability between animals, but a general trend towards a decrease in IgE in 11B11-
treated animals. An untreated Ttc7Pfsn/fsnP was used for a control. B. The average serum 
IgE concentration from the data in A, showed a reduction in serum IgE concentration 
in the animals treated to neutralize IL-4.  
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Figure 3.4. 11B11-Treated Serum IgG1. ELISA specific for IgG1 was performed on 
sera collected from 10-week 11B11 or isotype control animals. A. Serum IgG1 in 
11B11-treated animals was reduced from isotype control and untreated Ttc7Pfsn/fsnP mice. 
Data were fairly consistent among 11B11 treated animals, and more variable among 
other groups. B. The data from A were averaged, and showed a significant reduction 
of serum IgG1 in the 11B11-treated group.  
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Figure 3.5. 11B11-Treated Serum IgG3. ELISA specific for IgG3 was performed on 
sera collected from 10-week 11B11 or isotype control animals. A. Serum IgG3 
concentration was fairly consistent in all groups. Data shown is from individual 
animals. B. The data from A were averaged and presented in µg/mL. 
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74.38 ± 6.72 µg/mL. Thus, it is difficult to determine the effect of 11B11 on IgG3 
production. 
Interestingly, the average total serum Ig concentration of the 11B11-treated group 
was slightly more elevated (4567 ± 1000 µg/mL) than the untreated group (3564 ± 489 
µg/mL, Figure 3.6B), although highly variable (Figure 3.6A). The average of the isotype 
control group was similar to the untreated (3515 ± 351 µg/mL). As mentioned previously, 
the importance of serum antibody measurements lies in the correlation between high 
serum antibody levels and the presence of autoantibodies and immune complexes. Some 
antibody isotypes are believed to be more “pathogenic” than others, and the evidence is 
conflicting about the role immune complexes play in autoimmune pathology (Ebling and 
Hahn 1989; Rüger, Erb et al. 2000; Morris, Dragula et al. 2002; Deocharan, Marambio et 
al. 2003; Singh, Saxena et al. 2003). Therefore, the significance of an elevation in total 
serum Ig must be evaluated in context of the ensuing pathology, and any confounding 
factors such as the limitations of experimental design and treatment with exogenous 
antibodies. Ttc7Pfsn/fsnP mice spontaneously secrete high levels of antibody with great 
variability between animals. It is unknown when this pattern of antibody production is 
established. Therefore, it appears that anti-IL-4 treatment altered the isotype profile with 
reduced levels of IgE and IgG1, which are known to be influenced by IL-4, but did not 
affect the overall level of production of Ig, which is also influenced by the action of IL-4 
on B cells, but is more dependent on the activation state of the secreting B cells.  
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Figure 3.6. 11B11-Treated Total Serum Ig. ELISA specific for total serum Ig 
concentration  in µg/mL. Sera was collected from 10-week 11B11 or isotype control 
animals before sacrifice. A. Total serum Ig concentrations presented for individual 
animals showed variability but a general increase in the 11B11 group. B. The data 
from A were averaged and presented as average µg/mL. All groups had similar 
concentrations of total Ig. The increase in the 11B11-treated group shown was not 
significant.  
 158
 
Anti-IL-4 treated Ttc7Pfsn/fsnP mice have lower absorbance values of anti-DNA 
antibodies than untreated Ttc7Pfsn/fsnP mice 
The presence of anti-dsDNA antibodies has been established in Ttc7Pfsn/fsnP mice 
(Withington, Maltby-Askari et al. 2002), as well as inflammation and immune complex 
deposition in the kidneys, mild proteinuria, and autoantibodies of other specificities. It is 
unknown exactly how IL-4 contributes to the extent and pathology of these conditions. 
Therefore, we performed serum ELISA to evaluate the presence of anti-DNA antibodies 
in 11B11- treated Ttc7Pfsn/fsnP mice (Figure 3.7).  
Treatment with 11B11 lowered the absorbance values in ELISA of both IgM and 
IgG anti-DNA antibodies from that of untreated Ttc7Pfsn/fsnP mice. Average absorbance 
values of the 11B11-treated group were 1.13 ± 0.6 for IgG and 0.65 ± 0.35 for IgM while 
untreated Ttc7Pfsn/fsnP mice averaged 1.26 ± 0.76 for IgG and 0.706 ± 0.14 for IgM. GL113-
treated isotype controls averaged 0.87 ± 0.15 for IgG and 0.72 ± 0.36 for IgM anti-DNA 
antibodies. Interestingly, the reduction in IgM anti-DNA antibodies in the 11B11 group 
correlates with the reduction in the percentage of immature B cells also found in that 
group, in contrast to the Stat6 deficient group which had a dramatic rise in anti-DNA IgM 
absorbance as well as a dramatic rise in the percentage of immature B cells. Perhaps IL-4 
is functioning to prolong survival in this group of cells which is then able to produce IgM 
autoantibodies, which then leads to the ramping up of autoimmunity.  
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Figure 3.7. 11B11-Treated Serum anti-DNA Antibodies. An anti-DNA ELISA was 
performed on sera collected at 10-weeks from 11B11-treated, GL113-treated (isotype 
control) and untreated Ttc7Pfsn/fsnP mice. IgG- and IgM-conjugated antibodies were used 
for detection. The data are presented in absorbance values obtained per individual 
animal. In general, anti-DNA IgGs have higher absorbance values than IgM in all 
groups. “0” represents background absorbance, and WT is a Ttc7 WT age-matched 
animal with absorbance values just above background.  
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11B11-Treated Ttc7Pfsn/fsnP mice exhibit autoantibody staining patterns similar to 
untreated Ttc7Pfsn/fsn P 
Although we saw a reduction in absorbance values for IgG and IgM anti-DNA in 
11B11-treated mice, the absorbance was still well-above background. Therefore, we 
wanted to examine serum staining patterns in HEp-2 cells to see if treatment with anti-IL-
4 altered the staining patterns seen previously in untreated Ttc7Pfsn/fsnP mice (Withington, 
Maltby-Askari et al. 2002). Representative images of staining from 11B11-treated serum 
are shown in Figure 3.8A-F. Patterns identified include nuclear homogeneous (A), 
nucleolar (B), nuclear rim (C), nuclear rim with cyoplasmic staining (D), and cytoplasmic 
staining (E). These patterns are associated with antibodies to nuclear antigens such as 
dsDNA, histones, Sm, fibrillarin, and cytoplasmic antigens such as RNA, ribosomal 
antigens, mitochondrial antigens and cytoskeletal antigens. 11B11-treated animals have 
both IgM and IgG antibodies in these patterns which are typically found in human 
systemic sclerosis, overlap syndromes and SLE (Bradwell 1995). For comparison, Figure 
3.8A-C shows representative images of untreated Ttc7Pfsn/fsnP serum as well as a GL113 
control (3.9C). Most of the patterns associated with the treated animals were also found 
in the untreated and control, with the exception of the nucleolar pattern (3.8B). This 
suggests that IL-4 may not influence the specificity of autoantibodies, but may have more 
of an effect on isotype.  
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Figure 3.8. 11B11-Treated Ttc7Pfsn/fsnP HEp-2 Slide Staining: Autoantibody 
Patterns. HEp-2 cell staining for autoantibody staining patterns of 11B11-
treated serum. Commercially prepared HEp-2 slides were incubated with serum 
from 11B11-treated Ttc7Pfsn/fsnP animals and detected with either IgM or IgG-FITC 
conjugated antibodies and visualized with Fluorescent microscopy. Images are 
representative of 5 animals with similar staining patterns. A. Nuclear 
homogenous B. nucleolar staining pattern C. Nuclear rim D. nuclear rim with 
cytoplasmic staining E. cytoplasmic pattern typical of ribosomal, mitochondrial 
and RNA antigens F. cytoplasmic with rim. Patterns identified were both 
nuclear and cytoplasmic with both IgM and IgG. Patterns shown are typically 
found in human systemic sclerosis, overlap syndromes and SLE. 200X  
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Figure 3.9  Staining of HEp-2 Slides for IgM and IgG Autoantibodies in 
Ttc7Pfsn/fs Pand GL113-treated control animals. HEp-2 cell staining for 
autoantibody staining patterns of untreated Ttc7Pfsn/fsnP mice (A and B) and isotype 
control (C). A. nuclear speckled B. nuclear with cytoplasmic C. nuclear rim. 
Nuclear antigens typically showing these patterns include dsDNA, histones and 
Sm. Images are representative of staining patterns found in all animals 
examined. 200X   
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Results: Section 4: Cell Cycle Analysis of Ttc7Pfsn/fsnP, Stat6-/-Ttc7Pfsn/fsnP, and 11B11-
Treated Ttc7Pfsn/fsnP miceP 
Immune cells are programmed to proliferate when necessary in order to effect a 
response to an invading pathogen, and then to die off when the threat is over. These cells 
also proliferate during development and to maintain homeostasis of cell numbers. Thus, 
proliferation depends on tissue-specific programming and signals provided by extra-
cellular proteins produced by other cells, which are controlled by the cell cycle to drive 
the cell toward a proper response (Morgan 1999 & 2007). IL-4 both drives the cell cycle 
to induce a proliferative response in many cell types and needs cell cycle activity to 
upregulate its production. The production of IL-4 depends on a naïve cell to enter into the 
S phase of the cell cycle upon primary activation and then enter into several rounds of 
cell division to maintain an IL-4 memory response. Once a memory response is 
established, IL-4 is produced irrespective of the stage of the cell cycle (Lohning, Richter 
et al. 2003).  
When IL-4 binds to a cell via the IL-4 receptor, signals are transduced that 
activate proliferation and connect IL-4 to the cell cycle by at least two pathways. Upon 
phosphorylation of Stat6 and translocation to the nucleus, several cell cycle regulatory 
genes are upregulated including Cdc25A and members of the minichromosome 
maintenance (MCM) family (McDonald, Vanscoy et al. 2004). Stat6 activation also 
decreases the expression of p27Kip which is a cyclin dependent kinase that prevents 
activation of G1 cyclins and prevents progression through the cell cycle (Carey, 
Semenova et al. 2007). Stat6 can also bind to the same DNA target sequences as E2F 
proteins (Weisman, Creaner et al. 1996).  
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The binding of IL-4 to its receptor also activates the insulin receptor 1/2 pathway 
independently of Stat6, which leads to cell growth, proliferation and survival through a 
PI-3K dependent pathway. Proliferation through this pathway appears to function more 
efficiently when Stat6 is present; however, it has been shown to induce proliferation in 
the absence of Stat6 as well (Lohning, Richter et al. 2003).  
Cell cycle defects have been shown to lead to autoimmune syndromes similar to 
that of Ttc7Pfsn/fsnP mice (Murga, Fernandez-Capetillo et al. 2001). Since Ttc7Pfsn/fsnP mice 
have both hyper-proliferative cells and produce high levels of IL-4 we thought it 
important to examine the status of the cell cycle in Ttc7Pfsn/fsnP T cells. Because the 
production of IL-4 requires different cell cycle events at different stages of cellular 
differentiation and we have demonstrated that T cells are distributed differently at 4- and 
10-weeks, we looked at both 4- and 10-week T cells to evaluate any changes. 
Additionally, having both Stat6 deficient T cells and anti-IL-4 treated T cells gave us the 
ability to examine the cell cycle under different conditions in order to evaluate the 
response. We used flow cytometry and propidium iodide staining to look at DNA content 
and determine the percentage of  cells in G1/G0, designated as non-cycling cells, as well 
as the percentage of cells in S, G2 and M, which are designated as cycling cells (Carey, 
Semenova et al. 2007). We accomplished this by using double-stained cells and gating 
first on CD3+ cells (or CD4+), then on PI stained cells and gating on the appropriate 
peaks. An example of our gating is shown in Figure 4.1. 
Figure 4.2 represents 4-week CD3+ cells with non-cycling cells in black columns 
and cycling cells in white. We saw significantly more cycling Ttc7Pfsn/fsnP CD3+ T cells 
(13.76 ± 5.72%) as compared to WT (8.06 ± 2.01%, p=0.05). Hence, Ttc7Pfsn/fsnP CD3+  
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Figure 4.1.  Gating Example For Cell Cycle Analysis. Splenocytes were stained 
with either CD3- or CD4-congugated with FITC and Propidium Iodide. The CD3+ or 
CD4+ population was gated on as shown (R1) and then a histogram was constructed 
for PI staining. 65,000 total events were recorded per sample. Gating shown pertains 
to Figures 4.2-4.5. All data shown is presented as mean percentage of the number of 
indicated experiments  ± SEM.  
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Figure 4.2. 4-Week CD3+ T cell Cell Cycle Analysis. Ttc7Pfsn/fsnP CD3+ cells have a 
higher percentage of cycling cells (13.76 ± 5.72%) than do WT CD3+ cells (8.06 ± 
2.01%). WT animals have a significantly higher percentage of non-cycling cells 
(91.54  ± 0.79%, p=0.05) than Ttc7Pfsn/fsnP (85.19  ± 4.1%). Data was similar for CD4+ 
cells (not shown). N=4 for both groups.  
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cells had a lower percentage of non-cycling cells (85.19 ± 4.1%) than WT (91.54 ± 
0.79%). 
Ten-week T cell analysis is shown in Figure 4.3A&B. Here again there  was a 
significantly higher percentage of cycling CD3+ cells (6.23 ± 1.01%) in Ttc7Pfsn/fsnP cells 
than in WT (3.78 ± 0.4%, p=0.03)(Figure 4.3A). Thus, 4-week-old mice in both the 
Ttc7Pfsn/fsnP and WT animals had a higher percentage of cycling cell than did 10-week mice. 
Figure 4.3B illustrates CD4+ cells, which follows the same trend as CD3+ cells, with 
some minor variation in percentages.  
Stat6-/- CD3+ and CD4+ cell cycle analysis is shown in Figure 4.4A and B. At 
10-weeks, Stat6-/-Ttc7Pfsn/fsnP animals have a higher percentage of cycling CD3+ cells (9.9 
%) than do Ttc7Pfsn/fsnP Stat6 intact animals, although they show greater variability. These 
animals also have a dramatically elevated percentage of activated T cells, 
(CD62LPhiPCD44PhiP) which have been reported to be newly activated and dependent on the 
cell cycle for IL-4 production (Lohning, Richter et al. 2003). This may account for the 
high level of IL-4 produced by these animals and the increase in percentage of cycling 
cells, although the reason for the expansion of this population is unknown.  
When Ttc7Pfsn/fsnP mice are treated with anti-IL-4 (11B11) for seven weeks and then 
sacrificed at 10-weeks-of-age and analyzed, the percentage of cycling CD3+ cells (9.19 ±  
0.02%) is actually higher than that of untreated Ttc7Pfsn/fsnP mice (6.23 ± 1.01%)(Figure 
4.5). However, when compared to the isotype control treated Ttc7Pfsn/fsnP mice (14 ± 
1.25%), the 11B11-treated have a lower percentage of CD3+ cycling cells, suggesting 
that they are responding to the neutralizing effect of anti-IL-4. Interestingly, the isotype  
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Figure 4.3. 10-Week T Cell Cycle Analysis.  A. Ttc7Pfsn/fsnP CD3+ cells have a 
significantly higher percentage of cycling cells (6.23  ± 1.01, p=0.03) than do WT 
CD3+ cells (3.78  ± 0.4%). Ttc7Pfsn/fsnP also has a significantly lower percentage of 
CD3+ cells in G1 (91  ± 0.33%, p=0.0062) than WT (96  ± 0.88%). B. Ttc7Pfsn/fsnP mice 
also have a significantly higher percentage of cycling CD4+ cells (7.9  ± 1.8, p=0.03) 
than do WT (3.32  ± 1.0%). N=5 for all groups.  
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Figure 4.4. Stat6-/-Ttc7 T Cell Cycle Analysis. 10-week Stat6-/-Ttc7Pfsn/fsnP and Stat6-
/-Ttc7WT cell cycle analysis. A. Stat6-/-Ttc7Pfsn/fsnP CD3+ cells have a higher 
percentage of cycling cells (9.9  ± 7.3%) than do Stat6-/-Ttc7WT CD3+ cells (5.6  ± 
2.7%). B. Stat6-/-Ttc7Pfsn/fsnP also had a higher percentage of cycling CD4+ cells (8.1  ± 
4.4%) than did Stat6-/-Ttc7WT CD4+ cells (6.03  ± 0.45%). N=4 for all groups.  
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Figure 4.5. 11B11-Treated T Cell Cycle Analysis. Treated animals were sacrificed at 
10-weeks, after 7 weeks of treatment with anti-IL-4 and splenocytes were stained for 
cell cycle analysis. The percentage of cycling CD3+ cells (9.19  ± 0.02%) and cycling 
CD4+ cells (7.6  ± 0.2%) was similar to untreated Ttc7Pfsn/fsnP (see Figure 4.3). n=5  
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control-treated mice, have a higher percentage of activated CD3+ cells than do the 
11B11-treated, which have a higher percentage of activated CD3+ than the untreated. 
Even though the antibody was filter-sterilized and tested for contaminants, it is possible 
that the increase in activation of T cells may be a result of treatment with a rat antibody 
which can prove to be antigenic in mice.  
When comparing all of these groups directly, as shown in Table 4.1 for clarity, we 
can see a few trends in these data. 
 
Comparison of  Ttc7Pfsn/fsnP CD3+ Cells Under Different Conditions 
group G1/G0 S/G2/M 
4-week 85.19 ± 4.1 13.76 ± 5.72 
10-week 91 ± 0.33 6.23 ± 1.01 
Stat6-/- 87.8 ± 7.6 9.9 ± 7.3 
11B11 90.03 ± 0.3 9.19 ± 0.02 
GL113 80.02 ± 0.86 14.03 ± 1.25 
Table 4.1. Comparison of CD3+ Cell Cycle Data  
 
Under the different conditions listed above, the cell cycle, as measured by DNA 
content, appears to be responding to the changes in ways that can be explained by the 
activation state of the CD3+ cells. An increase in cycling correlates with an increase in T 
cell activation state, particularly of the CD62LPhiP/CD44PhiP phenotype. We would expect 
this to be an IL-4 producing population, which at the “activated” stage of cell maturity 
would still require the cell cycle for IL-4 production. Although Stat6 has been identified 
as decreasing the cell cycle inhibitory protein p27kip, which seems contrary to the 
increase in cycling in the Stat6 deficient group, IL-4 is still produced at extremely high 
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levels and the percentage of CD3+ activated T cells is the highest seen here. Therefore 
we can imagine that one of the other pathways activated by IL-4, such as the IRS-1/2 
pathway, may make up for the deficiency in Stat6. Thus, it appears that the cell cycle in 
Ttc7Pfsn/fsnP mice is being regulated and responding to changes, however at a higher level of 
activation than in WT animals.  
 
Results: Section 5: Assessment of Autoimmunity in Ttc7Pfsn/fsnP, Stat6-/-Ttc7Pfsn/fsnP, and 
11B11-Treated Ttc7Pfsn/fsnP Mice: Renal Disease 
 
Stat6-/-Ttc7Pfsn/fsnP mice have increased proteinuria and more severe kidney pathology 
than Ttc7Pfsn/fsnP Stat6 intact mice, whereas, anti-IL-4 treated mice have improved 
proteinuria and milder kidney disease 
Clinicians and researchers have long used increased urine protein levels as a 
marker of more severe renal disease in systemic autoimmunity as kidney failure has 
traditionally been one of the major consequences and outcomes of severe systemic 
autoimmune disease (Daikh 2001; Bagavant, Deshmukh et al. 2006). As the kidney 
becomes more diseased, capillaries in the glomeruli become “leaky” and allow serum 
protein into the urine. This can then be measured using commercially available 
colorimetric urinalysis. Mild renal disease is defined as proteinuria under 100 mg/mL, 
with advanced disease measuring over 100 mg/mL (Daikh 2001).  
To assess potential kidney pathology, we measured proteinuria in the urine of 
Stat6-/- animals between 10- and 16-weeks old, and 11B11 and isotype controls at the 
end-point of treatment at 10-weeks old. All measurements taken of Ttc7Pfsn/fsnP mice (n=12) 
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were between 30 mg/mL and 100 mg/mL starting at 7-weeks throughout their remaining 
lifespan. These numbers classify Ttc7Pfsn/fsnP mice as having “mild disease.” Interestingly, 
as these animals advanced in age, proteinuria didn’t rise above 100 mg/mL even when 
their urine output became negligible; consistent with the findings of Daikh and Wofsy, 
(2001), who had to end their study due to inadequate urine output for further assessment.  
Stat6-/-Ttc7Pfsn/fsnP (n=14) mice exhibited advanced to severe disease (over 300 
mg/mL) based on proteinuria measurements. Figure 5.1A-C presents data of several 
individual mice collected at approximately 2-week intervals starting at 10-weeks old. All 
of the Stat6-/-Ttc7Pfsn/fsnP mice had proteinuria measuring above 100 mg/mL, with several 
over 300 mg/mL, and even over 1000-2000 mg/mL. The animals with the highest 
proteinuria measurements died within 1-2 weeks after urinalysis. Stat6-/-Ttc7WT (n=12), 
as well as Ttc7WT Stat6 intact mice (n=8) consistently had measurements between 0 and 
trace (10 mg/mL) amounts, except for one Stat6-/-Ttc7WT (#880, B&C) which measured 
65 mg/mL throughout the time-course.  
The anti-IL-4 treatment appeared to have a mild effect on the amount of 
proteinuria in Ttc7Pfsn/fsnP mice as only one individual (#1488) in the treatment group (n=5) 
measured above 30 mg/mL (Figure 5.2). All of the isotype control mice (n=4) were 
unchanged from that of untreated Ttc7Pfsn/fsnP mice (65 mg/mL).  
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Figure 5.1. Stat6-/-Ttc7 Proteinuria. Urine was tested with commercial protein 
detection strips at 2 week intervals for several mice as indicated by animal 
number for 3 test periods. Stat6-/-Ttc7Pfsn/fsnP and Ttc7Pfsn/fsnP mice are identified 
with gray arrows below the animal number. A. First test period indicated that 
Stat6-/-Ttc7Pfsn/fsnP mice had elevated levels of proteinuria, with 2 mice testing for 
severe renal disease (#850 and # 815). Stat6-/-Ttc7WT tested all had negative 
readings. Ttc7Pfsn/fsnP mice had consistent measurements of between 30 and 100 
mg/mL. B. Test period 2 weeks after A. Mice #850 and 815 had died. Several 
mice measured previously had elevated levels. New mice were added to test 
group to replace deceased animals. One Stat6-/-Ttc7WT animal (#880) tested 
positive for proteinuria, but measurement was under 100 mg/mL. C. Two weeks 
after test period in B. Some Stat6-/-Ttc7Pfsn/fsnP animals remained at constant but 
high levels of proteinuria, while 2 mice had elevated levels. One of the animals 
with elevated proteinuria died immediately after the test period (#869). Mouse 
number 880 remained constant from 2 weeks prior. One Ttc7Pfsn/fsnP had died over 
the two-week interval.  
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Figure 5.2. 11B11-Treated Ttc7Pfsn/fsnP Proteinuria. Urine from 10-week animals was 
tested with commercial protein detection strips before sacrifice. 4 out of 5 11B11 
treated animals had reduced proteinuria (30 mg/mL) from isotype controls and 
untreated Ttc7Pfsn/fsnP. Isotype controls and untreated values were comparable.  
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Ttc7Pfsn/fsnP mice have membranoproliferative-glomerulonephritis which increases in 
severity with the deletion of Stat6 
Pathologies of the kidney arise from a variety of maladies such as infection, 
diabetes, drug reactions and vascular disease, but kidneys are particularly prone to 
immunological disorders compared to other organs and have been useful in monitoring 
the progression of immunological disease such as autoimmune diabetes and SLE. In 
general, there is not a direct one-to-one relationship between a particular mechanism of 
damage and a histological appearance or clinical syndrome, but glomerular damage can 
give rise to five clinical syndromes within which a particular glomerular disease may be 
more commonly associated. SLE, or systemic autoimmune disease, spans all five clinical 
syndromes and has been associated with deposits of most classes of immunoglobulins 
and many complement components at any site in the glomerulus (Stevens, Lowe et al. 
2002). Recently, immune cell infiltrates, particularly T cells, have been shown to be an 
important part of the disease process through the local production of cytokines and 
inflammation (Daikh 2001; Bagavant, Deshmukh et al. 2006). 
To assess the type and extent of kidney disease in Ttc7Pfsn/fsnP mice, Stat6-/-
Ttc7Pfsn/fsnP, and anti-IL-4 treated mice, kidneys from these and WT controls were 
harvested immediately upon sacrifice and fixed in 4% paraformaldehyde or 10% formalin 
for PAS and H&E staining. We sent the fixed kidneys, identified only by number, to Dr. 
Harini Bagavant at the University of Virginia, Division of Rheumatology and 
Immunology Specialized Center of Research on Systemic Lupus Erythematosus, for 
staining and blind scoring for kidney disease as described in Bagavant et al., 2006. The 
images presented herein were supplied by Dr. Bagavant.  
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Figure 5.3 presents representative images of Ttc7Pfsn/fsnP kidney from 15-week-old 
mice with membranoproliferative-glomerulonephritis. This type of GN is identified by 
the thickening of the capillary walls and basement membrane caused by interposition of 
mesangial cytoplasm into the peripheral capillary loop. This is thought to be in response 
to subendothelial immune complex deposition which causes new matrix to be laid down 
resulting in the replication of basement membrane material (Stevens, Lowe et al. 2002). 
This results in the loops of the glomeruli becoming more globular and enlarged, reducing 
the urinary space of the Bowman’s capsule. The inflammatory cells of this type of GN 
are seen in the medulla of the kidney instead of the glomeruli as shown in the bottom 
image.  
The next figure (Figure 5.4) focuses on some of the cell types found which 
included F4/80+ macrophages, CD11c+ dendritic cells, CD5+ T cells, and B220+ B cells. 
Dr. Bagavant pointed out the unusual presence of dendritic cells and macrophages inside 
the glomeruli and suggested these may be the pathogenic cells.  
It is interesting to note that this type of kidney disease is often associated with 
normocytic, normochromic anemia, which is exhibited by Ttc7Pfsn/fsnP mice (Beamer, 
Pelsue et al. 1995), although a specific mechanistic connection has not been identified. In 
humans, this type of GN is also often associated with hypocomplementemia and a 
circulating autoantibody identified as C3 nephritic factor, which binds to the C3 
convertase of the alternative complement pathway 
(Uwww.gamewood.net/rnet/renalpath/ch1.htmU: site of the University of North Carolina 
Nephropathology Laboratory).  
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Figure 5.3. Ttc7Pfsn/fsnP Kidney Sections: Membranoproliferative-
Glomerulonephritis. The images on the left are from mouse 1356. The 
glomeruli look like a textbook picture of Membranoproliferative GN.  (Lots of 
mesangium – but little immune cell infiltration). The major distinction from 
other SLE is the lack of inflammatory infiltrates and the normal looking 
Bowman’s capsule as well as tubules and interstitium.  The bottom left picture 
shows a foci of inflammatory cells in the medulla – seen in all the mice. Areas 
like these stain for the immune cells shown in Figure 5.4. 
Author’s note: PAS and H&E stained kidney sections from 20-week Ttc7Pfsn/fsnP
mice as indicated in the image. The images and explanation included for the 
images was written by Dr. Harini Bagavant as indicated in the text. The 
section in the right column is a Ttc7WT animal without kidney disease for 
comparison. 200X  
PAS staining of WT: negative for GN 
PAS 
H&E 
H&E 
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Figure 5.4. Immunofluorescent Staining of Kidney Sections. The images 
below are from Mouse no. 1356 and two pictures from mouse F1337 /F1377. 
Stained for macrophages (F4/80), dendritic cells (CD11c), T (CD5) and B 
(B220) cells. Patterns of staining in F1356 were typical and also seen in the 
other mice F1354, F1362.  All the cell types were seen in the medullary regions.  
T, B and CD11c were seen mainly near large blood vessels in the medulla.   
Macrophages were abundant in the medullary interstitium – and not only 
restricted to the peri-vascular regions.T and B cells were infrequent in the 
cortex.  Few T cells were seen near /around glomeruli.CD11c were a little more 
frequent and seen in the cortical interstitium – mainly around glomeruli.  In 
mouse 1337, CD11c cells were seen INSIDE several glomeruli (one example in 
the picture).  Another very striking feature was that F4/80 macrophages were 
abundant in the cortex.  In our SLE mice we have rarely /almost never seen 
glomerular infiltration on F4/80+ cells into the glomeruli.  However, in these, 
cells were present infrequently in F1356, but 1337 showed a lot of glomeruli 
with F4/80+ cells.  The lack of T and B cell infiltrates and the presence of 
CD11c and F4/80 + cells in the gloms is very exciting – especially since you 
have found that these mice have immune complex deposits. I have not tried 
double staining on these mice yet but CD11c and F4/80 double positive cells 
have been described in the kidney in other models and it would be interesting to 
see if they are the pathogenic cells here.       
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Author’s note on Figure 5.4:  Fluorescently stained sections above are from the same 
animals as in Figure 5.3, stained for individual cell types. Explanation in the caption on 
preceding page and images were provided by Dr. Bagavant. 200X   
 
 
Glomerular/ Cortical Medullary/ peri-
vascular 
1337 /glomerular
F4/80 
CD11c 
CD5
B220
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Figure 5.5 is H&E staining and representative of renal disease found in Stat6-/-
Ttc7Pfsn/fsnP (#793 and #797) mice. In images #793 and 797 the thickening of the glomeruli 
and lobular appearance of the mesangium can clearly be seen. The urinary space of the 
Bowman’s capsule is almost completely gone. Dr. Bagavant indicated that these looked 
much like the Ttc7Pfsn/fsnP sections and classified them as having more severe glomerular 
disease (rated 2-3+). The center image, #796, is actually a Stat6-/-Ttc7WT animal (rated 
0-0.5+), which showed some mild mesangial changes in some of the glomeruli. 
Proteinuria information is not available for this animal, but only one Stat6-/-Ttc7WT 
(n=12) had elevated urine protein. No signs of renal disease or proteinuria have been 
reported in the literature for Stat6-/- animals of any strain, therefore the mesangial 
changes may be due to individual variation. It is important to note that the Stat6-/- mice 
analyzed here were 10-weeks old, hence younger than the Ttc7Pfsn/fsnP above.  
Figure 5.6 is PAS staining of 11B11-treated mice on the left and isotype control 
mice (GL113) on the right. Evidence of glomerular disease was seen in all images, with 
mesangial proliferation, dilated capillary loops and cellular infiltration. However, slightly 
less severe changes were evident in the 11B11-treated animals on the left (rated 1+) who 
exhibited a decrease in cellularity as compared to those on the right (rated 1.5-2+). 
Therefore, 11B11-treated mice had slightly milder renal disease than the isotype controls, 
which correlated with the lower proteinuria measurements.  
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Figure 5.5. H and E Staining of Stat6-/-Ttc7 Kidney Sections. Sections from Stat6-
/-Ttc7Pfsn/fsnP (#793 and #797) and Stat6-/-Ttc7WT (#796) kidney stained with H&E. 
Both Stat6-/-Ttc7Pfsn/fsnP sections show severe glomerular disease as scored by Dr. 
Bagavant with severity index scores of 2-3+. The increased cellularity, lack of 
Bowman’s space, and thickened mesangium can clearly be seen in the images. #796 
had some mild GN; only a few glomeruli had mesangial changes. This section rated a 
severity index of 0-0.5+. 200X 
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Figure 5.6. PAS Staining of 11B11- and GL113-Treated Ttc7Pfsn/fsnP Kidney 
Sections. Sections from 10-week 11B11-treated on the left and GL113 isotype-
control-treated animals on the right. All sections were stained with PAS. Two animals 
are shown from each group as representative sections from all animals analyzed with 
similar results and scores. All of the 11B11-treated animals scored a 1+ on the severity 
index for mesangial thickening and cell infiltration but had fewer than 100% of the 
glomeruli effected. The GL113-treated animals all scored 1.5+ except for one which 
had a score of 2+ for more glomeruli involved, increased cellularity and infiltration 
and more mesangial thickening than the 11B11 mice. The lobular appearance of the 
glomeruli capillary loops can be seen clearly with PAS staining. 200X  
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Thus, from these data, it appears that the lack of Stat6-/- in Ttc7Pfsn/fsnP results in an 
increase in the severity of autoimmunity as measured by renal disease. The neutralization 
of IL-4 results in a slight decrease in the severity of autoimmunity. Therefore we suggest 
that Ttc7Pfsn/fsnP mice exhibit an autoimmune syndrome that is phenotypically-driven by IL-
4 due to the background genetic effects of the Th2-skewed Balb/c strain, and results from 
the dysregulated activation of lymphocytes due to the defective Ttc7 gene. We further 
suggest that Ttc7 functions to negatively regulate lymphocyte activation and cytokine 
production and when the downstream inhibitory action of Stat6 is removed in the Stat6 
deficient animals, IL-4 production becomes elevated and increases the severity of the 
pathology. The question of whether Ttc7 and Stat6 interact remains to be answered when 
the tools for the study of Ttc7 become more readily available for such analysis. However, 
these data suggest the possibility that Stat6 and Ttc7 may function in a similar or 
complementary fashion as when both are deficient we see more lymphocyte activation 
and proliferation, and more autoimmune pathology.  
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DISCUSSION 
Since IL-4 has been shown to have a protective effect on B cells by increasing 
their survival and proliferative capacity thus contributing to autoimmune disease, and 
because Stat6 is unique to the IL-4 signaling pathway (Morris, Dragula et al. 2002), the 
first aim of this thesis was to examine the behavior of Stat6 in Ttc7Pfsn/fsnP lymphocytes to 
determine the downstream effects of IL-4 signaling. We sought to ascertain whether there 
is defective signal transduction regulation downstream of the IL-4 receptor in Ttc7Pfsn/fsnP B 
cells or if overproduction of IL-4 is responsible for the constitutive activation of Stat6. 
Whereas Ttc7Pfsn/fsn Pmice have highly elevated levels of IL-4 we hypothesized that if B 
cells possessed the inherent ability to deactivate Stat6 when the IL-4 signal was removed 
(ex vivo), then it was likely that the overproduction of IL-4 was driving the autoimmune 
phenotype of Ttc7Pfsn/fsnP.  
Preliminary work indicated that Stat6 appeared constitutively activated in 8-week 
Ttc7Pfsn/fsnP splenic lymphocytes (Welner, Hastings et al. 2004) and (Figure 1.1 and 1.2). 
Stat6 exists as a latent transcription factor present in the cytoplasm in an inactive 
monomeric state in IL-4 responsive cells. Upon binding of IL-4 to the IL-4 receptor, 
Stat6 becomes phosphorylated, forms a homo-dimer with another phosphorylated Stat6 
and translocates to the nucleus where it will bind to its recognition sequence on DNA. 
Here, it cooperates with other transcription factors to initiate transcription of IL-4 
responsive genes such as MHC class II, CD23, germline IgE and IgG1, and the IL-4Ra 
chain. Thus, Stat6 normally becomes activated in the cytoplasm, but is only functional 
when it has translocated to the nucleus. Daines et al (Daines, Andrews et al. 2003) 
recently showed that Stat6 is sequestered in the cytoplasm by a detergent-sensitive factor 
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which may involve the serine phosphorylation of Stat6 mediated through inhibition of 
protein phosphatase 2A (PP2A). When PP2A is active, the serine is unphosphorylated 
and Stat6 is able to bind to DNA (Woetmann, Brockdorff et al. 2003). When released, 
Stat6 is able to enter the nucleus, where it binds to DNA and exerts its influence on gene 
transcription, then becomes inactivated (dephosphorylated) and is shuttled back to the 
cytoplasm where it can be recycled for another round of activation. Thus, the overall 
levels of Stat6 appear to remain stable, but the amount of the activated phosphorylated 
Stat6 will change with the activation state of the cell. Recently it has been determined 
that the life cycle of Stat6 is dependant on the duration of the IL-4 signal received and 
that the shuttling of Stat6 back to the cytoplasm allows for reactivation if continued 
signaling is present (Andrews, Ericksen et al. 2002).  
In experimental models of constitutively expressed Stat6, Stat6 remained 
phosphorylated even in the absence of IL-4 (Bruns and Kaplan 2006). There existed an 
exaggerated Th2B Bcytokine response as well as an increase in IgE and IgG1 antibodies as 
is the case with Ttc7Pfsn/fsnP mice. T cells appeared to be hyperactivated in the Stat6 
transgenic but the researchers concluded that B cells were not as they did not 
hyperproliferate in response to a mitogen. They indicated that both the bone marrow and 
thymus showed normal lymphocyte development (Bruns, Schindler et al. 2003; Bruns 
and Kaplan 2006). Previous work by our group on Ttc7Pfsn/fsnP mice has shown that both 
splenic T and B cells show enhanced proliferation, increased size, increased surface 
MHC class II on B cells, and an increase in protein production suggesting that, unlike the 
Stat6 transgenic, both populations are hyperactivated (Welner et al. 2004). Therefore it 
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was important to examine the regulation of Stat6 in Ttc7Pfsn/fsnP mice and tease out the 
contributions that IL-4 and Stat6 make to the phenotype of Ttc7Pfsn/fsnP autoimmunity. 
B cell hyperactivation and response to IL-4 was studied by evaluating the 
expression and function Stat6. Initially, expression levels of phosphorylated and total 
Stat6 were analyzed as a measure of lymphocyte activation by IL-4 using 
immunoprecipitation and Western blot and comparing stimulated cells to unstimulated 
cells. Finding that Stat6 was constitutively activated even without stimulation by 
exogenous IL-4, we next sought to determine if there was a functional defect maintaining 
the phosphorylation and activation of Stat6.  
Intra-cellular fluorescent staining of Stat6 and the nucleus in purified splenic B 
cells and visualization with confocal microscopy allowed us to follow the functional 
translocation of Stat6 to the nucleus to confirm the co-localization of activated Stat6 with 
the nucleus and the resulting association of localization with activated cells (Figures 1.4 
and 1.5). This determined that Stat6 was responding to activation signals by IL-4 as even 
though the Ttc7Pfsn/fsnP cells had a higher percentage of activated cells without stimulation, 
the number increased upon stimulation to a level similar to WT although with an altered 
response curve. The curve exhibited by Ttc7Pfsn/fsnP B cells was reminiscent of previously 
activated B cells as shown by Andrews et al (Andrews, Ericksen et al. 2002) describing 
the life cycle of Stat6. They determined that activation and translocation of Stat6 to the 
nucleus was dependent on the shuttling of Stat6 out of the nucleus, thereby limiting the 
amount of phosphorylated Stat6 “allowed” in the nucleus at any one time. Therefore, in 
previously activated B cells which would have a certain amount of pStat6 already 
occupying the nuclear compartment, the timing of the translocation of newly activated 
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Stat6 to the nucleus would appear to be delayed from that of previously unstimulated 
cells.  
The inactivation or turnover of Stat6 is an important step in the regulation of gene 
transcription. Inability to de-activate or inhibit Stat6 activation could result in an 
uncontrolled activation signal leading to hyperactivation of cells. To study this 
possibility, negatively selected, magnetically purified B cells were activated with IL-4 
and assayed immediately after stimulation and at various time points after washing cells 
of residual, exogenous IL-4 and then visualized with confocal microscopy to evaluate the 
kinetics of de-activation (Figures 1.6 and 1.7) . Differences in the fall-off characteristics 
between Ttc7Pfsn/fsnP and WT cells provided us with information regarding the inherent 
ability of Ttc7Pfsn/fsnP B cells to downregulate IL-4 signals in the absence of IL-4 stimulus. 
Our analysis of Stat6 activation in Ttc7Pfsn/fsnP showed that Ttc7Pfsn/fsnP B cells were able to 
deactivate Stat6 when the IL-4 signal was removed suggesting that an inherent B cell 
defect of Stat6 regulation was not maintaining Stat6 phosphorylation but that IL-4 was 
driving the hyperactivation of Stat6. It was interesting to note the difference in the curve 
of Stat6 decay in Ttc7Pfsn/fsnP B cells, which suggested a sharper initial drop than WT. This 
also mirrors the behavior of previously activated B cells as shown by Hanson et al 
(Hanson, Dickensheets et al. 2003) and was most likely due to the activation of Ttc7Pfsn/fsnP 
cells in vivo.  
The information gathered above was then correlated to immunohistofluorescently 
stained Ttc7Pfsn/fsnP and WT splenic sections to evaluate the cellular activation on a 
structural level (Figure 1.8). Overall, the amount of staining of total Stat6 in the spleen is 
similar between Ttc7Pfsn/fsnP and WT, but, as is shown in Figure 1.9, there is an increase in 
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the number of follicles with phosphorylated Stat6 in Ttc7Pfsn/fsn Pmice as well as an increase 
in the amount of phosphorylated Stat6 within the follicles. The phospho-Stat6 coincides 
with areas of newly arrived B cells and plasmablasts which are usually outside of the 
follicle (Mattsson, Duzevik et al. 2005; William, Euler et al. 2005); however, due to the 
altered architecture of the Ttc7Pfsn/fsnP spleen, these B cells are inside what is left of the 
follicle in an area where they would be able to interact with T cells. When this is then 
compared to the IL-4 staining of the spleen (Figures 1.10 and 1.11), we find IL-4 being 
expressed in these same areas. Thus, it is possible that immature B cells are interacting 
with T cells at an inappropriate time in development, in an IL-4-rich environment which 
may enhance their survival and allow for autoreactive B cells to mature into autoantibody 
producing cells.  
Ttc7Pfsn/fsn Pmice display an increase in the ratio of CD4P+P to CD8P+P T cells in the 
spleen as compared to WT (Pelsue, Schweitzer et al. 1998) which may likely contribute 
to the increased levels of IL-4 found in Ttc7Pfsn/fsn Pserum and spleen (Figure 1.10 and 
1.15).  IgMP+P B cells are also increased, providing an abundant target for the IL-4 released 
by local T cells. As Ttc7Pfsn/fsn Pmice age, we see increasingly disrupted splenic 
architecture, positioning cells in locations where they may not normally be found thus 
subjecting them to factors in an untimely and/or at an abnormal level which may result in 
altered tolerance induction and survival (al-Janadi and Raziuddin 1993).  
This study shows that Ttc7Pfsn/fsnP splenic B cells exhibit high levels of activated 
Stat6 without additional stimulation, but upon stimulation with exogenous IL-4 they 
follow similar activation trends as wild type (WT) cells. In addition, when these cells are 
stimulated with IL-4, washed and allowed to rest, Stat6 becomes deactivated in the 
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nucleus and returns to the cytoplasm in a similar manner to WT. It is important to note 
that there have been no mutations or polymorphisms associated with the Ttc7Pfsn/fsnP mouse 
at the “Th2” locus on mouse Chromosome 11 which includes the genes for IL-4, IL-5 and 
IL-13 nor at the Stat6 locus on mouse Chromosome 10, therefore, we conclude that Stat6 
is hyper-activated due to continuous IL-4 signaling and not to inherent defects in Stat6 
regulation.  
 
T cell activation and IL-4 production 
IL-4 production is regulated in a positive feedback manner in which the presence 
of IL-4 and IL-4 receptors stimulate more IL-4 to be produced as well as more IL-4 
receptors to be upregulated on the cell surface (Dorado, Jerez et al. 2002; Harris, 
Goodrich et al. 2005). The primary stimulus initiating IL-4 production and the cell type 
that produces it is an area of intense research with general agreement being that various 
subtypes of T cells play a big part in production and that skewing towards a Th2 
phenotype is genetically determined (Yagi, Suzuki et al. 2002; Yamada, Zhu et al. 2002; 
Rose, Lichtenheld et al. 2007). IL-4 is produced by T cells upon antigen stimulation or 
cross-linking of the T cell receptor (TCR). The initial cellular source of IL-4 in an 
immune response has not been fully determined but it has recently been shown that naïve 
T cells have a minute pool of IL-4 mRNA, which becomes translated following a 
signaling event (Rose, Lichtenheld et al. 2007). When secreted, it can bind to the IL-4 
receptor of T cells in an autocrine or paracrine fashion to upregulate the production of 
more IL-4 (Cunningham, Serre et al. 2004). The production of IL-4 is maintained by cells 
until the initiating signal is discontinued or until inhibitory molecules and mechanisms 
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are upregulated to attenuate the signal and dampen production. Subsequent production of 
IL-4 becomes more efficient as chromatin remodeling occurs at the IL-4 locus, allowing 
for a quicker and more robust response (Dorado, Jerez et al. 2002). This is regulated in 
part by the presence of particular transcription factors (TFs), including Stat6, that regulate 
IL-4 gene transcription and drive the polarity of the Th1 and Th2 response (Li-Weber and 
Krammer 2003). Regulation of IL-4 production is tightly controlled and has been shown 
to be predominantly via transcriptional regulatory measures, however there has been 
recent evidence in studies using actinomycin D to block transcription that suggest 
increased mRNA stability may have an important role in maintaining an IL-4 rich 
environment (Dokter, Esselink et al. 1993; Norvell, Mandik et al. 1995; Pioli, Pucci et al. 
1998). Additional regulatory measures include a change in chromatin structure (Grogan, 
Wang et al. 2003; Baguet and Bix 2004; Yamashita, Shinnakasu et al. 2004), 
upregulation of inhibitory molecules such as SOCS and SHP, and a change in signal 
strength and duration. Initial research into this subject focused on the use of long-term 
cell lines, whereas recent use of primary cells have noted significant differences between 
the two (Kelly-Welch, Hanson et al. 2005). Therefore the second aim of this thesis was to 
examine Ttc7Pfsn/fsnP T cells and determine activation and IL-4 production. 
We have shown that altered IL-4 production and regulation due to hyperactivation 
of the Ttc7Pfsn/fsn PT cells is helping to drive the autoimmune process. When we compared 
Ttc7Pfsn/fsn PT cells to WT we found an increase in IL-4 mRNA expression upon anti-CD3 
stimulation and a slower turnover of IL-4 mRNA when further mRNA synthesis was 
blocked with Act D (Figures 1.12 and 1.13). As the results shown were given as a ratio of 
IL-4 mRNA to GADPH, there was not only a larger pool of IL-4 mRNA requiring longer 
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turn-over time, but also a change in the functional turn-over of the mRNA. Actinomycin 
D allows for the continued translation of protein, therefore our results demonstrate the 
effect that an increase in mRNA stability has in the dysregulation of protein production. 
IL-4 production in Ttc7Pfsn/fsnP T cells was still at a statistically significant higher level 24 
hours after the addition of Act D to cell culture of stimulated 4-weeks cells, and even in 
unstimulated 10-week T cells without Act D (Figure 1.15). Thus, we can imagine that in 
vivo where the signal to produce IL-4 is unchecked by the addition of any exogenous 
modifiers such as Act D, there exists a strong drive to keep producing IL-4 that is 
perpetuated by a normal positive feedback loop, whose inhibitory mechanisms may 
become overwhelmed or are perhaps defective. This is especially evident when 
examining protein production in 10-week T cells. In other systems it has been shown that 
IL-4 is regulated differently in cells that have been previously activated and in cells from 
older mice, which allows for the up-regulation of factors that function to modulate 
production (Dokter, Esselink et al. 1993). It appeared that there is some attempt in 
Ttc7Pfsn/fsn PT cells to regulate the magnitude of IL-4 production as stimulated Ttc7Pfsn/fsn P10-
week T cells did not reach the level of IL-4 as do 4-week T cells in a manner similar to 
WT T cells.  However, unstimulated 10-week Ttc7Pfsn/fsn PT cells still produced 1200-fold 
more IL-4 than WT cells, almost 300-fold more IL-4 in stimulated cells, and there was 
over 1000-fold more residual IL-4 after treatment with Act D. Therefore, Ttc7Pfsn/fsn PT 
cells are being pushed to produce IL-4 regardless of any inhibitory signals they may be 
receiving. 
When quantifying RNA to normalize the concentration for each RT-PCR 
reaction, it was found that unstimulated Ttc7Pfsn/fsn PT cells contain 3X more total RNA on a 
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per cell basis than do WT cells (Table 1.1). For the experimental method it was necessary 
to normalize RNA to 2µg per sample in order to determine the relative expression levels 
of IL-4 mRNA in both populations of T cells. The ELISA protein measurements were 
based on equal numbers of cells plated per sample. Thus, it was possible that Ttc7Pfsn/fsn PT 
cells have more IL-4 mRNA which would result in more IL-4. However, when we look at 
the RT-PCR results which compared equal concentrations of mRNA, at 4-weeks in 
unstimulated cells the expression of IL-4 mRNA in Ttc7Pfsn/fsnP mice was actually below 
that of WT. It is only upon stimulation with anti-CD3 that we saw a rise over that of WT. 
This difference was reflected in protein production as well since at 4-weeks in 
unstimulated cells both Ttc7Pfsn/fsn Pand WT had non-detectable concentrations of IL-4. At 
10-weeks in unstimulated cells the situation reversed and Ttc7Pfsn/fsn PT cells had IL-4 
mRNA expression above that of WT which was then reflected in the dramatic rise of IL-4 
protein that was produced. Thus, we see that there was an increased capacity in Ttc7Pfsn/fsn 
PT cells for IL-4 gene expression reminiscent of previously activated or “primed” cells 
(Bird, Brown et al. 1998; Cron, Bort et al. 1999; Grogan, Wang et al. 2003), and a delay 
in turnover suggestive of increased mRNA stability which had been demonstrated to 
exert differential control of IL-4 between younger and older mice (Pioli, Pucci et al. 
1998; Butler, Monick et al. 2002). An increase in overall RNA also supported the notion 
that Ttc7Pfsn/fsnP T cells are hyperactivated in vivo by as yet undetermined means.  This 
would be expected to exacerbate the condition, which we see reflected in the more severe 
autoimmune phenotype of 10-week-old mice. 
Cyclosporin A is known to inhibit CaP++P sensitive pathways by inhibiting the 
CaP++P-calmodulin dependent phosphatase calcineruin (Naora, Altin et al. 1994; Naora and 
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Young 1995). Our results demonstrated that IL-4 production in enriched T cells (ex vivo) 
is mediated by a CaP++P dependant pathway signaled by the TCR/CD3 complex in a similar 
manner in both Ttc7Pfsn/fsn Pand WT. It further demonstrates that IL-4 production actually 
requires a signal and is not produced in Ttc7Pfsn/fsnP T cells by an alternative mechanism.  
Previous work by our group on the Ttc7Pfsn/fsnP mice noted a distinct acceleration of 
autoimmune pathology starting at about 5-6 weeks of age, leading to death typically at 15 
weeks. The results presented here provide a molecular basis for this observation as we 
also provided evidence that the mRNA and protein differences we see in the 4-week mice 
have matured in 10-week mice and resulted in exaggerated protein production that is 
resistant to actinomycin D treatment. Other groups have noted altered IL-4 regulation in 
T cells that have been previously activated and differentiated into Th2 cells. Dorado et al, 
(Dorado, Jerez et al. 2002), demonstrated that the initial production of IL-4 in T cells was 
regulated differently in undifferentiated T helper cells, but once cells were committed to 
IL-4 production or “primed” they became more efficient in producing IL-4 which, in their 
system, may have been independent of IL-4 receptor stimulation (Cron, Bort et al. 1999; 
Grogan, Wang et al. 2003). Committed Th2 cells also produced altered levels of IL-4 
mRNA as compared to naïve and exhibited autoregulatory mechanisms involving the 
competition between Stat6 and NFAT1 for the P1 site of the IL-4 promotor which helped 
tip the balance between continued production and downregulation (Dorado, Jerez et al. 
2002).  
The differences observed in IL-4 mRNA stability and protein production between 
Ttc7Pfsn/fsnP T cells and WT suggested that Ttc7Pfsn/fsnP T cells were phenotypically different 
than WT. This was confirmed by flow cytometry using published markers for T cell 
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subsets designated as naïve (CD62LPhiP/CD44PloP), activated (CD62LPhiP/CD44PhiP) or memory 
cells (CD62LPloP/CD44PhiP). There were significantly fewer naïve CD4+ cells and 
significantly more (2-2.5X) activated and memory CD4+ cells in 4-week Ttc7Pfsn/fsnP mice 
than WT. The trend in subset alterations was maintained by 10-week mice.  
It is interesting that the ramping up of lymphocyte activation and IL-4 production 
closely correlates with disease progression of the Ttc7Pfsn/fsnP mice as they age. A 
seemingly slight increase in Stat6 activation in Ttc7Pfsn PB cells (Figure 1.5) resulted in 
continuous  expression of phosphorylated Stat6. The upregulation of Stat6 by IL-4 
normally results in the activation of molecules and factors that function to help shut down 
the production of IL-4. Under normal conditions IL-4 is a tightly regulated cytokine with 
multiple levels of regulation and has been shown to need continuous stimulation to 
maintain production.  In Ttc7Pfsn/fsn Pmice a slight change in IL-4 mRNA expression in T 
cells became amplified to make a statistically significant difference in actual IL-4 protein 
production. Experimentally, we could shut off the signal and still see an increased 
capacity for protein production as well as an increase in mRNA stability, however, in 
vivo it appears that IL-4 is continuously driven by autoreactive activation resulting in a 
state of overexpression severe enough to cause systemic autoimmune disease resulting in 
a dramatic decrease in life expectancy.  
Ttc7PfsnP mice in many ways mimic the autoimmune phenotype of the IL-4 
transgenic murine model developed by Erb et al (Erb 1994; Erb, Ruger et al. 1997) 
especially in regards to B cell hyperactivity, increase in self-reactive antibody titers, 
splenomegaly, anemia and kidney disease. These researchers suggested that the increased 
expression of MHC class II and costimulatory molecules on B cells contributed to the 
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activated phenotypes of the T cells. The elevated production of IL-4 in the T cells in turn 
enhanced the Stat6-induced phenotype of the B cells as well as other IL-4 driven 
processes. Singh et al (Singh, Saxena et al. 2003) provided evidence of IL-4 
overproduction in New Zealand Mixed 2410 mice that resulted in systemic autoimmune 
pathology in which many of the symptoms were ameliorated when the strain was crossed 
with a Stat6 knockout. The cause of the dysregulation in IL-4 production was unknown; 
however, they noticed a significant increase in the number of IL-4 secreting CD4P+P T 
cells.  
As mentioned previously, the Ttc7Pfsn/fsnP gene mutation has recently been identified 
as an ETn retroviral insertion at the distal end of mouse Chromosome 17; however, the 
gene function is still unknown. Because of the severe phenotype of Ttc7Pfsn/fsnP mice we 
speculate that the Ttc7Pfsn/snP gene product has an important function in immune system 
regulation which is disrupted in these mice. Many of the pathologies seen in Ttc7Pfsn/fsnP 
have been found to be IL-4 driven in this as well as other systemic autoimmune models. 
Whereas Ttc7Pfsn/fsn Pis on a BALB/c background we would expect a Th2 skewing in 
cytokine production upon immune activation (Bix, Wang et al. 1998; Butler, Monick et 
al. 2002; Yagi, Suzuki et al. 2002). What is not yet clear is why on a genetically identical 
background as WT, except for the Ttc7Pfsn/fsn Pmutation, the regulation of IL-4 starts to 
change early on and becomes so rapidly dysregulated that it leads to such a dramatic 
reduction in lifespan.  
Our results suggested an increased capacity for IL-4 production in Ttc7Pfsn/fsnP T 
cells that was mirrored by IL-4 mRNA expression. There was a detectable difference in 
mRNA stability in Ttc7Pfsn/fsnP T cells as compared to WT which resulted in statistically 
 200
significant residual protein expression in Ttc7Pfsn/fsnP after transcription was blocked with 
actinomycin D (Act D). Signaling appeared to be mediated by the TCR/CD3 complex as 
cyclosporine A (CsA) shut down both mRNA as well as protein production in both WT 
and mutant T cells. This also supports the idea that the pathology results from an antigen-
driven process as both the increased presence of activated T cells, suggesting antigen 
stimulation, and the ability to block IL-4 production by CsA is mediated by the T cell 
antigen receptor. 
These data suggested that Ttc7Pfsn/fsnP T cells exhibited a “primed” phenotype at 4- 
weeks of age, a time when WT cells still appeared relatively naïve. These primed cells 
could then recruit more cells capable of producing IL-4 while they display an increased 
capacity for production, and may eventually overwhelm the counter-regulatory 
mechanisms normally in place to prevent IL-4 overproduction. Previous data has shown 
that both Ttc7Pfsn/fsn Pand WT cells produced similar levels of interferon-gamma in response 
to anti-CD3 stimulation and that regulation of this IL-4-opposing cytokine (So, Park et al. 
2000) appeared to be normal with no exaggeration of production. This further suggests 
that over-production of IL-4 significantly contributes to the development of 
autoimmunity in Ttc7Pfsn/fsnP mice.  
 
 Stat6 deficiency and 11B11-Treatment of Ttc7Pfsn/fsnP Mice 
The third aim of this thesis was to evaluate the contribution of Stat6 and IL-4 to 
the phenotype of Ttc7Pfsn/fsnP mice. Several groups have found that the deletion of Stat6 led 
to the lessening or elimination of autoimmunity and disease pathology in other mouse 
models of autoimmunity (Jankovic, Kullberg et al. 2000; Bruns, Schindler et al. 2003; 
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Singh, Saxena et al. 2003; Xu, Duan et al. 2006). It was determined that a deletion of 
Stat6 resulted in a concurrent decline in the hyperactivation of lymphocytes, a decline in 
the production of IL-4 and an alteration in serum Ig levels resulting in a lower expression 
of autoantibodies. Thus, to determine the contribution of Stat6 to the Ttc7Pfsn/fsnP 
autoimmune phenotype we developed a Stat6 knock-out X Ttc7Pfsn/fsnP model by crossing 
Stat6 deficient animals with Ttc7 heterozygotes to fix the Stat6 deficiency with the 
Ttc7Pfsn/fsnP mutation. The resulting Stat6-/-Ttc7Pfsn/fsnP mice were produced in an expected 
Mendelian distribution of 1 in 16 animals.  
Previous attempts to establish an IL-4 deficient Ttc7Pfsn/fsnP model were 
unsuccessful, therefore to evaluate the contribution of IL-4 to the pathology of Ttc7Pfsn/fsnP 
mice we used a monoclonal IL-4-neutralizing antibody (11B11) and injected 250 µg IP, 
three times per week starting at 3-weeks of age. Another monoclonal antibody, GL113, 
was used as an isotype control and administered in the same manner as the 11B11. This 
was continued until 10 weeks of age whereupon mice were bled and sacrificed for 
analysis (Erb, Ruger et al. 1997; Singh, Saxena et al. 2003). 
Previous work by us and others has contributed to a body of knowledge 
illuminating the autoimmune and inflammatory pathology of the Ttc7Pfsn/fsnP mouse. We 
used this as a model and frame-of-reference to compare the phenotype of the Stat6-/-
Ttc7Pfsn/fsnP as well as the 11B11-treated Ttc7Pfsn/fsnP mice. One of the striking features of the 
Ttc7Pfsn/fsnP mouse is the marked splenomegaly and altered cell population in the spleen. 
Therefore we evaluated the identity and percentages of CD3+, B220+, Mac-1+, CD4+, 
CD8+, F4/80+, Gr-1+ and TER-119+ cells in the spleens of 10-week-old mice using flow 
cytometry as described previously in Pelsue, et al (1998). In addition, we determined 
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alterations in T cell subsets as well as B cell subsets using the ratio and expression of cell 
surface markers to identify subsets categorized here and in other works. 
As mentioned earlier in the introduction, B cells play a central role in autoimmune 
pathology. Thus, we analyzed Stat6-/-Ttc7Pfsn/fsnP and 11B11-Treated mice sera for the 
production of anti-nuclear antibodies (ANA). This was done in two ways. ELISAs 
specific for IgM and IgG anti-DNA antibodies and a HEp-2 immunofluorescence assay 
(IFA) were used to detect the general presence of antibodies against nuclear antigens and 
characteristic staining patterns of antibodies specific for nuclear and cytoplasmic antigens 
respectively. Anti-dsDNA is the major component of the anti-DNA measured by the 
ELISA and is indicative of systemic autoimmunity where higher than normal titers have 
been correlated with disease activity in humans (Koh, Dunphy et al. 1995; Fields and 
Erikson 2003; Woetmann, Brockdorff et al. 2003; Craig, Ledue et al. 2006; Stahl, 
Hoemberg et al. 2006; Bizzaro 2007; Khan, Witsch et al. 2008; Yung and Chan 2008).  
In humans with systemic autoimmune disease, kidney pathology is a major cause 
of morbidity and mortality. Likewise, Ttc7Pfsn/fsnP mutant mice exhibit elevated urine 
protein levels, infiltrates of immune cells into the kidney and severe glomerulonephritis. 
Histological studies performed previously with 12-week-old Ttc7Pfsn/fsnP mice show 
increased size and cellularity of the glomeruli as well as moderate IgG deposits and 
immune complex formation (Pelsue, Schweitzer et al. 1998). Stat6-/-Ttc7Pfsn/fsnP and 
11B11-treated Ttc7Pfsn/fsnP kidneys from 10-week-old mice were sectioned and stained with 
hemotoxylin and eosin for glomerular size and cellularity, and periodic acid-Schiff for 
thickening of the basement membrane indicating immune complex deposition. In 
addition, urinalysis with commercial protein dip-sticks was performed to measure protein 
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excreted into the urine, a sign of kidney pathology, which correlated the development of 
glomerulonephritis with renal function. Ttc7Pfsn/fsnP IL-4-competent age-matched mice as 
well as normal WT littermates were used as controls.  
 
11B11 Treatment 
One of the great difficulties in the study of autoimmunity is to determine initiating 
events that drive the autoimmune process and to distinguish these from downstream 
events caused by the process itself. Often, these may be the same or similar events, which 
become dysregulated due to the nature of the intrinsic defect and the fact that there exists 
many positive feedback mechanisms in the immune system that help to augment an 
immune response under normal conditions. For example, lymphocytes must become 
activated by antigen and proliferate and differentiate into effector cells to mount a 
response against invading pathogens. Cytokines are often secreted under these conditions 
which may then activate other cell types and drive inflammation to neutralize and clear 
the unwanted foreigners. When these mechanisms go awry, due to inappropriate 
activation, defects in regulatory molecules, defects in clearance mechanisms or apoptosis, 
overproduction of cytokines or other chemical messengers or a number of other means, 
autoimmunity often results from the lack of resolution of the response. This usually 
involves a “ramping up” of symptoms and inflammation, which then drives more 
inflammation and more severe symptoms until the animal of study becomes 
physiologically overwhelmed and expires. Ttc7Pfsn/fsnP mice exhibit such characteristics of 
the ramping up of symptoms and inflammation, with hyper-activated lymphocytes and 
high levels of IL-4. However, the underlying defect is unknown, thus it has been difficult 
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to determine if the hyperactivation of lymphocytes precedes the over-production of IL-4, 
or, if a defect in the intrinsic regulation of IL-4 production causes the hyperactivation of 
lymphocytes due to the ability of IL-4 to behave as a growth factor.  
The neutralizing monoclonal antibody, 11B11, was used to treat Ttc7Pfsn/fsnP mice in 
order to render IL-4 ineffective and tease out some of the downstream effects that IL-4 
may be contributing to autoimmunity pathogenesis. This of course, is not as effective as a 
genetic deletion of IL-4 to halt production, however, as mentioned earlier, attempts to do 
this were unsuccessful. Treatment with 11B11 began at 3 weeks-of-age before the onset 
of many of the more severe symptoms of autoimmunity, and continued for 7 weeks until 
10-weeks of age in order to compare these animals with the numerous data that were 
previously collected on 10-week Ttc7Pfsn/fsnP mice. Care was taken in the preparation of the 
antibody to ensure compatibility with other published data using 11B11 as a neutralizing 
antibody. 
The 11B11-treated Ttc7Pfsn/fsnP mice were essentially unchanged in outward 
phenotype as they developed skin lesions and distended abdomens in a similar manner to 
their untreated counterparts. The size of the spleen and number of cells were also similar, 
however, there was an alteration in the percentages of cell populations indicating that the 
animals were responding to the IL-4-neutralizing treatment. 11B11-treated Ttc7Pfsn/fsnP 
mice experienced a rebound of the percentage of CD3+ cells suggesting that 
neutralization of IL-4 had an effect on either reducing cell death of CD3+ cells or had 
enhanced their development or survival.  The percentages of CD4+ and CD8+ cells 
remained unchanged.  
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The effect of 11B11-treatment on CD4+ T cell subsets is difficult to determine. It 
appeared that the percentage of cells in the naïve population (CD62LPhiP/CD44PloP) was 
essentially unchanged (Figure 3.1) between treated Ttc7Pfsn/fsnP, GL113-treated, and 
untreated Ttc7Pfsn/fsnP animals but that there was a reduction in the percentage of memory 
cells (CD62LPloP/CD44PhiP) in 11B11 mice. This reduction brought the percentage of 
memory cells in 11B11-treated mice more in line with the percentage of memory cells 
found in the spleens of 10-week WT mice, with normal levels of IL-4, as shown in Figure 
1.18 (18% and 16% respectively). The activated population (CD62LPhiP/CD44PhiP) however, 
was actually increased in 11B11-treated mice as compared to untreated Ttc7Pfsn/fsnP mice. 
The reason for this is undetermined at this time however, when compared to isotype 
control-treated Ttc7Pfsn/fsnP mice, the percentage of activated CD4+ cells is reduced (Figure 
3.1). When compared to untreated Ttc7Pfsn/fsnP mice, the isotype–control treated group also 
had an increase in activated CD4+ cells, when similar percentages would be expected. 
Thus, the antibodies used may have caused an immune response and activated T cells in 
the treated mice as the antibodies were of rat origin and could have been detected by the 
immune system as foreign antigens. Therefore, it’s possible that the 11B11-treatment 
actually reduced the percentage of activated CD4+ cells aside from the effects of the 
antibody treatment. If this is true, then the 11B11-treatment had a “normalizing” effect on 
the percentages of CD4+ cells that we would consider to be “primed” by IL-4 in vivo and 
thus brought them more in line with the percentages of subtypes found in WT animals. 
However, the naïve population, which is reduced from WT in Ttc7Pfsn/fsnP mice but similar 
in Ttc7Pfsn/fsnP treated and untreated animals, would not be expected to change much as this 
population is more developmentally defined by the Ttc7 defect as opposed to the 
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downstream effects of a high IL-4 environment which would push activation, and 
influence proliferation and differentiation.  
Flow cytometric analysis of spleen also revealed distinct differences in B cells 
between 11B11-treated and untreated Ttc7Pfsn/fsnP mice. Interestingly, the 11B11-treated 
group had a reduction in the percentage of CD19+ cells as compared to untreated. CD19 
is part of the BCR signaling system which has a positive role in B cell signaling by 
increasing the sensitivity of the receptor. An increase in CD19 expression has been 
shown to make B cells hyper-responsive to antigen signaling and mitogens, while 
decreased expression renders them hyporesponsive (Sato, Ono et al. 1996). CD19 works 
in concert with CD22, an inhibitory receptor, to regulate the signaling threshold of the 
BCR (Marshall, Niiro et al. 2000), a system which, when defective can lead to 
autoimmunity (Fujimoto and Sato 2007). CD19 expression is important in B cell 
development and induction of tolerance, and whose expression has been shown to be high 
in pro-B to mature B cell stages and low in plasma cells (Casola 2007), but does not 
appear to increase when B cells are activated or in response to activation by mitogens or 
IL-4 (Sato, Ono et al. 1996). Signals generated through CD19 appear to be important for 
the development and maintenance of B1 B cells which show increased CD19 expression, 
in contrast to CD19 deficient mice which have a significant reduction of this cell 
population (Sato, Ono et al. 1996). CD19 has not been shown to be directly regulated by 
IL-4, and although CD22 is directly downregulated by signals generated through the IL-4 
receptor there is no evidence linking CD22 to the regulation of CD19 expression (Rudge, 
Cutler et al. 2002). Therefore, we suggest that anti-IL-4 treatment altered the splenic B 
cell population by decreasing the survival effects that IL-4 exhibited on the expanded 
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immature population of B cells present in Ttc7Pfsn/fsnP spleens as had previously been shown 
by Morris et al (Morris, Dragula et al. 2002) and Mori et al (Mori, Morris et al. 2000).  In 
addition, Ttc7Pfsn/fsnP mice have been previously shown by our group to have an increased 
population of B1 cells in the spleen which is included in the immature B cell subset 
identified by Mattsson et al, (Mattsson, Duzevik et al. 2005). Thus, the reduction in the 
percentage of CD19+ cells is probably due to a reduction in the B1 cell population 
through either induction of an alternate developmental pathway or reduced survival 
through blocking IL-4.  
The functional consequences of an alteration in the B cell subsets have not been 
determined, however, it appears that there is a significant reduction in activation as CD23 
and MHC II, both surface markers of B cell activation were significantly reduced (from 
36% to 3% and 60% to 12% respectively, see Table 3.1). These are both directly 
regulated by IL-4 and provide confirmation that IL-4 signaling was blocked by the 
11B11, as well as an indication that B cells were responding to an IL-4 rich or deficient 
environment in a manner that would be expected (i.e., no intrinsic defects in downstream 
IL-4 signaling).  
The fact that B cells responded to the neutralization of IL-4 was also reflected in a 
reduction of serum IgE (Figure 3.3) as well as a substantial reduction in serum IgG1 
(Figure 3.4) both of which are influenced by IL-4. There was a slight reduction in serum 
IgG3 (Figure 3.5) but overall, total serum Ig was increased (Figure 3.6). Other isotypes 
were not measured so it is difficult to determine the type of Ig(s) that may have made up 
the difference. What is striking however, is that even though IL-4 was neutralized and 
altered the expression of IL-4-regulated genes, B cells still secreted increased levels of 
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antibodies that included anti-DNA antibodies as shown in Figure 3.7. This suggested that 
IL-4 influenced the class of antibody produced by hyperactive B cells, but that the level 
of antibody secreted and the presence of anti-DNA antibodies were independent of the 
stimulating and survival effects of IL-4.  
11B11-treated mice B cells still produced predominantly IgG anti-DNA 
antibodies, but had a slight reduction in serum concentration of IgM anti-DNA antibodies 
as measured by average absorbance (Figure 3.7), probably due to the reduction in the 
percentage of immature B cells (Figure 3.2A). The 11B11 animals also produced auto-
reactive serum antibodies with HEp-2 staining patterns similar to untreated and isotype-
control treated Ttc7Pfsn/fsnP mice (Figures 3.8 and 3.9). This attests to the activated nature of 
the B cells present in the 11B11-treated animals and the presence of autoreactive cells 
despite the 11B11 treatment. 
 Overall, this suggests the presence of an underlying defect that heightens 
lymphocyte activation and autoreactivity, which manifests in an IL-4 driven pathology 
that changes but does not completely resolve when IL-4 is neutralized. It’s possible that 
starting treatment earlier or prolonged treatment with 11B11 may induce more dramatic 
changes, but there are additional problems associated with both of these. Early treatment 
is very stressful for young animals and where they are born with visible indicators of a 
Ttc7 defect may not change the outcome we observed. Longer treatment increases the 
risk of treated animals generating an immune response and increased immune complexes 
to the antibody and would more seriously confound the results. However these data 
provide evidence that lymphocytes responded to changes in IL-4 modulation that 
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indicates the downstream regulatory mechanisms of IL-4 signaling are intact in Ttc7Pfsn/fsnP 
mice. 
 
Stat6 Deficiency 
Based on the reports of several research groups, described earlier, we expected 
that the elimination of Stat6 would possibly lessen the production of IL-4 in Ttc7Pfsn/fsnP 
mice and reduce the severity of the autoimmune phenotype. However, this was not the 
case. We were able to identify the presence of the defective Ttc7 gene in Stat6-/- animals 
early in life by the characteristic belly hair striations, abdominal distention due to the 
enlarged spleen, and the paleness of the ears, tails and feet due to the presence of anemia. 
As the mice aged, many, but not all, of them developed similar skin pathology as their 
Stat6 intact Ttc7Pfsn/fsnP counterparts, and both groups had a similar shortened lifespan, 
which averaged approximately 12-weeks.  
The overall increase in size of the spleen was similar between the Stat6 intact 
Ttc7Pfsn/fsnP and Stat6 deficient groups, however, there was a change in population 
distribution. CD23 was virtually eliminated on the surface of splenocytes in the Stat6 
deficient animals, attesting to the functional elimination of Stat6 signaling as well as the 
necessity of Stat6 in the expression of CD23, but MHC II expression was only reduced 
and not eradicated, suggesting alternate pathways of activation. There was a recovery in 
the percentage of CD3+, CD4+ and CD8+ expression in the Stat6 deficient group. 
However, in contrast to other Stat6 deficient animals which had a decrease in T cell 
activation, there was also a significant increase in the percentage of activated CD4+ T 
cells from 17% in the Stat6 intact Ttc7Pfsn/fsnP animals to 39% in the Stat6 deficient animals. 
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The increase in activation of CD4+ cells was not accompanied by an increase in 
percentage of background intracellular levels of IL-4+ (Figure 2.9) or IFN-γ+ (Figure 
2.10) cells, but when these cells were stimulated for 24 hours with anti-CD3, both 
cytokines showed a percent increase in cells positive for intracellular staining, albeit at 
slightly lower levels than their Stat6 intact Ttc7Pfsn/fsnP counterparts.  
Interestingly, lymphocytes from the Stat6 deficient Ttc7Pfsn/fsnP mice produced 
almost 6 times more IL-4 than the same number of cells from the Stat6 sufficient 
Ttc7Pfsn/fsnP mice (Figure 2.11). This is most likely reflective of the expanded activated 
population of CD4+ cells in Stat6-/-Ttc7Pfsn/fsnP (Table 2.3). It is unlikely that individual 
cells had an increased capacity for IL-4 production as the mean fluorescent intensity of 
IL-4+ cells is actually slightly higher in Stat6 intact Ttc7Pfsn/fsnP CD4+ T cells, but given 
that the percentage of CD4+ cells in Stat6 deficient animals was almost 3X higher, there 
were that many more cells producing IL-4. Although IFN-γ secretion was not measured 
by ELISA in Stat6-/- lymphocytes, there was not as significant an increase in CD4+ IFN- 
γ+ cells upon anti-CD3 stimulation (approximately 1.75 X higher in Stat6-/-Ttc7Pfsn/fsnP, 
Figure 2.10). Stat6 intact Ttc7Pfsn/fsnP CD4+ cells actually had a higher mean fluorescence 
intensity, which suggested that individual Stat6 intact cells have a slightly increased 
capacity for IFN- γ production than do Stat6 deficient cells. Therefore, the deficiency of 
Stat6 in Ttc7Pfsn/fsnP mice does not decrease the production of IL-4 as has been shown in 
other Stat6 deficient models, nor does it promote skewing towards a Th1 phenotype, but 
in fact, provides for a significant increase in IL-4 production. One possibility for this 
increase could be that the loss of Stat6 results in lack of competition for the binding of 
NFAT to the IL-4 promoter, thereby reducing the negative feedback usually in place to 
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help downregulate IL-4 production. In addition, it has been shown previously by other 
groups that CD8+ T cells, CD4/CD8 double-positive T cells and human tonsillar B cells 
can all be induced into producing IL-4 in other systems, thus it is possible that they may 
also contribute to the high IL-4 production measured here (Cronin, Stack et al. 1995; 
Harris, Goodrich et al. 2005; Parel, Aurrand-Lions et al. 2007).   
The alteration in B cell subsets in Stat6 deficient Ttc7Pfsn/fsnP splenocytes mainly 
resided in the significant increase in the percentage of immature B cells as measured by 
the ratio of IgM to IgD (Figures 2.6 and 2.7). Ttc7Pfsn/fsnP immature B cells made up about 
20% of the population, whereas their Stat6 disrupted counterparts increased to 45% of the 
population. IL-4 has actually been shown to accelerate and promote the maturation and 
differentiation of B cells; however this was also shown to be Stat6 dependent (Mori, 
Morris et al. 2000; Morris, Dragula et al. 2002). Therefore, it appears that the disruption 
of Stat6 had a more significant impact on the maturation of B cells here than did the level 
of IL-4. Mature and Transitional subsets were very similar between the two groups, as 
was the percentage of CD19+ cells overall (Table 2.1). It is likely that the population of 
immature B cells identified here are the IgM bright cells seen in the spleen sections 
stained for p-Stat6 and IL-4 (Figures 1.8 C&D, and 1.11). These would be the IgM bright 
cells seen outside of the follicles, that, when exposed to the concentrations of IL-4 seen in 
the spleen may be induced to survive, escape tolerance and proliferate. This extra-
follicular population has recently been shown to contain a population of activated B cells 
called plasmablasts that participate in the development of autoimmunity through the 
secretion of autoantibodies and undergo somatic mutation outside of the spleen follicles 
(William, Euler et al. 2005). Mattsson et al, 2005, from our lab, identified this population 
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as CD22PloP/IgMPbrightP immature B cells which agrees with the description provided by 
William et al and appears to be the population that is activated early in the induction of 
autoimmunity which, because of their location, may escape tolerance. These self-reactive 
cells would then be able to produce autoantibodies, proliferate to form new autoantibody-
producing cells, and act as effector cells to activate autoreactive T cells. Thus, a “ramping 
up” of activated lymphocytes occurs that can go on to mediate the inflammation 
associated with continuing autoimmunity.  
The functional consequences of the presence and activation of auto-reactive, 
autoantibody-secreting immature B cells were seen in the higher-than-WT concentrations 
of IgM anti-DNA antibodies (Figure 2.15), higher IgG1 (Figure 2.12), IgG3 (Figure 2.13) 
and total serum Ig (Figure 2.14), and positive staining for anti-nuclear and cytoplasmic 
staining patterns in HEp-2 cells (Figure 2.16) in the serum from Stat6-/-Ttc7Pfsn/fsnP mice. 
Although the concentrations of these antibodies were similar to those of Stat6 intact 
Ttc7Pfsn/fsnP serum, the switch to a more predominant IgM class reflected the higher 
percentage of immature B cells in the Stat6 deficient animals. There is little research 
available describing the significance and pathogenicity of IgM antibodies, however, due 
to the pentameric structure of the secretory form, IgM is highly efficient in activating 
complement which can then mediate inflammation. In addition, due to its low affinity, 
epitope spreading is more likely with IgM resulting in crossreactivity that may become 
self-reactive, or broaden the reach of primary self-reactive IgM antibodies produced in 
development. It is interesting that there appeared to be a predominance of cytoplasmic 
staining of HEp-2 cells from the Stat6 deficient Ttc7Pfsn/fsnP animals. Recently, Wardemann 
et al. (Wardemann, Yurasov et al. 2003), found that 58.6% of the antibodies expressed by 
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early immature B cells showed either a nuclear or nuclear/cytoplasmic staining pattern in 
HEp-2 cells, while 13.8% stained the cytoplasm. The antibodies with nuclear or 
nuclear/cytoplasmic staining were subsequently removed from the repertoire during 
developmental checkpoints of tolerance, however, the antibodies reactive with 
cytoplasmic components were not removed from the B cell pool as efficiently. Thus, it is 
possible that the increased presence of IgM cytoplasmic autoantibodies represents a 
“normal” process that, due to the increase in IgM and immature B cells in the Stat6 
deficient Ttc7Pfsn/fsnP mice, are not removed and are allowed to survive and undergo 
isotype-switching to become IgG antibodies that are specific for cytoplasmic antigens. 
Interestingly, Khan et al (Khan, Witsch et al. 2008) recently described a mechanism by 
which B cells bearing IgM antibodies specific for cytoplasmic antigens are able to escape 
tolerance. In their VH56R/Vκ38c transgenic model of anti-DNA specific heavy and light 
chain combinations they found the IgM antibody produced to be specific for a Golgi-
associated antigen, but also cross-reactive with DNA. Because IgM antibodies traffic 
through the Golgi on the way to the cell surface, specificity for an antigen there caused an 
intracellular accumulation of IgM which was not degraded. These Golgi-specific B cells 
were subsequently found in the marginal zone of the spleen. We also identified Golgi-
specific IgM autoantibodies in our Stat6-/-Ttc7Pfsn/fsnP HEp-2 staining, as well as other IgM 
cytoplasmic-specific staining patterns. The mechanism described for central tolerance 
avoidance may play a role in our system as well.  
 214
Assessment of Autoimmunity: Renal Pathology 
Researchers and clinicians involved in studying the etiology and pathology of 
autoimmunity have long used the status of kidney disease to determine disease 
progression as this is a common element among many different models and types of 
systemic autoimmunity and for many years was a major source of morbidity and 
mortality for humans and animals alike. Advancements in treatment options for humans 
have reduced the mortality rate due to kidney failure among patients, but kidney 
pathology is still a useful measure of disease progression and severity in animal models 
of autoimmunity. Because of the ease of measuring protein in urine and the strong 
association between increased urinary protein and increased kidney disease severity, 
proteinuria is a useful and non-invasive way to measure the progression of pathology 
until histological analysis can confirm cellular damage. Prior measurements of 
proteinuria (unpublished data by Daniel Swett of the Pelsue Lab) and kidney histology 
have confirmed the presence of renal disease of Ttc7Pfsn/fsnP mice. Proteinuria has generally 
been measured between 30-100 mg/mL in Ttc7Pfsn/fsnP urine, which stayed in that range as 
mice aged and succumb to advanced autoimmune disease. The disruption of Stat6 in 
these mice actually caused a significant increase in proteinuria, with all Stat6-/-Ttc7Pfsn/fsnP 
mice measured having levels starting at 100 mg/mL and going as high as 2000+ mg/mL 
(Figure 5.1). When measurements were taken at 2-week intervals, most proteinuria 
measurements increased, sometimes dramatically. The mice with the highest measured 
levels of 2000+ died very shortly after the measurements were taken (hours to days).  
To correlate the high urinary protein found in both Stat6 deficient and Stat6 intact 
mice, we harvested kidneys from newly sacrificed animals and sent them to be processed 
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and scored by Dr. Harini Bagavant, an experienced expert in the evaluation of SLE 
kidney nephritis at the University of Virginia. Her comments can be read in the “Results” 
section (Figures 5.3-5.5). Both Stat6 intact and Stat6 deficient, Ttc7Pfsn/fsnP mice were 
classified as having “severe glomerular disease” of the membranoproliferative-
glomerulonephritis-type. This was described as a little different from some forms of GN 
in SLE due to the lack of inflammatory infiltrates in the glomeruli and the presence of 
normal looking Bowman’s capsules, tubules and interstitium. Both Ttc7Pfsn/fsnP and Stat6-/-
Ttc7Pfsn/fsnP were scored as having a rating of 2-3+ on a disease severity index with 4 being 
the most severe, however, the kidney sections scored from Ttc7Pfsn/fsnP mice were from 20-
week-old mice, whereas, the Stat6-/-Ttc7Pfsn/fsnP sections scored were from 10-week-old 
mice. The number of glomeruli involved was similar in both groups as were the cell-
types and location of inflammatory foci. Thus, the absence of Stat6, which in some 
animal models was shown to reduce renal disease, actually increased and accelerated 
renal disease in the Stat6 deficient Ttc7Pfsn/fsnP animals. The absence of Stat6 was also 
accompanied by an increase in activated T cells, which have been found to be important 
in the pathogenesis of lupus GN and progression to renal failure (Waters, Fu et al. 2001; 
Bagavant, Deshmukh et al. 2006). This same group has also associated lower levels of 
proteinuria to distinguish acute GN, and higher levels of proteinuria to distinguish the 
change to chronic GN and progression to renal failure.  
Therefore, these data suggest that the disruption of Stat6 in Ttc7Pfsn/fsnP animals 
results in an increase in renal pathology, by changing an acute state to a chronic state of 
GN, with higher percentages of activated peripheral T cells, and immature B cells, 
leading to a slightly altered, but severe state of systemic autoimmune disease. This is in 
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contrast to other models wherein the disruption of Stat6 lessens autoimmunity with less 
lymphocyte activation, milder renal disease, lower levels of serum antibodies including 
self-reactive antibodies, and lower levels of IL-4.  
The neutralization of IL-4 by treatment with 11B11 actually seemed to reduce the 
severity of renal disease as measured by proteinuria and scoring of kidney sections. 
Proteinuria was reduced to 30 mg/mL in all but one of the 11B11-treated Ttc7Pfsn/fsnP which 
was lower than the untreated Ttc7Pfsn/fsnP and isotype control treated groups, but not as low 
at WT (untreated) animals (Figure 5.2). The kidney sections corresponding to the protein 
measurements in the 11B11-treated animals all rated a disease severity index score of 
~1+ (out of 4, with 4 the most severe). 
These data, taken with the 11B11 data given previously suggest that IL-4 
definitively contributes to the downstream autoimmune pathology of Ttc7Pfsn/fsnP mice and 
when neutralized, pathology is reduced. This is demonstrated by the reduction in the 
population of effector activated and memory T cells, a reduction in the activation markers 
of B cells, CD23 and MHC II, and a reduction in the immature population of B cells, and 
lower levels of proteinuria coupled with a lower disease severity index score. That the 
underlying defect in Ttc7 actually promotes an abnormally activated state in lymphocytes 
that leads to IL-4 overproduction is supported by the observation that 11B11 did not 
change the percentage of naïve T cells (which is reduced compared to WT animals) nor 
did it change the overall level of antibody production or the presence of anti-DNA 
antibodies, attesting to the hyper-active state of B cells, similar to that seen by Kin and 
Saunders (Rose, Lichtenheld et al. 2007). Therefore, this indicates that the Ttc7 defect 
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promotes autoreactivity and autoimmunity, while IL-4 contributes to the expression and 
progression of the pathology. 
 
Cell Cycle Regulation 
Many of the hematopoietic abnormalities associated with Ttc7Pfsn/fsnP mice are 
similar to those associated with mice engineered to have defects in cell cycle regulatory 
proteins. This is understandable since the proper regulation of hematopoiesis requires 
precise regulation of the cell cycle machinery. Entry into the cell cycle is necessary for 
expansion of cell populations and proliferation, while properly timed exit is necessary for 
maturation and differentiation to occur (Woetmann, Brockdorff et al. 2003). Thus, 
prolonged cycling of a cell diminishes its ability to mature and differentiate. Mice with 
targeted E2F2 mutations for example, (a member of a protein family that regulates 
proliferation, differentiation, and apoptosis), exhibit an autoimmune syndrome similar to 
Ttc7Pfsn/fsnP mice, with skin lesions, anemia, splenomegaly and inflammatory infiltrates in 
many organs, although the E2F2 mice exhibit symptoms much later in life, with life 
expectancy to 15 months or longer (Murga, Fernandez-Capetillo et al. 2001). Indeed, Th2 
differentiation and the production of IL-4 require entry into the cell cycle, and IL-4 itself 
has been shown to promote the entry of various cell types into the cell cycle. Thus it is 
difficult to separate a defect in one from a defect in the other.  
The differences in the percentages of cycling CD3+ cells, as shown in Table 4.1, 
suggest that the cell cycle is operating in a predictable manner in Ttc7Pfsn/fsnP which 
corresponds to the activation and/or differentiation state of the cells. 4-week Ttc7Pfsn/fsnP 
mice have the highest percentage of naïve cells which are producing IL-4 at a stage when 
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cycling would be necessary for IL-4 production, as well as having high populations of 
activated and memory cells. At 10-weeks a higher population of cells would likely have 
become “primed” and IL-4 production would no longer require entry into the cell cycle. 
Stat6-/- and 11B11-treated Ttc7Pfsn/fsnP mice both have higher percentages of activated 
CD3+ cells than 10-week Ttc7Pfsn/fsnP mice and higher percentages of cycling cells. 
Although DNA content was not examined in B cells, 11B11-treatment reduced the 
percentage of immature B cells in Ttc7Pfsn/fsnP spleens and resulted in differentiation to a 
more mature population. Thus, although these data are in no way definitive, they suggest 
that cell cycle regulation is not the primary defect in Ttc7Pfsn/fsnP mice.  
 
Conclusion 
The goal of this thesis project was to evaluate the production of IL-4 and its 
contribution to lymphocyte activation and autoimmune pathology in Ttc7Pfsn/fsnP. This was 
done in keeping with our general hypothesis that the Ttc7PfsnP mutation results in the 
hyperactivation of lymphocytes leading to the overproduction of IL-4 and systemic 
pathogenic autoimmunity.  
Our results suggest that IL-4 plays a major role in the pathology of Ttc7Pfsn/fsnP mice 
but that the role of Stat6 is more complicated. We have demonstrated that altered IL-4 
signaling is not due to defects in IL-4 responsive genes but is influenced by a mutation in 
the as yet uncharacterized Ttc7 gene which we hypothesize to be important in 
lymphocyte regulation.  
Thus, from these data, it appears that the lack of Stat6-/- in Ttc7Pfsn/fsnP results in an 
increase in the severity of autoimmunity as measured by renal disease. The neutralization 
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of IL-4 results in a slight decrease in the severity of autoimmunity. Therefore we suggest 
that Ttc7Pfsn/fsnP mice exhibit an autoimmune syndrome that is phenotypically-driven by IL-
4 due to the background genetic effects of the Th2-skewed BALB/c strain, and results 
from the dysregulated activation of lymphocytes due to the defective Ttc7 gene. We 
further suggest that Ttc7 functions to negatively regulate lymphocyte activation and 
cytokine production and when the downstream inhibitory action of Stat6 is removed in 
the Stat6 deficient animals, IL-4 production becomes elevated and increases the severity 
of the pathology. The question of whether Ttc7 and Stat6 interact remains to be answered 
when the tools for the study of Ttc7 become more readily available for such analysis. 
However, these data suggest the possibility that Stat6 and Ttc7 may function in a similar 
or complementary fashion as when both are deficient we see more lymphocyte activation 
and proliferation, and more autoimmune pathology.  
Recently, Heery and colleagues (Heery, Kalkhoven et al. 1997) identified a 
protein-recognition motif defined by the sequence LxxLL (Leu-Xaa-Xaa-Leu-Leu) that is 
present on many transcription factors and cofactors that mediate both activation and 
repression of transcription. Many of the proteins identified with LxxLL sequences have 
multiple motifs as well as LxxLL binding sites, which are minimally understood, and are 
thought to possibly mediate transcriptional coactivator complexes (Plevin, Mills et al. 
2005). Stat6 has recently been shown to have LxxLL motifs, one of which binds to the 
cofactor NCoA-1 and is required for IL-4-induced eotaxin-3, with other IL-4 responsive 
genes still under study (Litterst and Pfitzner 2002). Other LxxLL- containing proteins 
include cyclic AMP response element-binding protein (CREB)-binding protein (CBP), 
p300, c-Myb, and several E proteins which are important in lymphocyte development and 
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regulation of activation. These proteins have been implicated in disease processes as well. 
For example, Zhang et al (Zhang, Kalkum et al. 2004) identified a fusion protein 
commonly associated with acute myeloid leukemia, AML1-ETO that binds to an E 
protein via an LxxLL domain and inhibits the binding of CBP/p300, thus silencing the E 
protein. We have identified four putative LxxLL domains in the Ttc7Pfsn/fsnP protein, three 
of which potentially form alpha-helical secondary structures similar to the functional 
LxxLL motifs identified to date (Razeto, Ramakrishnan et al. 2004). Since the function of 
Ttc7PfsnfsnP is unknown, it is interesting to speculate that it may be involved in 
transcriptional regulation in lymphocytes mediated by its LxxLL motifs through 
interactions with other cofactors and regulatory proteins, and possibly Stat6.  
Interestingly, these data are very reminiscent of reports of Stat6 deficiency 
combined with the disruption of a negative regulator of lymphocyte activation such as 
Bcl-6 (Linehan, Warren et al. 1998) or CTLA-4 (BOUR-JORDAN, GROGAN ET AL. 
2003) or the combination of a positive and negative regulator of activation such as 
NFATc2 and NFATc3 (Rengarajan, Mowen et al. 2002). Bcl-6 is a transcription factor 
that has been shown to be important in Th2 development and when knocked out, mice 
deficient in Bcl-6 die early from severe lung and heart inflammation. Bcl-6/Stat6 double-
knockouts also develop a severe Th2 inflammatory disease with levels of IL-4 from 7 to 
1000 times that of Stat6 knock out animals. These animals did not develop a 
corresponding elevation in the Th1 cytokine, IFN-γ, indicating that they were not pushed 
into a more inflammatory Th1 phenotype. Thus it appears that Bcl-6 controls an alternate 
pathway of Th2 differentiation that is independent of Stat6 (Linehan, Warren et al. 1998). 
This situation also exists in Ttc7Pfsn/fsnP mice which produce high levels of IL-4, but even 
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higher levels when Stat6 is interrupted. Stat6-/-Ttc7Pfsn/fsnP CD4+ cells do not produce 
increased levels of IFN- γ but in fact exhibit a reduction in the percentage of IFN- γ+ 
cells as well as lower levels of cytokine produced per cell. Thus, the Ttc7Pfsn/fsnP/Stat6 
“double-knockout” does not become skewed towards a Th1 phenotype, but differentiates 
into Th2 IL-4 producing cells in the absence of Stat6.  
Cytolytic T lymphocyte-associated antigen-4 (CTLA-4) is a cytosolic protein that 
is considered to be an immune attenuator that, when engaged, promotes Th1 
differentiation in T lymphocytes. CTLA-4 is considered to function by controlling the 
strength of the signal after T-cell activation, thus determining the Th1 or Th2 fate of the 
population. CTLA-4 deficient CD4+ T cells produce increased levels of IL-4 and possess 
a Th2 phenotype. CTLA-4 and Stat6 double-knock out mice produce elevated levels of 
IL-4 as compared to CTLA-4 or Stat6 single knock outs. Double knock-out T cells also 
exhibit an activated phenotype and an expanded population as compared to singly 
deficient cells (Bour-Jourdan et al., 2003). Thus the CTLA-4/Stat6 double-knockout and 
Stat6-/-Ttc7Pfsn/fsnP are both able to produce stably differentiated IL-4 producing Th2-driven 
cell populations that bypass the need for Stat6 in that process. Furthermore, mice with 
these deficiencies are unable to attenuate activation resulting in fatal lymphoproliferative 
disease. 
Mice with a targeted NFATc2 disruption exhibit an increase in IL-4 production 
and a skewing towards the Th2 phenotype (Rengarajan, Mowen et al. 2002). They also 
show an increase in IL-4 mRNA stability, an increase in activated and memory T cells 
and sensitivity to CsA. When combined with a targeted NFATc3 disruption, doubly-
deficient mice show a dramatic increase in IL-4 production, increased IgG1 and IgE 
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titers, severe inflammation, and differentiate into a Th2 phenotype even in the absence of 
IL-4. These data suggest that NFATc2 and NFATc3 have inhibitory functions in vivo that 
may regulate negative feedback mechanisms that perturb Th2 polarization. However, 
these mice do not show a concomitant increase in Th1 cytokines such as IFN-γ, but in 
fact produce less upon stimulation in Th1 skewing conditions.  
What all of these animal models have in common is an intrinsic defect which 
results in a change in signaling threshold that permits functional activation and alters the 
cellular response. It is understood that strong TCR signals favor Th2 differentiation while 
weaker signals push T cells into a Th1 phenotype (Bour-Jourdan et al. 2003). The 
strength of the signal through the TCR has also been shown to bypass the need for Stat6 
in IL-4 production (Sehra, Patel et al. 2005). Thus, in a similar manner, a higher 
percentage of Ttc7Pfsn/fsnP T cells are activated as compared to WT, due to an intrinsic 
defect that promotes autoreactivity and allows for a lower threshold of activation. 
Intracellularly, this translates into a signal strong enough to drive Th2 differentiation and 
increased levels of IL-4, even in the absence of Stat6. The IL-4-rich environment then, 
provides the means by which continued activation occurs, resulting in more IL-4 
production and a cascade into autoimmune-related pathology. 
While the above describes T cell processes there is ample evidence to suggest that 
B cells are equally activated and participate in the development of the systemic pathology 
described herein. It is not unreasonable to imagine that the same defect that alters and 
reduces the signaling threshold in T cells, functions to increase reactivity and 
autoreactivity in B cells as well. In fact, Gong and Malek (Gong and Malek 2007) and 
Kallies et al., (Kallies and Nutt 2007), have recently demonstrated a role for B 
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lymphocyte induced maturation protein -1 (Blimp-1), a protein essential for terminal 
differentiation in B cells, to be essential for T lymphocyte homeostasis and regulation of 
activation as well. Interestingly, a role for regulation by Blimp-1 was also determined in 
some non-hematopoietic cells.  In addition, NFATs, originally discovered in T cells, have 
been found to be present and activated by signals generated through the BCR and 
important in B cell activation and differentiation (Foucault, Le Bras et al. 2005). 
Therefore, we suggest that the intrinsic defect in Ttc7 in B cells, increases the 
autoreactivity and reactivity of Ttc7Pfsn/fsnP B cells. The presence of autoantigens, released 
through normal cellular turn-over, may participate to activate autoreactive B cells, which 
respond to increased levels of IL-4 by proliferating and differentiating into autoantibody 
producing cells, and help to further activate T cells via their antigen-presenting capacity. 
This is a highly simplified scenario to describe an exquisitely complex process, as there 
are regulatory and counter-regulatory molecules that are also unique in B and T cells. 
However, determining the function of Ttc7 will undoubtedly provide valuable insight into 
lymphocyte regulation and the early changes determining the course of autoimmunity and 
autoimmune disease. 
 
Future Work 
On-going work in our lab seeks to determine the function of Ttc7Pfsn/fsn Pand how it 
contributes to the dysregulation of IL-4 and the hyperactivation of B cells leading to 
systemic autoimmunity. While a human homologue to Ttc7Pfsn/fsn Phas not currently been 
identified, cytokine dysregulation and B cell hyperactivation have been found to 
contribute to human systemic autoimmune disease.  We propose that the mechanisms 
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active in Ttc7Pfsn/fsn Pwill contribute to a greater understanding of IL-4 regulation and T and 
B lymphocyte activation in humans.  Determining these mechanisms will be important in 
leading to an understanding of the pathology and to ultimately develop effective 
specifically targeted therapies for those so affected.  
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